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ABSTRACT
 Chronic intake of alcohol can result in a range of pathology in the liver.  Whilst the 
earliest changes observed with chronic ethanol, including the accumulation of lipid, or steatosis, 
are readily reversible upon cessation of alcohol consumption, longer exposure to ethanol may 
achieve more complex disease states including steatohepatitis, fibrosis, and cirrhosis that can 
cause irreversible damage and progress to fulminant hepatic failure.  A key concept in the 
pathogenesis of alcoholic liver disease is that chronic ethanol primes the liver to increased injury 
through an interplay between hepatocytes and non-parenchymal cells, chiefly immune cells, of 
the liver.  These relationships between hepatocytes and non-parenchymal cell types in alcoholic 
liver disease are reviewed in Chapter 1A.
 The Hypoxia Inducible Factors are a set of transcription factors that classically have been 
described as affecting a homeostatic response to conditions of low oxygen tension.  Alcoholic 
liver disease is marked by increased hepatic metabolic demands, and some evidence exists for 
increased hepatic tissue hypoxia and upregulation of hypoxia-inducible factor mRNA with 
chronic alcohol. However, the biological significance of these findings is unknown.  In Chapter 
1B, we review the literature on recent investigations on the role of hypoxia inducible factors in a 
broad array of liver diseases, seeking to find common themes of biological function
 In subsequent chapters, we investigate the hypothesis that a member of the hypoxia-
inducible-factor family, HIF1! , has a role in the pathogenesis of alcoholic liver disease.  In 
Chapter 2, we establish a mouse model of alcoholic liver disease and report data confirming 
HIF1!  activation with chronic ethanol.  We demonstrate that HIF1! protein, mRNA, and DNA 
binding activity is upregulated in ethanol-fed mice versus pair-fed mice, and that some 
v
upregulation of HIF2! protein is observable as well.  In Chapter 3, we utilize a mouse model of 
hepatocyte-specific HIF1!  activation and demonstrate that such mice have exacerbated liver 
injury, including greater triglyceride accumulation than control mice.  Using cre-lox technology, 
we introduce a degradation resistant mutant of HIF1! in hepatocytes, and after four weeks of 
ethanol feeding, we demonstrate that mice with the HIF1! transgene have increased liver-weight 
to body weight ratio and higher hepatic triglyceride levels.  Additionally, several HIF1! target 
genes are upregulated.  In Chapter 4, we examine the relationship between HIF1!  activation and 
hepatic lipid accumulation using a recently published in vitro system, in which lipid 
accumulation was observed after treating Huh7 cells with the chemokine Monocyte 
Chemoattractant Protein-1 (MCP-1).  We report that MCP-1 treatment induces HIF1! nuclear 
protein accumulation, that HIF1! overexpression in Huh7 cells induces lipid accumulation, and 
finally, that HIF1! siRNA prevents MCP-1 induced lipid accumulation. In Chapter 5, we use 
mouse models to investigate the hypothesis that suppression of HIF1!  in hepatocytes or cells of 
the myeloid lineage may have differing effects on the pathogenesis of alcoholic liver disease.  
We find that ethanol-fed mice expressing a hepatocyte-specific HIF1! deletion mutant exhibit 
less elevation in liver-weight body ratio and diminished hepatic triglycerides versus wild-type 
mice; furthermore, we find that challenging these mice with lipopolysaccharide (LPS) results in 
less liver enzyme elevation and inflammatory cytokine secretion than in wild-type mice.  In 
Chapter 6, we offer a final summary of our findings and some directions for future work.
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PREFACE
Much of the introductory material is adapted from Bharath Nath and Gyongyi Szabo, ‘Alcohol-
induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: 
implications for immunity.‘   Seminars in Liver Diseases. 2009 May;29(2):166-77
Data for some figures in subsequent chapters were gathered in collaboration with other members 
of the Szabo laboratory.  Figures generated from such data are identified in prefatory material in 
the relevant chapters of the dissertation.
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CHAPTER 1
INTRODUCTION
Summary
 Alcoholic liver injury involves a complex array of derangements in cellular signaling of 
hepatic parenchymal and non-parenchymal cells as well as cells of the immune system.  In the 
first part of the introduction, we review the literature on the role of parenchymal and non-
parenchymal cells of the liver in the pathogenesis of alcoholic liver disease.  In the hepatocyte, 
chronic ethanol abuse leads to lipid accumulation and liver steatosis. Multiple pathways are 
affected to promote lipid accumulation in the ethanol-exposed hepatocyte. Chronic ethanol 
renders Kupffer cells hyper-responsive to endotoxin, which results in production of 
inflammatory cytokines and the tumor necrosis factor-! via a Toll-like receptor 4 dependent 
pathway, leading to inflammation and hepatic necrosis. Dysfunction of the innate and adaptive 
immune responses caused by ethanol contributes to impaired anti-viral response, inflammatory 
injury, and autoimmune activation. Recent developments in the literature are reviewed, and we 
suggest lipid accumulation, dysregulation of immunity, and impaired anti-viral and autoimmune 
responses as three distinct though interwoven pathophysiological mechanisms of alcoholic liver 
injury. 
 Hypoxia has been shown to have a role in the pathogenesis of several forms of liver 
disease.  In the second part of the introduction, we review the evidence for a role of hypoxia and 
the Hypoxia -Inducible Factors, a family of transcription factors that affect a homeostatic 
response to low oxygen tension, in liver diseases.  We describe regulation of the hypoxia 
1
inducible factors, and review earlier investigations that demonstrate a role for HIFs in the 
development of liver fibrosis, activation of innate immune pathways, hepatocellular carcinoma, 
as well as other liver diseases in both human disease and murine models.
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CHAPTER 1A
 Alcohol and cellular signaling pathways in hepatic parenchymal and non-parenchymal cells
 Alcoholic liver disease [ALD] can be broadly described as varying degrees of impairment 
of hepatic function following chronic and excessive ethanol consumption. The 
pathophysiological changes in ALD are provoked by complex effects of ethanol on all cell types 
within the liver, affecting metabolic, immunologic, and inflammatory processes. Within the 
effects of alcohol, a few broad trends emerge. First, chronic ethanol (CE) consumption diverts 
metabolic pathways in the hepatocyte towards the accumulation of intracellular lipid in the form 
of triglycerides.[1] Recent investigation reveals that this accumulation of lipid is unlikely to be 
an effect of ethanol alone on the hepatocyte, but rather a complex  interplay of ethanol-induced 
alterations in cellular redox state, the transcription of lipogenic and anti-lipolytic factors, and 
cellular signaling from other cell types and distant tissues. Second, ALD involves activation of 
the signaling axis of the innate immune pathway, which is characterized by a hepatic 
inflammatory response to gut derived endotoxin, chiefly orchestrated by the Kupffer cell (KpfC), 
the resident macrophage of the liver. The main output of this inflammatory response is the 
production of tumor necrosis factor-alpha and other pro-inflammatory cytokines, which in turn 
are major determinants and causative agents of subsequent liver damage. Third, prolonged 
inflammation and hepatocyte damage appear to give rise to several other cellular and immune 
events that provoke further deterioration of hepatic function, including effects that span a range 
from impaired anti-viral response, fibrotic change, and autoimmune attack. Thus, (for purposes 
of this introductory review), we will adopt a three-part description of signaling pathways in 
alcoholic liver disease, one that summarizes pathways leading to lipid accumulation, the 
3
  
endotoxin/innate immune signaling axis, and other cellular and immune events as three distinct, 
though overlapping, themes in the biological narrative of liver injury as a consequence of 
prolonged ethanol exposure. 
Ethanol and Pathways of Lipid Accumulation in the Hepatocyte
 Ethanol exerts effects on the hepatocyte that divert metabolic pathways to favor the 
accumulation of intracellular lipid (Figure 1). This correlates with the earliest histopathological 
alterations detectable in murine models of acute ethanol or CE consumption, and the clinical 
observation that virtually all individuals who chronically consume ethanol develop steatosis.[2] 
In vitro work using precision-cut thin slices of liver tissue have demonstrated lipid accumulation 
within 48 hours of ethanol exposure.[3] Ethanol directly affects the activity of several nuclear 
receptors that exert transcriptional control on lipid metabolism, including the peroxisome 
proliferator-activated receptors alpha and gamma (PPAR! and PPAR"), the sterol regulatory 
element binding protein-1 (SREBP1), the liver retinoic acid/X receptors (RXR and LXR), and 
other associated regulators and cofactors.  
Peroxisome Proliferator Activated Receptors (PPAR) and Steatosis. The peroxisome-proliferator-
activated-receptors are a family of proteins that act as nuclear receptors and exert transcriptional 
effects on pathways of lipid metabolism. Natural PPAR ligands include various lipid derived 
biomolecules, including eicosanoids, leukotrienes, prostaglandins, and free fatty acids.[4] PPAR! 
may be pharmacologically activated by drugs of the fibrate class, whereas PPAR" may be 
activated by thiazolidinediones. Upon ligand activation, all PPARs bind with the retinoid-X 
4
  
Figure 1.  Chronic Ethanol and Pathways to Lipid Accumulation in the Hepatocyte.   PPAR! 
suppresses lipid accumulation which may be mimicked by (A) PPAR! agonists that induce 
PPAR-DNA binding.  (B) PPAR! is downregulated by chronic ethanol,  and knockout of PPAR! 
or its binding partner RXR exacerbated liver injury.  (C)  PPAR" agonists activate PPAR" and 
inhibit lipid accumulation, possibly by a PPAR" independent mechanism.  (D)Inhibition of 
PGC-1! or its interacting partner SIRT by ethanol relieves the suppressive effect of these factors 
on SREBP1c.  (E) Induction of SREBP1c by ethanol upregulated lipid accumulation, and 
knockout of SREBP1 partially reduced ethanol-induced hepatic triglyceride (F) Stat3 signaling 
appears to limit SREBP1 activation. (G) Ethanol stimulated osteopontin, and knockout of 
osteopontin resulted in higher PPAR!.  (H)  Ethanol upregulated CYP2E1, which in turn blocked 
PPAR! though conflicting results have been reported.  (I) AMPK signaling induces PPAR! and 
ethanol suppressed AMPK. (J) Adiponectin maintains PPAR! levels, and is decreased by chronic 
ethanol.
5
  
Figure 1
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receptor (RXR), and the heterodimer formed thereby binds to peroxisome-proliferator response 
elements (PPREs) in the genome.[4] Suppression of PPAR gene expression by ethanol was 
described over a decade ago.[5] CE feeding diminishes PPAR!/RXR DNA binding in the liver, 
and ethanol-induced hepatic lipid accumulation can be reversed by treatment with PPAR! 
agonists in mouse and rat models of ethanol feeding.[6, 7]   Conversely, CE feeding resulted in 
worsened liver injury in PPAR!-knockout mice versus wild-type mice, indicating that PPAR! 
activation may be protective in ALD.[8] Similarly, hepatocyte RXR deficient mice displayed 
worsened liver injury with CE.[9]
Osteopontin and PPAR!. To date, the mechanism of ethanol-induced decrease in PPAR! 
activation remains controversial. Some evidence suggests that the glycoprotein osteopontin may 
have a role.[10] Treatment of macrophages with PPAR! agonists suppressed osteopontin 
production and circulating osteopontin was diminished in patients treated with PPAR! agonists. 
Conversely, CE feeding in osteopontin-null mice resulted in greater lipid accumulation and liver 
injury than in wild-type mice, with higher PPAR! mRNA levels.[11]  
Adiponectin and PPAR!. Another potential mechanism involves adiponectin, an adipocyte-
derived hormone that is dysregulated in rats with CE exposure.[12] In vitro studies suggest that 
adiponectin is a potent stimulator of PPAR! DNA binding.[13] Treatment of mice with a 
pharmacological inhibitor of the Inhibitory Kappa Kinase-2 in a mouse model of diet-induced 
non-alcoholic steatohepatitis (NASH) maintained adiponectin levels and PPAR! activation, 
strengthening the link between adiponectin and PPAR! and suggesting that the dysregulation of 
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NF#B signaling in CE exposure, discussed below, may interface hepatic lipid accumulation 
along an adiponectin-PPAR! axis.[14]  
 While compelling, the data linking adiponectin to hepatic lipid accumulation is not 
without controversy. Adiponectin is known to exert some of its effects via activation of the AMP-
activated protein kinase (AMPK) which in turn acts to downregulate lipid accumulation by a 
variety of mechanisms.[15] Briefly, stimulation of AMPK is thought to inactivate acetyl-coA 
carboxylase, which in turn prevents the formation of malonyl-CoA, itself an inhibitor of the fatty 
acid transporter carnitine palmitoyl transferase. Treatment of ethanol-fed animals with an AMPK 
inhibitor (AICAR) prevented lipid accumulation and normalized serum alanine aminotransferase 
(ALT) levels, suggesting that the beneficial effect of adiponectin may be modulated through 
adiponectin effects on AMPK.[16] While these studies were conducted in models of CE, a recent 
study investigated the effects of metformin, a biguanide pharmaceutical agent known to act in 
part through AMPK pathway activation, in both AE and CE fed mice.[17] Despite robust 
prevention of hepatic lipid accumulation in mice treated with metformin and AE, AMPK 
activation was not observed. In metformin/CE fed mice, hepatic lipid accumulation remained 
lower than mice fed ethanol alone, and AMPK activation again appeared unchanged.[17]
Plasminogen Activator Inhibitor-1. Metformin treatment in alcohol-fed mice also correlated with 
diminished Plasminogen-activator-inhibitor-1 (PAI-1), expression and PAI-1 knockout mice were 
protected from ethanol-induced liver injury.[17] In support of the notion that inhibition of PAI-1 
may be an important mechanism of the protective effects of adiponectin on hepatic lipid 
8
  
accumulation in CE feeding, investigators found that treatment of HepG2 cells with the PPAR! 
agonist fenofibrate suppressed PAI-1 levels.[18]
Oxidant Stress and Lipid Accumulation. Evidence also suggests that hepatic lipid accumulation  
and PPAR! activation are profoundly affected by oxidant stress. An inhibiting effect of 
antioxidant administration on hepatic lipid accumulation in CE was described almost 40 years 
ago. Knockout of the p47 NADPH oxidase subunit was able to prevent ethanol induced liver 
injury in a model of continuous enteral CE feeding.[19] Cytochrome P4502E1 (CYP2E1), a 
member of the p450 mixed-oxidase system of xenobiotic metabolizing enzymes, has been 
proposed as a potential source of oxidant stress in response to ethanol feeding.[20]  CYP2E1 
mRNA is upregulated by ethanol.[21] However, conflicting experimental results suggest that the 
role of CYP2E1 is as yet unresolved. Most recently, in an oral CE feeding model, neither 
CYP2E1 null mice nor wild-type mice fed ethanol and a chemical inhibitor of CYP2E1 
developed steatosis.[22] Intriguingly, ethanol caused an upregulation in hepatic PPAR! in 
CYP2E1-null mice, suggesting a role for endogenous CYP2E1 in the negative regulation of 
PPAR!.[22] In distinction, earlier studies found that AE or CE in CYP2E1-knockout mice had no 
effect or increased lipid accumulation and liver injury.[23, 24]
Other Pathways and Hepatic Lipid Accumulation. 
The developing picture of decreased PPAR! activation and subsequent hepatic lipid 
accumulation is complicated by observations that PPAR" activation may have a protective effect 
on ALD. The PPAR" agonist pioglitazone repeatedly prevented injury in rat models of 
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ALD[25-27]  However, though several studies report a reduction of PPAR" mRNA with ethanol 
treatment in vivo and in vitro, others report no effect of ethanol on PPAR"  protein expression.
[28, 29] Indeed, in the studies cited previously, no effect of pioglitazone on PPAR" gene 
expression was observed in one study, whereas PPAR" mRNA levels were restored by 
pioglitazone in ethanol treated animals in a second study.[26, 27]  Although studies on a third 
member of the PPAR family, PPAR$, are limited in ALD, a recent report demonstrated that 
PPAR$ activation ameliorates hepatic steatosis in a mouse-model of non-alcoholic fatty liver 
disease.[30]  
  An alternative mechanism may involve activation of the peroxisome proliferator 
activated receptor-gamma coactivator 1 alpha (PGC-1!). PGC1! interacts both with PPAR" as 
well as with the histone deacetylase Sirtuin 1 (SIRT1). Both PGC1! and SIRT1 protein are 
suppressed by ethanol, and reversal of these effects (with resveratrol treatment, which 
upregulates both SIRT1 and PGC1!) prevented ALD in a mouse model.[31, 32] This effect of 
resveratrol was coupled with AMPK activation and increased expression of adiponectin and 
adiponectin receptors. However, in a rat model of continuous enteral CE feeding, conjunct 
resveratrol treatment exacerbated liver injury.[33] Sirt1 was recently identified as a regulator of 
sterol-regulatory element binding protein1c (SREBP1c)[31] CE upregulated SREBP1c and its 
downstream targets, and overexpression of SREBP1c caused steatosis in a mouse model.[34] 
However, ethanol feeding in an SREBP-null mouse resulted in only a partial reduction of hepatic 
triglyceride.[35] STAT3 activation may limit SREBP1c activation in ethanol-fed animals, as a 
hepatocyte-specific STAT3 knockout model accumulated greater lipid and showed increased 
SREBP1 induction versus wild-type controls.[36] As SREBP1c protein levels and activity may 
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be regulated by PPAR!,[37, 38]  it is possible that the failure of the SREBP1c knockout to 
completely protect against ethanol-induced effects on lipid accumulation is due to coordinate 
regulation of multiple pathways of lipid accumulation by PPAR!.
Ethanol and the TLR4-Innate Immune Signaling Axis in Kupffer cells
Toll-like Receptor Signaling Pathways. 
A second broad area of liver physiology that is impacted by CE exposure involves signaling 
pathways of innate immunity (Figure 2.)  Kupffer cells (KpfCs) play a major role in hepatic 
innate immunity and the development of ALD [39]. KpfCs, along with other cell types in the 
liver, express the Toll-like Receptor 4 (TLR4) which responds to endotoxin and results in 
production of  pro-inflammatory cytokines such as Tumor Necrosis Factor Alpha (TNF!.)[40] 
TNF! alpha plays an important role in the pathobiology of alcoholic liver disease, as 
administration of anti-TNF! antibodies or utilization of a TNF-Receptor 1 knockout mouse 
resulted in diminished liver injury in an enteral CE feeding model.[41, 42]
A major concept in the pathogenesis of liver injury in the setting of CE exposure postulates that 
endotoxin from commensal gram-negative gut flora enters the hepatic portal vein as a 
consequence of CE-induced heightened gut permeability, with subsequent stimulation of KpfCs. 
ALD has been correlated with increased portal vein endotoxin levels.[43, 44]  Gut permeability 
may be increased by ethanol-induced increases in levels of mir212, a microRNA that 
downregulates proteins of the zona occludens in intestinal cell culture, and whose levels are 
higher in human colonic biopsy samples in patients with ALD.[45] Alternatively, studies in other 
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Figure 2.  The Endotoxin-Innate Immune Signaling Axis in Ethanol mediated liver injury.  
Ethanol causes increased gut permeability and results in exposure of the liver to LPS.  
Components of the LPS receptor complex, including TLR4, MD2, and CD14 are upregulated by 
ethanol. TLR4 and CD14 are essential for the development of ALD.  Alcohol causes hyper-
responsiveness in downstream signaling from the TLR4 receptor leading to increased 
inflammatory cytokine production, which is potentiated by alcohol induction of P47 and PDE4B, 
and suppressed by alcohol induction of STAT3.  The TRIF-dependent limb of the TLR4 pathway 
is essential for alcohol-induced liver injury, and leads to TNF! induction via NF#B activation. 
TNFR knockout or anti-TNF!antibody prevents TNF! -induced apoptosis.  ERK1 signaling is 
upregulated by ethanol, prevented by adiponectin, and leads to increased EGR1, which 
contributes to enhanced NF#B activation. Ethanol upregulates hepcidin expression in the 
hepatocyte, which leads to increased gut iron uptake, one mechanism for the ethanol-induced 
increase in KpfC iron. Increased KpfC iron contributes to LPS hyper-responsiveness.
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models suggest a role for TNF!, IL-6, and other inflammatory cytokines in altered gut 
permeability.[46, 47]
 In the circulation, free endotoxin is in equilibrium with endotoxin bound to LPS Binding 
Protein (LBP). LBP facilitates the dissociation of LPS into a monomeric form that enhances LPS 
transfer to TLR4 and its associated co-receptors, CD14 and MD-2.[48] Both KpfC CD14 
expression and hepatic LBP binding protein were demonstrated to be upregulated by CE, 
offering some insight into the manner by which CE confers hypersensitivity to LPS stimulation 
(LPS hyper-responsiveness.)[49] The effect of CE on TLR4 or TLR2 mRNA is more 
controversial, as CE feeding for several weeks did not result in any change in TLR4 or TLR2 
expression.[50] However, another model demonstrated an increase in the mRNA expression of 
almost all TLRs in response to a shorter term (10 day) ethanol feeding protocol.[51] 
Demonstrating the dependence of ALD on TLR4 signaling, CD14 knockout mice in an 
intragastric CE model had less ALT elevation but had similar increase in liver-weight to body-
weight ratios as wild-type mice, [52] while LBP knockout mice fed on an intragastric CE model 
had diminished ALT, inflammation, and necrosis and diminished liver weight/body weight ratios 
in comparison to wild-type mice. No changes were observed in CYP2E1, TGFB1, or portal vein 
endotoxin levels, but IL-6 and TNF! were reduced in LBP KO mice versus controls.[53] 
 Signaling through the TLR4 receptor complex results in activation of at least two distinct 
intracellular signaling cascades.[54] The first of these, the MyD88 (Myeloid Differentiation 
Primary Response Gene 88) -dependent pathway utilizes the common adaptor protein MyD88 
that is used by all TLRs with the exception of TLR3.[55] The MyD88 dependent pathway leads 
to activation of the Nuclear Factor Kappa B (NF#B ) and subsequent stimulation of TNF!. A 
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second pathway of TLR4 dependent signaling, the MyD88-independent pathway, converges with 
a TLR3 signaling pathway utilizing the adaptor molecule Tir-domain-containing-adaptor-
inducing-IFNB (TRIF). TRIF activation results in production of type I interferons through the 
Interferon Regulatory Factor-3 (IRF3), and delayed NF#B activation.[56, 57] A recent finding 
reported from our laboratory is that the hepatoprotective effect of TLR4 knockout is independent 
of the MyD88 pathway.[58] MyD88-knockout mice developed steatosis and elevated ALTs after 
CE similar to wild-type mice, though TLR4-knockout mice were protected from this effect. The 
involvement of the MyD88-independent TLR4 signaling pathway was indicated by upregulation 
of Interferon-Regulatory-Factor 7 (IRF7), an IRF3-inducible gene, in KpfCs. [55] A recent study 
corroborates this finding using TRIF pathway knock-out animals, as TRIF knockout mice were 
protected against alcoholic liver injury, showing diminished lipid accumulation by microscopy 
and normalized ALT after CE plus endotoxin injection.[59] In that model, the authors argued for 
an IRF3-dependent mechanism of LPS hyper-responsiveness and TNF! secretion, using 
strategies including mutation of the IRF3 response element in a TNF! promoter fragment. 
The Nuclear Factor Kappa B
The Nuclear Factor Kappa B (NF#B) serves as a master regulator in the inflammatory response. 
NF#B subunits are normally sequestered in an inactive form but pro-inflammatory stimuli, such 
as TLR4 ligand stimulation, cause NF#B activation and TNF! production. Some NF#B activity 
is essential to prevent massive hepatocyte apoptosis in response to TNF!.[60, 61] NF#B 
activation in response to ethanol has been widely investigated in many hepatic and non-hepatic 
cell types. In isolated human monocytes, AE suppresses NF#B activation and the inflammatory 
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response to LPS by inhibiting p65 phosphorylation and I#K activity, but CE causes LPS 
hypersensitivity and NF#B activation.[62] Changes in LPS sensitivity have been linked to 
chromatin remodeling in other experimental systems.[63] 
 Several other mechanisms of regulation of NF#B signaling have been investigated in 
KpfCs. Among these, recent work utilizing a myeloid-lineage specific cre-recombinase enzyme 
to achieve specific deletion of Stat3 in KpfCs revealed that STAT3 signaling is essential to 
suppress inflammatory cytokine production from KpfCs from CE-fed mice.[36] Several lines of 
evidence implicate oxidative stress as a cause of ethanol-induced LPS hyper-responsiveness in 
macrophages. Adiponectin, which prevented steatotic change in CE, also exerts modulating 
effects on KpfCs, and was shown to downregulate LPS-responsive TNF! secretion in a fashion 
dependent on NF#B and the transcription factors EGR-1 and AP-1.[64]
Cyclic AMP. 
Another line of evidence implicates ethanol-induced decreases in cyclic AMP as a mechanism 
for LPS hyper-responsiveness in macrophages. CE was shown to increase phosphodiesterase 4-
B(PDE4B), which in turn degrades cyclic AMP. Treatment of human and murine macrophage 
cell lines with an inhibitor of PDE4B  diminished the LPS-induced increase in TNF!. [65]
MAPK.
Other lines of evidence implicate oxidant stress pathways as mediators of LPS hyper-
responsiveness in CE. Knockout of the Early Growth Response-1 (EGR-1) transcription factor 
conferred protection against the development of liver injury after CE feeding.[66] Following 
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lines of evidence that indicated that Extracellular-signal-regulated kinase-1 (ERK-1) promotes 
LPS hyper-responsiveness in macrophages stimulated with ethanol, potentially by upregulation 
of EGR-1, Thakur and coworkers examined the role of NADPH-derived reactive oxygen species 
(ROS) in macrophages.  Treatment of macrophages with an inhibitor of NADPH oxidase (DPI) 
prevented TNF! secretion from macrophages in a p38-dependent manner. However, CE feeding 
prevented DPI from changing the ratio of phosphorylated p38 observed in pair-fed animals. 
Administration of DPI suppressed LPS-stimulated ERK  phosphorylation, even in ethanol fed-
animals, suggesting that ERK phosphorylation is indispensable to TNF! secretion in response to 
LPS, but that ethanol exerts actions through NADPH-oxidase-independent mechanisms that 
affect the p38 MAPK and NF#B pathways. [67] 
Macrophage Iron
CE causes iron accumulates in hepatocytes and macrophages.[68] Ethanol upregulates the 
transferrin receptor in primary rat hepatocytes.[69] CE also may increase gut uptake of iron via 
downregulation of the iron transport hormonal mediator, hepcidin. Hepcidin, produced by 
hepatocytes, has been demonstrated to suppress iron uptake by the small bowel, and low levels 
of hepcidin have been observed in patients with ALD as well as in mouse models of CE feeding.
[70] Additionally, alcohol disrupted iron-stimulated production of hepcidin from the liver, thus 
interrupting a negative feedback loop between serum iron and gut iron absorption.[71]
 Iron accumulation in macrophages is associated with enhanced NF#B activation in 
ethanol feeding models.[72] Administration of iron dextran to CE-fed mice resulted in higher 
ALT and TNF!, and worsened liver inflammation.[73] Other investigators suggest a role for 
17
  
endotoxin in increasing macrophage free iron, and propose a heme-oxygenase-1 dependent 
mechanism.[74]
Ethanol and Immunity
 The liver has a well-characterized role in immunity, containing large numbers of tissue 
macrophages (KpfCs), plasmacytoid and myelocytoid dendritic cells (DC), T lymphocytes, 
natural killer (NK) cells, and natural killer-T cells (NKTs). Virtually all of these cell types have 
been demonstrated to be affected by CE.[75] Stellate cells have commanded significant interest 
due to evidence indicating their pivotal role in fibrotic change in the liver. [76, 77]  
 Broadly speaking, the central role of the endotoxin-mediated inflammatory cascade in 
ALD occurs in parallel with immunosuppressive effects of ethanol.[78] Ethanol is associated 
with increased susceptibility to bacterial infections, including salmonella, listeria, and others, 
particularly pulmonary infections.[79]  Recognition of invading pathogens and initiation of 
innate and adaptive immune responses relies on the function of antigen presenting DCs, the 
function of which is impaired by ethanol.[80] DC populations in the liver are found in an 
immature phenotype, which may contribute to a tolerogenic environment.[80]
Ethanol Abuse and Antiviral Immunity
Alcohol abuse is a major cofactor for the development of cirrhosis and hepatocellular carcinoma 
in patients with chronic hepatitis B and C, and has been shown to be a predictor of negative 
outcomes in patients with chronic HCV or HBV.[81] Several lines of evidence implicate 
dysregulated cellular signaling events in the increased risk of disease progression in the setting of 
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viral exposure.  Ethanol suppresses the effectivity of interferon therapy as a disease-modifying 
agent in HCV infection.[82]  The molecular mechanisms of these effects remain unclear. Ethanol 
potentiates HCV viral replicon expression in vitro.[83]  Ethanol activates the interferon-response 
element (ISRE), P38 and Jak/Stat signaling pathways in hepatocyte cell lines and fetal 
hepatocytes. AE inhibited HCV viral replication, but AE also suppressed the ability of IFN to 
inhibit HCV viral replication.[84] However, the application of these findings to CE are unclear. 
In Huh7 cells, co-expression of HCV core protein and alcohol induction of CYP2E1 additively 
increased mitochondrial ROS production and cellular death.[85]  Taken in the aggregate, the 
weight of evidence suggests that ethanol impairs the  host anti-viral response.
Alcohol and Autoimmune Host Response
Aside from the pathways of innate immunity described above, ethanol has significant effects on 
adaptive immunity that contribute to hepatic inflammation and dysfunction via several distinct, 
though potentially overlapping mechanisms. First, CE results in increased circulation of 
acetaldehyde and malondialdehyde, both of which can form antigenic adducts (singularly or in 
tandem) with native liver proteins.[86]   Second, the prolonged inflammation, necrosis, and 
apoptosis present in ALD exposes damaged cellular material to immature antigen-presenting 
cells in the liver, which may cause autoantibody formation.[87]  Supporting this, increased serum 
TNF! in patients with ALD was associated with higher prevalence of antibodies against oxidized 
cardiolipin and malondialdehyde-albumin adducts.[88] Autoantibodies were also demonstrated 
to be more prevalent in patients with ALD than non-drinking alcohol consumers.[89] This study 
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has been verified by others which have described increased IgG and IgA autoantibodies in 
patients with ALD versus moderate or non-alcohol consuming control subjects.[90]
 60-80% of patients with alcoholic hepatitis or cirrhosis may have anti-phospholipid 
antibodies (aPl). A recent study by Vay et al. offers good evidence that aPl in ALD recognize 
oxidized phosphatidylserine residues on apoptotic cell membranes. Incubation of aPl serum from 
ALD patients with synthesized phosphatidyl serine micelles diminished their ability to bind 
apoptotic cells, and serum from ALD patients was able to target the plasma membrane of 
apoptotic HepG2 cells stimulated with ethanol.[87]  
 Anti-CYP2E1 antibodies are also highly prevalent in patients with ALD. In one study, up 
to 86% of cirrhotic patients had sera with positivity for immunoreactivity against CYP2E1.[91] 
Anti Cardiolipin antibodies are also reported to occur more frequently in patients with ALD than 
liver disease from other causes or healthy control subjects.[92]  Antibodies are produced in the 
adaptive immune response by B lymphocytes.  The effect of ethanol on B cells remains 
controversial. Although polyclonal hyperglobulinemia and increased circulating autoantibodies 
are found in alcoholics, recent investigations in a mouse model of chronic ethanol consumption 
demonstrates little effect of ethanol on B cell numbers.[93]
Summary and Conclusions
 The disease-promoting effects of ethanol consumption on hepatic parenchymal and non-
parenchymal cells is a complex phenomenon that incorporates changes at many different levels. 
On the one hand, the passage of ethanol through the metabolic pathways towards acetaldehyde or 
through the CYP2E1 system alters the cellular redox state, creates ROS, and alter lipid metabolic 
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pathways to favor lipid accumulation. While these changes are priming the hepatocyte to have 
increased susceptibility to TNF!-mediated apoptosis, ethanol is simultaneously inducing hyper-
responsiveness to gut-derived endotoxin in hepatic Kupffer cells. The inflammatory effect of 
these changes induces recruitment of other cell types, including T cells, NK cells, and NKT cells, 
and the production of autoantibodies that further exacerbate liver injury. In the past decade, the 
use of transgenic mouse models, including cre-lox tissue specific knockout/knock-in models, has 
offered great insight into disease mechanisms.  Future work promises additional insight towards 
the development of treatment strategies for the array of disease caused by alcohol use.
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CHAPTER 1B.  
Hypoxia Inducible Factors: Diverse Roles in Hepatic Health and Disease
 The unique anatomical and functional niche occupied by the liver within the body 
profoundly affects its physiology and pathophysiology.  Afferent blood flow to the liver derives 
from both highly oxygenated blood in the hepatic artery as well as oxygen-depleted blood in the 
hepatic portal vein.  Furthermore, the directional flow of mixed oxygenated and deoxygenated 
blood towards the central vein of the hepatic lobule creates a physiological oxygen gradient.[94]  
This gradient has been reported to result in oxygen tensions from about 60-65mmHg in 
periportal blood, falling to about 30-35 mmHg in perivenous portions of the liver parenchyma; 
by comparison, physiological arterial oxygen concentration in most other body tissues is about 
74-104 mmHg, and venous oxygen concentration is 34-46 mmHg.[94]
 Hypoxia has profound consequences for the body tissues of an aerobic organism, and 
would rapidly lead to organ dysfunction and organismal death were it not for finely regulated 
homeostatic responses to low oxygen tension.  In the past several decades, our knowledge of the 
homeostatic response to hypoxia has increased, expanding from reflexive neural regulation of 
physiological parameters, such as respiratory rate and heart rate, to humoral factors affecting the 
avidity of hemoglobin-oxygen binding, such as 2-3 bisphosphoglycerate, and finally to 
molecular genetic mechanisms.  The Hypoxia Inducible Factors are a family of heterodimeric 
transcription factors that act as master regulators of a homeostatic transcriptional response to 
hypoxia in virtually all cells and tissues of the body.  Active Hypoxia-Inducible Factor (HIF) 
consists of an alpha subunit and a beta subunit.  Three alpha subunits, named Hypoxia Inducible 
Factor 1-! [HIF1!], Hypoxia Inducible Factor 2-! [HIF2!, also known as the Endothelial Per-
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Arnt-Sim Domain-containing-1, EPAS1], or Hypoxia Inducible Factor 3! [HIF3!], have been 
described in humans, mice, and rats; all bind to a common % subunit named, alternatively, 
HIF1% , or the Aryl-Hyrdocarbon-Nuclear Receptor Translocator [ARNT].[95]  Active HIF is 
named by its alpha subunit, hence, HIF1 is the active transcription factor consisting of HIF1! 
and ARNT, HIF2 is the dimer of HIF2! and ARNT, etc.  HIF1 and HIF2 are the major hypoxia-
inducible factors in humans, mice, and rats.  Far less is known about the function of HIF3, which 
is thought to act as a dominant-negative suppressor of HIF activity in some systems.[95]  (Figure 
3).  The hyroxylase mediated mechanism of oxygen-dependent HIF regulation is summarized in 
Figure 3. 
 Post-translational degradation by the proteasome is known to be a major pathway of HIF 
regulation.  Under conditions of normoxia, and in the absence of other metabolic or molecular 
perturbations, the alpha subunits of HIF are rapidly hydroxylated by prolyl-hydroxylases (PHD1, 
PHD2, or PHD3) and scaffolded on a multimeric protein complex that includes the product of 
the Von Hippel Lindau tumor suppressor gene.  Prolyl hydroxylation and presentation of HIF on 
the VHL scaffold leads to rapid ubiquitination and proteasomal degradation.[96]  Under 
conditions of hypoxia, or perturbations in cellular redox state, HIFs escape hydroxylation and are 
free to form dimers with ARNT.  Active HIF then translocates to the nucleus, where it binds to 
hypoxia-responsive elements (HREs) in the promoter region of target genes. HIF1 and HIF2 
activate transcription of a broad range of target genes with some overlap between the two factors 
[97].  
Oxygen and the liver
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 Numerous reports have offered evidence that the physiological gradient of oxygen 
tension across the hepatic lobule has profound effects on the function of hepatic parenchymal 
and nonparenchymal cells.  Periportal hepatocytes and perivenous hepatocytes differ in their 
expression of many enzymes involved in glucose transport or metabolism, including insulin 
receptor, glucagon receptor, phosphoglycerate kinase (PGK1), L-type pyruvate kinase, and 
numerous others.[98-100]  Consequently, periportal hepatocytes tend to sub-specialize in 
oxidative energy metabolism, glucose production, and synthesis of urea and bile, whereas 
perivenous hepatocytes are major sites of glucose uptake, glutamine formation and xenobiotic 
metabolism.[94]
 Physiological exposure of hepatocytes to varying levels of oxygen tension also has 
consequences for the ability of hepatocytes to respond to hypoxic stress.  Primary rat hepatocytes 
cultured in conditions approximating periportal oxygen tensions were able to survive transient 
anoxia with less cell death and cytokine release than hepatocytes cultured in conditions 
approximating perivenous oxygen tension.  This suggests that in conditions of oxygen 
deprivation, such as increased hepatic metabolic demand, tissue ischemia, or other conditions, 
not only are the perivenous hepatocytes exposed to lower oxygen conditions, but despite chronic 
exposure to low oxygen tensions perivenous hepatocytes may be primed to increased injury 
when oxygen tension drops beneath a threshold level.[101]  Indeed, centrilobular or perivenous 
hepatic necrosis is pathognomonic for ischemic hepatitis. 
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Figure 3.  A General Schematic of HIF1! activation.
Under conditions of normoxia, HIF alpha subunits are rapidly hydroxylated at proline and 
asparagine residues by hydroxylase enzymes.  Hydroxylation of HIF1! and assembly on a 
protein scaffold consisting of the VHL tumor suppressor, along with other co-factors, results in 
the rapid ubiquitination of the alpha subunit and subsequent degradation by the proteasome.  
Conversely, in conditions of hypoxia, HIF alpha subunits escape degradation and are free to 
dimerize with the binding partner, the Aryl Hydrocarbon Nuclear Translocator (ARNT).  The 
HIF heterodimer is named by the alpha subunit (hence, HIF1!-ARNT heterodimer is the active 
HIF1 transcription factor) which translocates to the nucleus and affects transcription of target 
genes, typically by binding to a hypoxia response element in the upstream promoter region of the 
target gene.
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Ischemia-Reperfusion Injury and Ischemic Hepatitis
 The role of HIF1! in ischemia-reperfusion injury is controversial.  Variable results have 
been reported in different tissues.  For example, HIF1! siRNA pretreatment was able to protect 
against ischemia-reperfusion brain injury in rats.[102]  In a different study, however, 
upregulation of HIF1! was associated with protection in cardiac post-conditioning, suggesting 
that HIF1!  activation is an adaptive response.[103]  Heterozygous HIF1!(+/-) mice were unable 
to respond to ischemic preconditioning.[104]  Yet another group found that renal ischemia-
reperfusion injury was prevented by acute inactivation of VHL (leading to HIF1! upregulation), 
prolyl hydroxylase inhibition, or by xenon preconditioning (again, with upregulation of HIF1!.)
[105-107] 
 In liver, HIF1! induction was described as an early event, preceding apoptosis, in 
ischemia-reperfusion injury.[108]  Others identified adenosine-dependent HIF1! activation as a 
protective event in late preconditioning.[109]  Ischemia induced HIF1! and subsequent 
upregulation of the transferrin receptor, which may contribute to iron-species related liver injury 
in reperfusion.[110]  Reperfusion, alternatively, was associated with decreased HIF1! DNA 
binding.[111]  Delivery of a soluble VEGF antagonist was reported to reduce ischemia-
reperfusion injury by inhibiting leukocyte migration and cytokine production, including TNF! 
and MCP-1, and  indicating that HIF1!-dependent gene transcription may simultaneously be  
cytoprotective and pro-inflammatory in hepatic ischemia/reperfusion.[112]
 A major concern in much of the work on HIFs in ischemia reperfusion injury is the 
reliance on HIF1! as the sole marker of hypoxia-dependent transcriptional activity.  Further 
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work may reveal upregulation of other isoforms, such as HIF2!, that may have similar or 
divergent effects.
 Hypoperfusion of the liver can also lead to hepatitis, a clinical entity described as 
ischemic hepatitis.   In this condition, a rapid, though reversible, increase in serum ALT is 
accompanied by centrilobular necrosis.[113]  In septic shock, ischemic hepatitis was described to 
occur in 13% of patients in one recent series.  The development of ischemic hepatitis was 
associated with a significant increase in mortality.[114]
 Ischemic hepatitis can arise as a complication of multiple primary disease processes, 
including hypovolemic shock in sepsis, cardiogenic shock, diabetic ketoacidosis, or hemorrhagic 
shock.  In one series of 31 patients with ischemic hepatitis, cardiac factors were present in all 
patients, though cardiogenic ischemia was attributed as a causative factor in 77% of patients.   
The remainder of cases in that series were due to hypovolemia from hemorrhage, excessive 
dialysis or diuresis, or sepsis.  94% of patients in the study[113]had evidence of right sided heart 
failure, and most had relatively brief durations of hypotension (15-20 minutes.)[113]  In a larger 
series of 142 patients, 56% of patients had congestive heart failure, and 14% had acute cardiac 
failure, with the remainder due to acute respiratory failure  (13%) or circulatory shock (13%).
[115]
 Hypoxic hepatocytes have been reported have increased expression of Bcl2/adenovirus 
EIB Interacting Protein 3 (BNIP3).  BNIP3 translocated into cytoplasm under conditions of low 
oxygen tension, including a murine model of ischemic liver injury, and knockdown of BNIP3 
was able to ameliorate hepatocyte cell death in an in vitro model of hypoxic injury. [116]
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Obstructive Sleep Apnea
 An association has been described between obstructive sleep apnea (OSA) and non-
alcoholic fatty liver disease and/or NASH, but remains controversial.[117]  Several studies have 
linked OSA, and in particular, the incidence of apneic-hypopneic episodes, to elevation of liver 
enzymes and the histologic appearance of NASH.[118, 119]  A major confounding factor is the 
frequent comorbidity of obesity and/or the metabolic syndrome; however, one recent study 
suggested that even among obese patients, nocturnal oxygen desaturation contributed to insulin 
resistance and liver injury, including fibrosis, inflammation and ballooning necrosis, but not the 
appearance of steatosis.[120]  A study of 83 patients with OSA and matched controls suggested 
that there was a relationship between OSA and progression of steatosis to steatohepatitis, based 
on serum levels of type III procollagen.[121]  In a larger study of 218 patients with OSA, severe 
OSA (defined as greater than 50 Apneic/Hypopneic episodes/hour, AHI) was associated with an 
increased liver enzymes (OR 5.9, p<0.02).  Patients with AHI greater than 50/hour were also 
much more likely to have steatosis, lobular necrosis, and fibrosis by liver biopsy.[122]   
 Several studies in mouse models have offered some data to corroborate this observation.  
In one study, chow-fed mice were exposed to either room air or 12 hours of room air and 12 
hours of chronic, intermittent hypoxia (CIH,  approximately 5% oxygen for periods of 30 
seconds followed by 21% oxygen for periods of 30 seconds).  After 12 weeks on the CIH 
regimen, mice developed increased serum ALT, serum triglycerides, and serum cholesterol, as 
well as increased NF#B DNA- binding activity in liver nuclear extracts.[123]   In mice 
genetically predisposed to obesity, CIH increased liver triglycerides and phospholipids, as well 
genes of lipid biosynthesis, including SREBP1c, Acetyl-coenzyme A Carboxylase, and Steroyl-
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CoA Desaturases 1 and 2.[124]  In a third study, WT mice were maintained on a high-fat diet and 
exposed to either room air (21% oxygen) or room air with period of intermittent hypoxia (as 
described above) for six months.  At the conclusion of the study, CIH mice had a marked 
elevation in serum AST and ALT, some increase in inflammatory cytokines, and increased serum 
and liver malondialdehyde, myeloperoxidase, and alpha-1 collagen; however, liver triglycerides 
were unchanged, and only a mild enhancement of oil-red O staining was observed in CIH-treated 
mice.[125]  The lack of an increase in steatosis (as quantified by increased oil-red O and liver 
triglyceride) in this model is surprising, but perhaps not unexpected given the significant 
metabolic stress induced by 6 months of high-fat-diet feeding.
Acetaminophen Poisoning
 The model that is emerging from these studies suggests that milder periods of hypoxia, 
such as moderate OSA, are insufficient by themselves to cause progression to hepatitis/
steatohepatitis.  However, when CIH is added to a primary insult, such as diet-induced steatosis, 
there is a predilection towards progression of liver injury.  Corroborating evidence from other 
disease models includes the observation that sublethal acetaminophen poisoning resulted in 
fulminant liver failure when given in combination with CIH.  [123]  A more recent extended this 
work by combining CIH with daily injections of low-dose acetaminophen (APAP, 200mg/kg) in 
mice for 4 weeks.  At the end of the study period, CIH/APAP mice had markedly elevated liver 
enzymes, including serum AST, ALT, GGT, and total bilirubin whereas no elevation was 
observed in mice with APAP alone, and only AST increased in mice with CIH alone.[126]
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 Some evidence related the HIF pathway and acetaminophen toxicity.  HIF1! nuclear 
protein was observed to accumulate within 1 hour after a toxic dose (300mg/kg) of APAP; this 
increase in HIF1! was prevented by N-Acetylcysteine.[127]  Pretreatment with Salidroside, an 
extract of an herbal compound used in Chinese medicine to ameliorate mountain sickness, was 
able to prevent ALT, AST, and serum TNF! in a mouse model of sublethal APAP toxicity when .  
Though HIF1! immunostaining was reported to be suppressed by salidroside pretreatment in that  
study, no immunoblots or mRNA data was presented.[128]  It is unknown whether the role of 
HIF1! in APAP injury is protective or deleterious; for example, treatment of APAP-challenged 
mice with hyperbaric oxygen was able to improve survival, even though it increased HIF1 
protein and the downstream target Glut1.[129]
Alcohol Mediated Liver Injury
 As has been previously reviewed, chronic ethanol has diverse effects on cellular signaling 
and profoundly affects cellular metabolism and organ physiology.[130]  The development of 
hypoxia in alcohol-exposed liver has also been reported and reviewed elsewhere.[131]  Exposure 
of thin liver slices to acute ethanol was reported to increase oxygen consumption over three 
decades ago.[132]  Acute ethanol causes a rapid increase in liver metabolism, including rapid 
induction of alcohol detoxifying enzymes and hepatic oxygen consumption within 2-3 hours.
[133]  More recently, acute ethanol was found to result in increased areas of staining using the 
hypoxia-specific marker pimonidazole; this effect appeared to be at least partially dependent on 
functional  hepatic Kupffer cells.[134]  This finding was replicated by the same group in a model 
of chronic continuous enteral alcohol treatment.[135]  
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 The metabolism of alcohol in the liver is complex and proceeds by at least three 
mechanisms.  First, and possibly best known, is the oxidation of alcohol to acetaldehyde by 
alcohol dehydrogenase (ADH) in a reaction that coordinately creates the reduced species NADH.  
Second, CYP2E1 catalyzes a hydroxylation of alcohol via an NADPH-dependent mechanism, 
primarily in the hepatocyte endoplasmic reticulum.  Lastly, peroxisomal catalase enables 
oxidation of alcohol via an H2O2-dependent mechanism.[94]  Each of these steps alters the 
cellular redox state and can result in the production of highly reactive oxygen intermediates.
 Recent gene array data from ethanol-fed and pair-fed mice demonstrated upregulation of 
multiple genes in the glycolytic pathway, as well as genes in lipid metabolic pathways in the 
livers of chronically alcohol fed mice.[136]  Although not explored in that publication, most, if 
not all of these genes may be regulated by HIF1!.  An earlier report suggested an upregulation of 
HIF1! mRNA in the livers of chronic alcoholics.[137]  One group offered some data to indicate 
that HIF1! mRNA is cyclically regulated with the urinary alcohol cycle in a model on 
continuous, intragastric ethanol feeding.[138]  More recently, in the hypercholesterolemic 
ApoE(-/-) mouse, ethanol significantly increased HIF1! protein in liver, and a synergistic 
upregulation with tobacco smoke was observed.[139]
 In addition to these mechanisms, it has been well established that alcoholic liver disease 
proceeds in part through a combination of prolonged metabolic insult coupled with activation of 
signaling through innate immune mechanisms. Given the role of HIFs in innate immunity as 
described further below, it is quite possible that the contribution of HIFs to alcoholic liver 
disease proceeds both through pathways of innate immunity as well as through pathways in the 
hepatocyte, including hepatic lipid accumulation.
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Hypoxia inducible factors and immunity
 In alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH), activation of 
Toll-like receptors by gut-derived endotoxin has been demonstrated to contribute to disease 
pathogenesis.[140]  Several reports indicate that activation of HIF1! plays a pivotal role 
downstream of LPS signaling through TLR4.  LPS upregulated hepatic HIF1! in rats, as well as 
HIF1! target gene aldolase.[141]  In macrophages, LPS stimulation was able to upregulate 
HIF1! target genes, including VEGF, PAI-1, and iNOS, as well as HIF DNA binding and HIF1! 
mRNA and protein.[142] Using a cre-lox system of targeted HIF1! mutation to a 
transcriptionally inactive form, one group recently reported that knockdown of HIF1! 
transcriptional activity in cells of the myeloid lineage (LysMCre/HIFflox/flox mice)  resulted in 
protection from LPS-induced sepsis.  LysMCre/HIFflox/flox mice had lower levels of pro-
inflammatory cytokines, including IL-6, IL-12, and TNF!, and maintained blood pressure and 
body temperature in the face of LPS challenge at levels that induced septic shock in wild-type 
mice.[143]  Subsequent work indicated that LPS-induced HIF1! activity is dependent upon 
transcriptional regulation through the inflammatory master regulator group of proteins NF#B.
[144]  NF#B transcriptional activity is predominantly regulated through the inhibitory action of 
Inhibitor of #B proteins (I#B), which themselves are targeted for degradation by phosphorylation 
via the action of I#B Kinases (IKK!, IKK%, the latter being the major isoform.)  IKK% deletion, 
then, renders cells unable to phosphorylate I#B and thereby inhibits NF#B signaling.  
Stimulation of bone-marrow-derived macrophages from mice in which IKK% had been deleted 
by cre-lox mediated recombination (IKK%-null mice) resulted in diminished HIF1! target gene 
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mRNAs.  Additionally, HIF1! mRNA was suppressed in  IKK%-null mice prior to any 
stimulation, indicating that NF#B may regulate HIF1! at the transcriptional level.[145]  Other 
investigators have found that virtually all NF#B subunits can transactivate the HIF1! promoter, 
that TNF! treatment recruited the NF#B subunits RelA and P65 to the HIF1! promoter, and that 
blockade of both IKK!  and IKK% proteins was required to suppress NF#B-induced HIF1! 
activation.[144]
 Although a role for HIF1! activation in NASH has not been thoroughly investigated, 
pharmacological inhibition of IKK proteins, analogous to IKK%-null strategies, was able to 
prevent steatosis and the development of NASH. IKK-inhibitor-treated animals on a high sucrose 
diet displaying lower levels of steatosis, hepatic triglyceride, and diminished secretion of pro-
inflammatory cytokines including IL-6, and TNF!.  Additionally, IKK-inhibitor treated animals 
were protected from the development of fibrosis.[14]  
 These data suggest that the activation of the pro-inflammatory cascade downstream of 
LPS-TLR4 signaling may be at least partially dependent upon functional HIF1!  signaling. In 
contrast, in other cell types, some data suggests that HIF1!  may suppress T-cell mediated 
inflammation.  HIF1! knockout in T-lymphocytes prevented sepsis and mortality after cecal 
ligation and puncture (CLP), and T-Cell specific HIF1!(-/-) mice had significantly lower levels 
of serum ALT 72 hours after CLP challenge than WT mice.[146]  Knockout of HIF1!  in T-and 
ex-vivo stimulation of T-cells from T-cell specific HIF1! (-/-)  mice resulted in higher levels of 
IL2 and IFNg, suggesting that the survival benefit of T-Cell specific HIF1!  knockout may be at 
least partially due to a derepression of HIF1!  inhibition of pro-inflammatory cytokine release.
[146]
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Hypoxia inducible factors: a common mechanism of lipid accumulation?
 Multiple lines of evidence suggest that hypoxia and/or HIF may play a role in hepatic 
lipid accumulation. Numerous studies have implicated a role for hypoxia in altering lipid storage 
in various cell types.  Rats exposed to chronic hypoxia accumulated foam cells in pulmonary 
alveoli.[147]  Hypoxia was described to cause lipid-loading of macrophages, and this effect was 
prevented by HIF1! siRNA treatment.[148, 149]  The differentiation of 3T3-L1 preadipocytes to 
an adipocytic phenotype was found to be partially dependent on HIF2!, which is 
transcriptionally regulated in adipocytic differentiation.[150]  Forced expression of HIF1! in 
cardiomyocytes resulted in increased lipid accumulation, and was correlated to a suppression of 
peroxisome-proliferator-alpha DNA binding.[151]  A recent study in breast cancer cell lines 
demonstrated an increase in HIF1 expression downstream of Akt signaling resulting in an 
increase in fatty acid synthase (FAS) which is over-expressed in several types of solid tumors.
[152]
 In hepatocytes, germline deletion of HIF2! resulted in neonatal death and a phenotype of 
severe steatosis.[153]  Although this study suggests that the absence of HIF2! predisposes to 
steatosis, numerous other studies in vitro and in vivo have suggested that this observation does 
not apply to the role of HIFs in the adult liver.  Hepatocyte specific deletion of the VHL gene is 
accompanied by a phenotype of hypervascularity and steatosis.[154] Simultaneous introduction 
of degradation-resistant transgenic constructs of HIF1! and HIF2! resulted in a similar 
phenotype of hepatic lipid accumulation; in that study, introduction of degradation-resistant 
HIF1! alone caused a mild phenotype of lipid accumulation, and introduction of degradation-
resistant HIF2! alone caused a phenotype of hypervascularity, including the formation of 
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cavernous hemangioma, without lipid accumulation.[97]  More recently, a different group 
described lipid accumulation in a murine model of liver-specific HIF2 activation.[155]  In that 
study, mouse models with cre-lox mediated deletion of VHLH, HIF1!, and/or HIF2! resulted in 
mice in which both HIF1 and HIF2 or only one or the other isoform was active.  HIF2 appeared 
to play a major role in regulating hepatic lipid by various mechanisms, including the 
upregulation of lipid biosynthetic pathways, the suppression of fatty acid %-oxidation, or 
upregulation of the lipid droplet surface protein ADFP.[155]
HIFs and metal accumulation in liver disease
Iron accumulation has a role in the pathogenesis of several hepatic diseases, including alcoholic 
liver disease, and hereditary hemochromatosis.  Macrophage iron increased the severity of 
alcoholic liver disease in a rodent model.[73]  In conditions of chronic iron deficiency, iron 
export is limited by production of hepcidin, which in turn degrades the iron efflux protein 
ferroportin.  Using a model of hepatocyte specific HIF1! deletion,  Peysonnaux and colleagues 
demonstrated that functional HIF1! is partially responsible for the downregulation of hepcidin in 
chronic iron deficiency.[156]  In support of this, ARNT-knockout mice, which are completely 
defective in HIF signaling, accumulated high levels of iron.[157]  Hypoxia Inducible factors 
have been implicated in gut iron absorption, where some recent data showed that deletion of 
HIF2!, but not HIF1!, in intestinal cells resulted in downregulation of serum iron and intestinal 
expression of the divalent metal ion transporter-1 (DMT1) .[158] A similar effect of HIF1! 
expression on DMT1 was observed in HEPG2 cells.[159]  
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Liver Fibrosis
 Recent evidence also indicates a profound effect of HIF1 on cholestatic liver injury.  
Moon et al.  recently described the effect of HIF1! deletion in bile-duct ligated mice, a model of 
cholestatic liver injury.  Mice with a floxed HIF1! exon were mated to Mx-Cre mice.  The Mx-
Cre promoter enables near total excision of floxed genetic elements in cells of the immune 
system and the liver and partial deletion in other body tissues following serial injections of poly-
I:C.  Deletion of HIF1! was followed with bile duct ligation (BDL) or sham ligation.  In WT 
mice, an increase of pimonidazole stained areas and accumulation of HIF1! was observed as 
early as 3 days following BDL.  Both HIF1!flox/MxCre and WT mice displayed similar 
increases in ALT, AST, and serum bile acids, but HIF1!flox/MxCre mice were protected from 
increases in collagen synthesis and alpha-smooth muscle actin staining, both markers for tissue 
fibrosis, as well as profibrotic mediators including PAI-1 and Platelet-Derived Growth Factor 
(PDGF) A and PDGF-B.[160]  In a series of in vitro experiments, the same group reported that 
production of profibrotic mediators was induced by culturing mouse hepatocytes in 1% oxygen.  
Using  an siRNA approach, the authors demonstrated that the production of profibrotic mediators 
was completely prevented in ARNT-null cells, but only partially prevented in HIF1!-null cells, 
suggesting that other HIF isoforms (particularly, HIF2) play a role.[161]
 These data in support of a role for HIF in liver fibrosis are rendered more compelling by 
evidence in other models of liver fibrosis.  After five weeks of once-weekly diethylnitrosamine 
(DEN) injections (100mg/kg), pronounced collagen septa may be observed, and progression to 
cirrhosis is observed by 8 weeks.  Collagen mRNA transcripts were increased in isolated hepatic 
stellate cells cultured under hypoxia.  In DEN-treated mice, Vascular Endothelial Growth Factor 
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(VEGF) isoforms were increased with increasing time of treatment, becoming strongly positive 
by northern blot and immunohistochemical staining by 8 weeks of DEN treatment, and were 
correlated with increase in tissue hypoxia as observed by pimonidazole staining.[162] 
 In vitro models have been in concordance with the previous findings.  Stellate cell 
activation has been described as an initiating factor in liver fibrosis.  Exposure of the hepatic 
stellate cell line LX-2 to hypoxia stimulated HIF1! and VEGF mRNA accumulation by 8 hours, 
and was associated with evidence of increased signaling through the TGFb-SMAD dependent 
pathway.  Comparison of a gene array using LX-2 cells in normoxia and hypoxia revealed 
several targets, including fibroblast growth factor-4, that have been implicated in fibrogenesis or 
[163]inflammation.[164]  Another study also reported activation of HSC by hypoxia, and 
demonstrated that this activation was accompanied by secretion of proangiogenic cytokines, such 
as VEGF and  ANG-1, which were able to stimulate HSC chemotaxis in an autocrine or 
paracrine fashion.
Viral Hepatitis
 Several studies have illuminated the role of HIFs in the pathogenesis of viral hepatitis, 
including hepatitis B, hepatitis C, and hepatitis E.   In a series of HCC cases secondary to 
primary HBV infection, Hepatitis B Virus  X protein [HBx] was found to correlate with HIF1! 
expression, and transfection of HBx in HepG2 cells was found to increase HIF1! protein 
accumulation.[165]   An earlier study similarly reported the stabilization of HIF1! protein in the 
presence of the HBx protein, and that this stability correlated with promoter activity of HIF1 at 
the Multi Drug Resistance-1 protein, an efflux drug transporter thought to be primarily 
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responsible for chemoresistance in HCC.  HIF1! siRNA treatment was able to abolish the 
activation of an MDR-1-luciferase construct induced by HBx transfection.[166]  These findings 
were confirmed and extended in another study that reported that HBx protein increased levels of 
Metastasis Associated Protein 1 (MTA1) and Histone Deacetylase 1 (HDAC1).  These two 
proteins in turn physically associated with HIF1!, and contributed to HIF1! stability.[167] 
 The hepatitis E virus (HEV) open reading frame protein 3 (ORF3) is a viral protein 
thought to be required for infection.  In an in vitro system of hepatocyte cell lines expressing 
HEV ORF3, upregulation of several glycolytic pathway enzymes was reported, and correlated 
with increased expression and DNA-binding activity of HIF1!.  This expression was correlated 
with increased Akt phosphorylation as well as increased phosphorylation of the CBP/p300 
transcriptional co-activator via an ERK-dependent mechanism.[168]
 Hepatitis C infection may interact with the HIF1! pathway via multiple mechanisms.  
Huh7 cells expressing the HCV core protein were reported to have increased VEGF expression 
and increased HIF1! DNA binding by EMSA; this binding was partially abrogated in the 
presence of PD98059, an ERK inhibitor.[169]  Transient HCV infection in Huh7 cells was 
associated with HIF1! stabilization by 3 days; furthermore, in Huh7 cells expressing subgenomic 
HCV replicons, HIF1! was also stabilized.  This stabilization again appeared to be dependent on 
multiple kinase and transcriptional pathways, as functional ERK and PI3K inhibition was able to 
prevent HIF1! protein accumulation, as was Stat3 inhibition and NF#B inhibition.  HIF1! 
stability was accompanied by production of functional VEGF. [169]
 
HIF in liver regeneration
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 HIF1! is rapidly induced in liver after partial hepatectomy, and remains upregulated for 
up to 24 hours.[170]  Prolactin treatment was able to increase the proliferative response after 
partial hepatectomy, and was also able to upregulate HIF1! protein and VEGF.[171]  However, 
in another study, hyperbaric oxygen pretreatment, which upregulates HIF1! protein, was unable 
to accelerate liver regeneration after partial hepatectomy; however, BRDU uptake, and indicator 
of cellular proliferation, was upregulated in hepatic sinusoidal endothelial cells.[172]
Oncostatin M (OSM) is an IL-6-type cytokine secreted by leukocytes that has been described to 
have a role in liver regeneration, liver development, and angiogenesis.[173]  A recent report 
offered data to demonstrate that OSM is able to up regulate HIF1! protein levels and HIF1! 
target genes, including PAI-1 and VEGF, in a Stat3 dependent mechanism.  Further, the 
upregulation of HIF1 appeared to be at the transcriptional level.[173] 
Hepatocellular Carcinoma
 Significant evidence indicates that the HIFs play an important role in the pathogenesis 
and pathophysiology of hepatocellular carcinoma.    HIF1! and VEGF were found to be 
expressed at higher levels in dysplastic nodules and implicated in malignant transformation.[174]  
This finding was confirmed in humans and extended by the description of HIF1 expression in 
chemically-induced preneoplastic lesions in mice.[175] Notably, this expression was independent 
of tissue hypoxia, as HIF1 positive areas did not differ from other regions of the liver in terms of 
needle-electrode measured oxygen tension and pimonidazole staining; however, HIF1 levels 
were effectively reduced by treatment with the PI3K inhibitor LY294002, raising the possibility 
of a PI3K-Akt dependent mechanism [175].  Recent data also suggest that inhibition of HIF may 
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have a role in cancer therapy.  Nonresectable hepatocellular carcinomas may be treated by 
transarterial catheter embolization (TAE) in which tumor vessels are occluded via catheter-
guided placement of a coil or other occluding agent.  Drawbacks of this approach include an 
uncertain survival benefit, as well as a possible induction of tumor neovascularization following 
TAE.  Following the observation that neovascularization of embolized tumors proceeds with 
upregulation of VEGF, delivery of antisense oligonucleotides against HIF1! in combination with 
TAE was able to improve efficacy of TAE in promoting tumor necrosis and preventing 
neovascularization.  Furthermore, in that study, the ability of tumor cells to survive on glycolytic 
metabolism alone (the so-called Warburg effect) was inhibited through suppression of HIF1! 
glycolytic target genes, including the glucose transporter GLUT1 and Lactate Dehydrogenase A.
[176]  
 The data from clinical studies paint a similar picture.  In one series of cases, up to 50% of 
HBV-association hepatocellular carcinomas expressed high levels of HIF1!, and HIF1! 
expression correlated with metastases and decreased survival.[165]  Poor prognosis was also 
associated with expression of Metastasis Associated Protein-1 (MTA-1), which is described as a 
stabilizer of HIF1!.  Patients with MTA-1 positive cancer had larger tumors with increased 
incidence of microvessel invasion and nodal extension.  The incidence of extrahepatic metastases 
was almost twofold higher (23% versus 12%, p<0.001) in patients with MTA positive lesions 
than in patients with MTA negative lesions.  The prevalence of MTA-1 positive staining was 
higher in patients with HCC secondary to primary HBV infection than from other causes, 
including HCV infection or nonviral etiologies.[177]
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 Both HIF1! and HIF2! isoforms have been reported to be overexpressed in 
hepatocellular cancer.  In one series of patients, HIF2! expression was found to be present in 
52% of HCC, and correlated with tumor size, capsule infiltration, portal vein invasion, and 
necrosis.[178]  A subsequent larger study found HIF2! expression in 69.5% of HCC cases, as 
well as 55% of adjacent tissue, but no expression in noncancerous tissue, suggesting that HIF2! 
expression may be a preneoplastic feature of tumors or a feature of tumor-associated stroma.  In 
that study, high HIF2! expression was also correlated with vascular endothelial growth factor 
expression, microvessel density, and decreased survival.[179]
 HIF1! inhibition may play a role in anticancer therapeutics.  RNA-mediated inhibition of 
HIF1! was able to slow tumor growth.[180]  The antitumor efficiency of doxorubicin was 
increased when combined with a HIF1! antisense oligonucleotide.[181]  Rapamycin inhibits 
signaling by the Mammalian target of Rapamycin (mTOR) complex pathway, and has shown 
some efficacy against hepatocellular carcinoma.  The prevention of HCC tumor growth by 
rapamycin in a rodent model was correlated to suppression of HIF1! by rapamycin.[182]  
Another compound, silibinin, was demonstrated to have some antitumor efficacy through 
phosphorylation of mTOR, and was also associated with suppression of HIF1! signaling.[183]
Summary
 Hypoxia has been implicated in the pathogenesis of a wide range of hepatic disease. 
(Figure 4)  In most of these models, some data exists to implicate a role for hypoxia inducible 
factors.  Consideration of the role of HIFs in liver diseases should include multiple cell types, as 
HIF1! activity has been implicated in hepatocytes as well as myeloid (Kupffer cells) and 
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lymphoid (T-cells) lineage immune cells.  Taken collectively, these findings strongly suggest that 
anti-HIF therapies will be greatly useful in the management of hepatic diseases of various 
etiologies.
 With regards to alcoholic liver disease, there are several broad questions that remain 
unresolved.  First, if HIFs are related to lipid accumulation, as some studies have suggested, a 
remaining question is whether an upregulation of HIF1! contributes to hepatic lipid 
accumulation in alcoholic liver disease.  For example, much of the information we have that 
relates HIFs to lipid accumulation relies on the use of conditional knockouts of VHL or HIF 
overexpression systems, which may manifest steatosis as an artifact of transgene expression.  
Hence, the first group of experiments described below were designed to rigorously establish a 
role for HIFs in ALD by examining protein, mRNA, DNA binding, and expression levels of 
target genes.  Though those studies, described below in Chapter 2, establish correlative evidence 
between the phenotype of alcoholic liver disease and detection of HIF isoform expression and 
activity, the question of the specific contribution of HIFs to steatosis in ALD remains unresolved.  
Three broad strategies were used to answer that question, first examining hepatocyte-specific 
HIF1! overexpression in a murine model of ALD, and determining that the presence of the 
HIF1! transgene was sufficient to drive increases in lipid accumulation.  The effect of HIF1! on 
lipid accumulation was then replicated in vitro, using a model system of in vitro lipid 
accumulation in a hepatoma cell line along with  plasmids that encoded active HIF-! isoforms or 
siRNAs targeting HIF-! subunits.  These experiments offered further strong evidence that HIF1! 
activation leads to increased lipid accumulation.  Following the finding that inhibition of the 
HIF1! subunit prevented lipid accumulation in vitro, we then sought to determine whether 
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limiting HIF1! activity would be able to prevent the development of ALD.  Using a Cre-Lox 
system with a floxed HIF1! allele, and by expressing Cre recombinase under control of two 
different promoters, we investigated the effect of limiting HIF1! activity in hepatocytes or cells 
of the myeloid lineage.  
 The latter experiments, described in chapter 5, also begin to consider another remaining 
question on the development or progression of alcoholic liver disease, namely, what the relative 
contribution of cell types in the liver is to the development of ALD, and whether HIF1! 
expression is a determinant of ALD in hepatocytes, cells of the myeloid lineage, or both.  As the 
progression of ALD appears to occur with repeated inflammatory attacks on a background of 
steatotic hepatocytes, one question is whether hepatocytes exposed to chronic ethanol actually 
participate in the inflammatory response, or whether it is solely a Kupffer cell mediated effect.  
In the latter case, in particular, steatotic hepatocytes may be more prone to cell death after 
proinflammatory stimulus.  In the former case, chronic alcohol-exposed hepatocytes themselves 
may contribute to the inflammatory response.  In support of that possibility, we report in chapter 
5 that modifying HIF1! activity in hepatocytes has a profound effect on the secretion of 
cytokines after chronic alcohol exposure.
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Figure 4.  Hypoxia Inducible Factors Across the Spectrum of Liver Diseases
(A.)  Normal livers have zonal oxygen gradients, and regions of relative hypoxia.  HIF1a, HIF2a, 
and HIF3a mRNA is observed.  (B, C, D) Chronic alcohol, Non-Alcoholic Fatty Liver Disease, 
and obstructive sleep apnea are all disease conditions that are related to steatosis.  The phenotype 
of fatty liver has been recapitulated by HIF activation in mouse models.  (E, G). Both non-
alcoholic and alcoholic steatohepatitis are marked by inflammatory processes downstream of 
TLR pathways, particularly TLR4; activation of TLR4 and subsequent release of TNFa may be 
influenced by HIF activation.  (F) Cholestatic liver injury can result in fibrosis; inducible knock-
out of HIF1a in a mouse model of bile-duct ligation was able to prevent fibrosis.  (G) Fibrosis is 
also marked by stellate cell activation, which has been shown to have some dependence on 
hypoxia.  (H) Chronic alcoholic steatohepatitis may also progress to fibrosis; the role HIF1a in 
this process is unknown, but may resemble HIF activation in other forms of fibrosis. (I) Ischemic 
hepatitis is marked by centrilobular necrosis and profound tissue hypoxia.   (J) Viral proteins in 
several forms of viral hepatitis can activate HIF1a.  (K) HIF1a is implicated in iron and copper 
metabolism, and thus may be related to the pathology observed in Wilson’s Disease, 
Hemochromatosis, and chronic alcoholism.  (L) HIF1a accumulation is an early event in 
acetaminophen-induced liver injury.   (M) Some upregulation of HIF mRNA was reported in 
cirrhosis.  (N) Hepatocellular cancer is often marked by HIF activation, which can be associated 
with aggressive phenotype and worse prognosis. 
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CHAPTER 2
HYPOXIA INDUCIBLE FACTORS IN A MURINE MODEL 
OF ALCOHOLIC LIVER DISEASE
Summary
Chronic ethanol consumption leads to a spectrum of liver pathology that begins with hepatic 
lipid accumulation, or steatosis, and may progress with prolonged inflammatory insult to 
steatohepatitis and cirrhosis; the latter being a major risk factor for hepatocellular carcinoma.  
The liver in chronic alcohol abuse develops regions of hypoxia, and scattered data have 
suggested that hypoxia-inducible factors may be upregulated in the livers of patients with 
alcoholic liver disease.  In the studies that follow, we offer evidence for the activation of hypoxia 
inducible factors in a murine model of chronic alcohol feeding.  We establish that HIF1! and 
HIF2! are upregulated at the protein and the mRNA level.  We further offer evidence that HIF 
protein is functional, based on increased HIF DNA binding using the electrophoretic mobility 
shift assay (EMSA).  We analyze expression of several genes that are downstream targets of 
HIF1, and demonstrate that some, but not all, HIF1 target genes are upregulated by chronic 
alcohol feeding.  
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Introduction
 Alcoholic liver disease [ALD] can be viewed as a spectrum of disorders ranging from the 
mild and reversible (e.g., steatotic accumulation) to the life-threatening and irreversible 
(cirrhosis).  The cellular and molecular mechanisms that contribute to damage in ALD continue 
to be elucidated, and over the past several decades, numerous paradigms have been proposed, 
including the pivotal inflammatory role of tumor necrosis factor alpha (TNF-alpha) signaling 
downstream of Toll-like-Receptor-4 (TLR4) stimulation by gut-derived endotoxin.
 The Hypoxia Inducible factors  (HIFs) are a family of heterodimeric transcription factors 
that promote a homeostatic transcriptional response to low oxygen tension.  Mature HIF is 
composed of one of three isoforms of an alpha- subunit (HIF1!, HIF2!, or HIF3!) and a ! 
subunit, the major isoform of which is termed HIF1! or the Aryl-Hydrocarbon Receptor Nuclear 
Translocator (ARNT).  Under conditions of normal oxygen tension, the alpha subunits of HIF are 
rapidly degraded in the cytoplasm.  The major pathway of degradation involves scaffolding of 
the alpha subunits on the protein product of the Von-Hippel Lindau tumor suppressor gene, 
where they are hydroxylated on specific proline residues.  Proline hydroxylation of HIF alpha 
subunits leads to their ubiquitination and degradation by the proteasome.  Under conditions of 
low oxygen tension, HIF alpha subunits escape hydroxylation and dimerize with HIF1B/ARNT, 
translocate to the nucleus and activate hypoxia response elements (HRE) in the genome.  HIFs 
are named by their alpha subunit, with HIF1 and HIF2 having a wide, overlapping but non-
identical set of transcriptional targets.  Recent investigation with a murine model of hepatocyte 
specific HIF activation demonstrated that simultaneous activation of HIF1 and HIF2 results in a 
phenotype of hepatomegaly with macrovesicular lipid accumulation.[97]  In that stud, activation 
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of HIF1 alone resulted in minimal lipid accumulation, while activation of HIF2 alone resulted in 
gross vascular changes without any appreciable increase in hepatic lipid.  However, the 
relationship of this phenotype to human diseases characterized by steatosis, e.g., alcoholic 
steatosis or non-alcoholic fatty liver disease, remains to be elucidated.
 Scattered data from the research literature support a role for hypoxia-inducible factors in 
the spectrum of ALD.  Liver hypoxia has been documented in rats on a continuous ethanol diet, 
and some investigators suggest that a process analogous to ischemia-reperfusion injury may be 
implicated.  Others have postulated an increase in HIF1 mRNA as a mechanism of ethanol-
induced liver injury.  However, the direct contribution of HIF1 to alcoholic liver injury is 
unknown.  
 We hypothesized that HIF1s protein would be upregulated in the livers of mice after 
chronic ethanol feeding.  As HIF1! is primarily regulated by post-translational hydroxylation and 
degradation though the ubiquitin-proteasome pathway, we postulated that changes in HIF1 levels 
might not correlate with changes in HIF1! mRNA.  Because both HIF1! and HIF2! were 
required for maximal lipid accumulation in a mouse model of constitutive activation of HIF 
isoforms, we postulated that both HIF1 and HIF2 protein would be increased with chronic 
ethanol feeding.  Finally, we hypothesized that an increase in HIF1 protein would be 
accompanied by an increase in the mRNA of HIF1 target genes.
 In this chapter, we present evidence that HIF1!  is upregulated in an oral, ad libitum 
model of ethanol-induced liver injury.  C57Bl6 mice were maintained on the Lieber-DeCarli 
ethanol-containing diet for four weeks. In order to demonstrate that functional HIF1 is increased 
in the livers of ethanol-fed mice, we utilize western blotting to show increased HIF1!  protein 
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and EMSA to demonstrate increased HIF DNA binding.  This increase in HIF1 expression 
correlated with the expression of some, but not all, HIF1 target genes.  In addition to HIF1, we 
present evidence that HIF2! protein is increased in the livers of mice maintained for four weeks 
on the Lieber De Carli ethanol-containing diet. Finally, we offer evidence that the hepatic 
regulation of HIF1!  and HIF2! with chronic alcohol is not only at the post-translational level, 
but that significant upregulation of HIF1! mRNA is also observed.
Methods
Animal Studies
All animals received care in compliance with protocols approved by the Institutional Animal Use 
and Care Committee of the University of Massachusetts Medical School.  For all mouse studies, 
mice were gradually habituated to a Lieber-DeCarli liquid diet with 5% ethanol (volume/volume) 
over a period to two weeks, then maintained on the 5% diet for four weeks.  Consumption was 
recorded daily, and isocaloric amounts of a non-alcohol containing diet (in which dextran-
maltose replaced calories from ethanol) were dispensed to pair-fed animals.  Weights were 
recorded before the introduction of the diet and weekly thereafter.  Wild-type mice (C57/Bl6) 
were purchased from Jackson Laboratories (Bar Harbor, Maine).  At the conclusion of the 
feeding, mice were weighed and euthanized.  Livers were excised and weighed, and divided and 
portions were snap frozen in liquid nitrogen for protein and biochemical assays, preserved in 
10% neutral-buffered formalin for histopathological analysis, or soaked in RNALater (Qiagen 
GmbH, Hilden, Germany) for RNA extraction.  Blood was collected and serum separated for 
biochemical analysis. 
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Biochemical Analysis
Serum alanine aminotransferase (ALT) was determined using a commercially available reagent 
(Advanced Diagnostics Inc, Plainfield, NJ).  Briefly, 15ul of serum was mixed with 100ul of 
reagent diluted according to the instructions of the manufacturer, and UV absorbance at 37 
degrees celsius was measured over three minutes.  The average change in absorbance per minute 
interval is then multiplied by a conversion factor to yield ALT levels.
For liver triglyceride levels, liver whole-cell lysates were prepared as described below and lipids 
separated by isopropanol precipitation of non-lipid components.  A commercially available kit 
(Wako Chemicals USA Inc., VA) was used to determine the triglyceride concentration.
Protein concentrations were determined by adding 1uL of whole-cell lysate or nuclear extract to 
Bradford reagent (BioRad) and by measuring the difference between absorbance at 650nM and 
595nM on a 96 well plate using a plate reader. Concentrations were determined using a standard 
curve of bovine serum albumin.
RNA analysis
RNA was purified using the RNeasy Mini kit (Qiagen Sciences, Maryland, USA) with on-
column DNA digestion (ProMega).  cDNA was prepared using random hexamer primers and the 
Reverse Transcription System kit (Promega Corp., Madison WI).  Real-time quantitative 
polymerase chain reaction was performed using an iCycler (Bio-Rad laboratories Inc., Hercules, 
CA), using specific primers.  Primer sequences are shown in  Table 1.  Fold-change in gene 
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Table 1:  Mouse Real-Time PCR Primers.
PAI-1
F: 5’-ATG CCA TCT TTG TCC AGC GG-3’
R: 5’-TTG GTA TGC CTT TCC ACC CAG-3’
ADRP
F: 5’ CTG TCT ACC AAG CTC TGC TC-3’
R: 5’-CGA TGC TTC TCT TCC ACT CC-3’ 
DEC1
F: 5’ CAT TTG CAC TTC AGG GAT T-3’
R: 5’ GCA CTT TCT CCA GCT GAT CC-3’
VEGF
F: 5’ CAT CTT CAA GCC GTC CTG TGT-3’ 
R: 5’ CAG GGC TTC ATC GTT ACA GCA-3’
HIF1a-
F: 5’- CAA GAT CTC GGC GAA GCA A-3’
R: 5’- GGT GAG CCT CAT AAC AGA AGC TTT-3’
HIF2a-
F: 5’-CCC AAG ACG GTG ACA TGA TCT-3’
R: 5’-CGC AAG GAT GAG TGA AGT CAA A-3’
EGLN3 
F: 5’-AGG CAA TGG TGG CTT GCT ATC-3’
R: 5’-GCG TCC CAA TTC TTA TTC AGG T-3’
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expression was determined by normalizing to a house keepig gene (18S mRNA) and calculating 
gene expression by the ""Ct method.  
Histopathological Analysis
Sections of formalin-fixed livers were stained with hematoxylin/eosin and analyzed by 
microscopy.
Whole Cell Lysate
60mg of liver tissue was washed and subsequently homogenized in lysis buffer (9.5ml RIPA 
buffer, 1mM NaF, 2mM Na3VO4, 1 protease inhibitor tablet, 500ul PMSF) using rotor-stator 
homogenization.  After 10 minutes of incubation on ice, homogenates were centrifuged at 
10,000RPM for 10 minutes at 4 degrees C.  The supernatant was collected and stored in aliquots 
at -80 degrees C.
Nuclear Extraction
60mg of snap-frozen liver tissue was washed in 10-fold excess volume TKM-0.32 buffer (0.32 
molal sucrose, 50mM Tris-HCl, 25mM KCl, 5mM MgCl, 5mM PMSF, with protease inhibitor 
tablets (1 per 10ml of buffer, Sigma) and homogenized using a rotor-stator homogenizer (Ika).  
Homogenates were transferred to microcentrifuge tubes and centrifuged (10mins/1000rpm/4 
degrees C.)  Pelleted material was resuspended in TKM-2.0 buffer (2 molal sucrose, 50mM Tris-
HCl, 25mM KCl, 5mM PMSF) and homogenized again by rotor-stator.  Pellets were collected by 
centrifugation (60mins/14000rpm/4 degrees C) and resuspended in 400ul Buffer A (10mM 
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Hepes/KOH, pH 7.9,  2mM MgCl, 1mM EDTA, 10mM KCl, 1mM DTT, 5mM PMSF, 1 
protease inhibitor tablet/5ml buffer).  Pellets were again collected by centrifugation (2mins/
14000rpm/4 degrees C) and resuspended in 50ul Buffer B (10mM Hepes/KOH pH 7.9, 2mM 
MgCl, 1mM EDTA, 50mM KCl, 300mM NaCl, 2mM DTT, 5mM PMSF, 1 protease inhibitor 
tablet (Sigma) per 5mL buffer, 10% glycerol).  Resuspended material was frozen at -80 degrees 
overnight, thawed with gentle agitation at 4 degrees C.  Supernatant containing nuclear extract 
was collected after centrifugation (10mins/14000rpm/4 degrees C) and assayed for protein 
concentration.
Electrophoretic Mobility Shift Assay
A consensus double-stranded Hypoxia Response Element (HRE) (Santa Cruz Biotech, CA) 
oligonucleotide was used for EMSA. End-labeling was accomplished by treatment with T4 
kinase in the presence of [32P]ATP. Labeled oligonucleotides were purified on a polyacrylamide 
copolymer column (BioRad). Five micrograms of nuclear protein was added to a binding 
reaction mixture containing 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM 
DTT, 250 mM NaCl, 20% glycerol, 20 &g/ml BSA, 2 &g poly(dI–dC) and 30,000 c.p.m. of 32P-
labeled NFB oligonucleotide. Samples were incubated at room temperature for 30 min.  
Reactions were run on a 5% polyacrylamide gel and the dried gel was exposed to an X-ray film 
at –80°C overnight.  Cold competition was done by adding a 20-fold excess of specific unlabeled 
double-stranded probe to the reaction mixture.  Band density was quantified using Labworks 4.0 
image analysis.
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Western Blotting
30-50ug of nuclear extract was resolved on 10% polyacrylamide gels and transferred overnight 
to nitrocellulose support.  Membranes were blocked overnight with blocking buffer (5% bovine 
serum albumin in Tris-Borate-SDS with 0.01% Tween 20) with refrigeration, and subsequently 
probed overnight with anti-HIF1! (R&D Biosciences) or anti-HIF2! (Chemicon) mouse 
monoclonal antibodies.  Detection was performed using an anti-mouse horseradish-peroxidase 
conjugated secondary antibody and chemiluminescent substrates.  Band density was  quantified 
using Labworks 4.0 image analysis.
Results
Liver pathology in ethanol fed mice
 We first undertook to reproduce liver pathology in an oral, ad libitum murine model of 
chronic alcohol-mediated liver injury.  Six-to-eight week-old C57/Bl6 mice were gradually 
habituated to a liquid diet, and subsequently randomized into alcohol-fed or pair-fed groups.  In 
the alcohol fed groups, the liquid diet was gradually supplemented with increasing percentages 
of 100% ethanol until a final ethanol concentration of 5% (v/v) was achieved.  Consumption was 
recorded daily, and a control liquid diet that was isocaloric by volume to the ethanol-containing 
diet was prepared and dispensed to pair-fed animals.  Over the five-week course of the feeding, 
weights were recorded weekly, and revealed similar weight-gain between pair-fed and ethanol-
fed animals. (Figure 5A).  
 At the conclusion of the feeding, mice were sacrificed and livers and sera were collected.  
Because chronic ethanol consumption is known to induce steatosis, we first examined the weight 
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of excised livers and expressed this weight as a ratio to the sacrifice weight of the animal.  We 
confirmed that ethanol fed mice had hepatomegaly as evidenced by higher liver-weight to body-
weight ratios than pair-fed mice (Figure 5B).  Hepatomegaly in chronic ethanol alcohol related 
liver injury is secondary to steatosis.  Thus we sought to quantify the triglyceride content in liver 
tissue, as liver triglycerides are known to accumulate in response to chronic ethanol feeding.  
Lysates were prepared from portions of snap-frozen liver and analyzed for triglyceride content 
using a biochemical assay.  In order to correct for inequalities between different initial tissue 
weights and sample-to-sample error in processing, final triglyceride concentration is expressed as 
a ratio to the protein concentration in each sample.  As expected, triglyceride concentration in 
liver tissue from ethanol-fed mice was elevated significantly over that observed in pair-fed mice. 
(Figure 5C) Chronic ethanol feeding is also known to result in elevation of liver enzymes 
through hepatocyte injury.  Using a biochemical assay, we found an increase in serum alanine 
aminotransferase (ALT) levels (Figure 5D). 
 We then examined the livers of ethanol-fed and pair-fed mice by histopathology.  
Formalin fixed tissue samples were processed onto slides and stained with hematoxylin and 
eosin.  Microscopy revealed significant macrovesicular steatosis, with accumulation of large 
lipid droplets, in ethanol fed animals; pair-fed animals displayed minimal lipid accumulation.  
(Figure 6)
Expression of Hypoxia Inducible Factors with chronic alcohol feeding
 We then turned to examine whether wild-type mice had increased expression of hypoxia-
inducible factors using three different strategies.  First, liver nuclear extracts were prepared and 
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Figure 5.  Parameters of Liver Injury with Chronic Ethanol Feeding in Wild-Type Mice.  
6-8 week old C57/Bl6 mice were maintained on the Lieber-DeCarli ethanol-containing diet for 5 
weeks.  All mice tolerated the diet well, and similar weight gain was observed between pair-fed 
and ethanol-fed animals (A).  Despite the similar weight gain to pair-fed animals, ethanol-fed 
animals had significant upregulation in liver-weight to body-weight ratio (B).  Serum ALT was 
measured using a biochemical assay, and it was found that ethanol fed animals had higher serum 
ALT values in comparison with pair-fed animals (C).  Whole-liver lysates were prepared and 
analyzed for protein and triglyceride concentration.  Ethanol-fed animals had higher levels of 
hepatic triglycerides (D) than pair-fed animals.
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Figure 6.  Liver Histology from pair-fed and ethanol-fed wild-type mice, H&E section.  
Pair-fed animals displayed minimal accumulation of hepatic lipid (Panels A and B, 200x and 
400x, respectively).  Ethanol fed animals displayed significant lipid accumulation in the form of 
macrovesicular steatosis (Panels C and D, 200x and 400x, respectively).
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assayed for HIF1! nuclear protein and HIF2! nuclear protein by immunoblotting.  Both HIF1! 
and HIF2! protein were significantly upregulated in ethanol-fed animals (Figure 7A-B, D-E).  
We then turned to examine mRNA levels for HIF1!  and HIF2!.  HIFs are primarily known to be 
degraded by post-translational hydroxylation and subsequent degradation of the alpha subunits 
by the ubiquitin/proteasomal system.  However, we found that HIF1! and HIF2! mRNA were 
both significantly upregulated by ethanol feeding in wild-type mice (Figure 7C and 7F). To 
confirm that HIF1! and HIF2! protein were indeed transcriptionally active, we performed an 
electrophoretic mobility shift assay (EMSA) using a commercially available HRE 
oligonucleotide.  We found a significant upregulation of HIF DNA-binding activity in ethanol-
fed animals versus pair-fed animals (Figure 8).
Functional significance of HIF expression with chronic alcohol feeding
 We then sought to determine whether HIF target gene expression was altered with 
chronic ethanol feeding.  We identified two groups of target genes: (1) by cross-referencing 
HIF1! target genes with genes known to be upregulated in chronic alcohol liver injury, we 
identified several candidate genes that were likely to be upregulated by chronic ethanol, with or 
without a HIF1! specific contribution: these included PAI-1 and inducible nitric oxide synthase 
(iNOS).  We then identified a subset of genes that were known to be upregulated by hepatic HIF1 
or HIF2 expression, but were not known to be upregulated in alcoholic liver disease, including 
Vascular Endothelial Growth Factor and Differentially Expressed in Chrondrocytes-1 (DEC1).  
We examined the levels of mRNA of these and other target genes in ethanol-versus pair-fed wild-
type mice.   We confirmed that expression of PAI-1 and iNOS was increased with chronic 
ethanol feeding.
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Figure 7.  Hypoxia Inducible Factors 1! and 2! are upregulated in the livers of chronic-
ethanol-fed mice.  In hepatic nuclear extracts, an upregulation of HIF1! protein was observed 
(Panel A).  Band density was quantified and normalized to the density of a loading control on the 
same gel. (Panel B.)  mRNA was quantified by real-time PCR, and we detected an elevation in 
HIF1 mRNA (Panel C).  Additionally, we found an upregulation in hepatic HIF2! in hepatic 
nuclear extracts (Panel D).  Similar quantification and normalization against loading control 
revealed a significant change in hepatic HIF2! protein concentration. (Panel E).  A similar extent 
of mRNA induction was also observed (Panel F).
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Figure 8.  Hepatic HIF DNA binding activity is increased by chronic ethanol.  Hepatic 
nuclear extracts were prepared and hybridized to radiolabelled DNA probe containing a HIF 
consensus sequence, or hypoxia-response element.  We found that chronic ethanol feeding 
resulted in an upregulation of HIF DNA binding activity in hepatic nuclear extracts (A).  Comp= 
competition lane; 10x unlabeled DNA probe was added to confirm specificity of binding.  Bands 
were quantified by densitometry (B).
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 (Figure 9) To our surprise, we found that expression of Vascular Endothelial Growth Factor was 
not significantly changed with alcohol feeding (Figure 9C). The HIF target gene DEC1 was also 
upregulated with chronic ethanol (Figure 9D).
 
Discussion
 Chronic alcohol feeding in C57/Bl6 mice results in an increase in liver steatosis as 
quantified by liver weight/body weight ratio, as well as increases in serum ALT and hepatic 
triglyceride as quantified through biochemical assays.  Several different mouse models of 
chronic alcohol have been used experimentally, including the Lieber DeCarli ethanol diet, 
chronic and continuous feeding through intragastric cannula, as well as alcohol supplementation 
in drinking water.[184-186]  For these and subsequent studies, we chose the Lieber DeCarli 
alcohol-containing diet, which allows mice an ad libitum access to alcohol, accurately matches 
caloric consumption between pair-fed and ethanol-fed groups, and avoids the stress and 
encumbrance of continuous intragastric feeding models.  In our hands, this model led to a 
reproducible model of liver injury observed through steatosis, quantification of liver weight/body 
weight ratio, and serum ALT levels after five weeks of feeding.
 Liver hypoxia is an established feature of alcoholic liver disease, and has been 
documented in chronic intragastric models of alcohol feeding.[135] We sought to determine 
whether HIF activation is observed in the Lieber DeCarli ethanol feeding model, and 
hypothesized that HIF activity would be increased with chronic ethanol in mouse livers.  
Consistent with our hypothesis, we found upregulation of HIF DNA binding in livers from 
chronic ethanol fed mice.  We also found increased accumulation of both HIF1! and HIF2! 
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Figure 9.  Selective HIF target gene upregulation with chronic ethanol feeding. 
Total RNA was prepared from whole liver.  Quantitative PCRs were performed using gene-
specific primers and normalized to 18S controls.  (A) Inducible Nitric Oxide Synthase showed a 
trend towards increased expression in WT ethanol fed mice.  (iNOS) (B)  Plasminogen Activator 
Inhibitor-1 mRNA was significantly increased in WT, ethanol-fed mice.  (C) Little difference 
was observed in Vascular Endothelial Growth Factor (VEGF) after chronic ethanol feeding.  (D) 
Differentially Expressed in Chondrocytes-1 (DEC-1), another HIF1! target gene, was 
significantly upregulated in livers of chronic ethanol-fed mice.
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isoforms in nuclear extracts from chronic ethanol-fed animals.  Downstream targets of HIF, 
including PAI-1 and iNOS were upregulated with chronic ethanol feeding.  Though those targets 
were already known to be upregulated by chronic alcohol, our analysis indicated that additional 
HIF targets, including DEC1, were upregulated by alcohol, though VEGF was not consistently 
upregulated by chronic ethanol in our model, suggesting other counter-regulatory mechanisms.
 Although our data provide convincing evidence for the upregulation of HIFs in the livers 
of chronically ethanol-fed mice, many questions about the functional significance of this remain.  
Based on work done in other mouse models, HIF activation could have a role in hepatic lipid 
accumulation.  Activation of HIF1! in hepatocytes resulted in a phenotype of mild lipid 
accumulation, whereas simultaneous activation of HIF1 and HIF2 in a murine model resulted in 
macrovesicular steatosis; conversely, in other models, knockout of HIF1! in combination with 
VHL knockout resulted in steatosis.  The complexity of the role of HIF in the liver, however, is 
supported by the observation that in a whole-body knockout of HIF2, gross hepatomegaly and 
steatosis was present.[187]  Additionally, HIF activation could have a role in the pathogenesis of 
liver injury with chronic ethanol through pro-inflammatory mechanisms, rather than pure effects 
on hepatic lipid accumulation.  These effects could be through recruitment and activation of 
leukocytes, and could be mediated through either hepatocytes or cells of other lineages.  In the 
following chapter, we explore the contribution of HIF1! to alcoholic liver disease by utilizing a 
mouse model of hepatocyte-specific constitutive HIF1! activation.
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CHAPTER 3
EFFECT OF ETHANOL FEEDING IN A MODEL OF HEPATOCYTE-SPECIFIC, 
CONSTITUTIVELY ACTIVE HYPOXIA INDUCIBLE FACTOR 1!
Summary
Functional HIF1 is increased in the livers of mice on the Lieber-deCarli diet, as is expression of 
some, but not all, HIF1 target genes.  To further determine the role of HIF1, we used a cre-lox 
model of hepatocyte-specific, degradation resistant HIF1!.  HIF1dPA mice were maintained on 
the Lieber-DeCarli ethanol-containing diet for up to four weeks.  We determined that the 
presence of this transgene conferred a susceptibility to increased hepatic lipid accumulation 
versus non-transgene bearing littermate controls.  The presence of several HIF1! downstream 
genes, including PAI-1, iNOS, and KC was significantly upregulated in ethanol-fed HIF1dPA 
mice compared to control mice.  Using the EMSA technique to assay DNA binding, HIF1dPA 
pair-fed mice had HIF DNA binding activity approximately equal to ethanol-fed control mice.  
Hepatic triglyceride in HIF1dPA pair-fed mice was approximately equal to that in control 
ethanol-fed mice, and increased dramatically in ethanol fed HIF1dPA mice.  Liver weight to 
body weight ratio showed a similar trend, with HIF1dPA pair-fed and control ethanol-fed mice 
having approximately equal liver weight to body weight ratios, and HIF1dPA ethanol fed mice 
having a significant elevation of liver weight to body weight ratios over HIF1dPA pair-fed mice.  
We conclude that constitutively active, hepatocyte-specific HIF1! increases the propensity to 
lipid accumulation and liver injury with chronic ethanol feeding.  These data support a role for 
HIF1! in ethanol induced steatosis.
71
  
Acknowledgements
 The LSL-HIF1dPA mice used in these experiments were the kind gift of Dr. William 
Kim, University of North Carolina, Chapel Hill, who developed them as a postdoctoral research 
fellow in the lab of Dr. William Kaelin, Dana Farber Cancer Center, Harvard University, Boston 
MA.
 The author is grateful for the assistance of Donna Catalano with mouse feedings 
associated with the work reported in this chapter.
 Multiplex cytokine array data was collected in collaboration with Karen Kodys, with 
equipment generously made available to us by the Flotte lab, and the assistance of Christian 
Mueller, PhD.
72
  
Introduction
 Much of our knowledge of the function of hypoxia inducible factors has been gained 
through innovative approaches using Cre-Lox recombinant DNA technology.  In this system, 
short (13bp) palindromic sequences of DNA known as LoxP sites are engineered to flank a target 
stretch of DNA of interest. A target stretch of DNA flanked by LoxP sites is described as 
‘floxed.’  The Cyclization Recombination protein (Cre), is an enzyme that catalyzes homologous 
recombination between palindromic sequences of DNA known as LoxP sites, resulting in 
excision of the DNA sequence between the LoxP sites.  The Cre-recombinase protein may be 
expressed under the control of promoters with varying types of specificity, including tissue 
specific (e.g., Albumin-cre for hepatocyte-specific expression) or inducible (e.g., Mx-Cre, which 
is inducibly expressed after stimulation with poly inosinic:polycytidylic acid in immune cells and 
liver tissue) promoters, with the resultant ability to tightly control levels of expression of the 
transgene of interest within specific tissues or the whole organism.
 Investigators in several laboratories have developed different approaches using Cre-Lox 
technology to study the function of HIFs.  One approach was the engineering of a mouse strain in 
which the Von Hippel Lindau tumor suppressor gene was flanked by LoxP sites (floxed VHL).  
Cre-mediated recombination resulted in tissue specific disruption of expression of the VHL 
protein (pVHL).[154]  As HIF alpha subunits are targeted for degradation by ubiquitination on a 
pVHL scaffold, pVHL deficiency leads to HIF activation in the target tissue of interest.  VHL 
inactivation in hepatocytes led to a phenotype of hypervascularity and steatosis.  However, a 
significant limitation of this approach was the possibility that other functions of pVHL are lost 
and contribute to the observed phenotype.  Thus, another approach was to engineer degradation-
73
  
resistant mutants of HIF1! and HIF2!.  The signal for ubiquitination and degradation of HIF1! 
and HIF2! is hydroxylation at specific proline residues. By site-directed mutagenesis, HIF1! and 
HIF2! alleles in which the degradation target proline residues were mutated to alanine residues 
(HIF1dPA or HIF2dPA) were engineered and introduced into murine embryonic cells.  In order 
to create tissue-specificity, a stop element flanked by loxP sites was placed upstream of the 
HIF1dPA or HIF2dPA transgenes.  Upon co-expression of the Cre-recombinase, excision of the 
stop element occurs, with subsequent expression of the degradation resistant mutant.  
Experiments with these mutants revealed that hepatocyte-specific HIF1dPA expression resulted 
in a phenotype of mild lipid accumulation, whereas hepatocyte-specific HIF2dPA expression 
resulted in a phenotype of hypervascularity with little to no observed lipid accumulation.  Co-
expression of both HIF1dPA and HIF2dPA in hepatocytes resulted in a phenotype of marked 
lipid accumulation and the formation of cavernous hemangiomas, i.e., recapitulation of the 
phenotype of hepatocyte-specific pVHL loss.[97]
 More recently, an alternate approach to study the specific functions of HIF1! or HIF2! 
has been described.  In this approach, Cre recombinase was expressed under control of the 
albumin promoted in mice with floxed VHL and floxed HIF1! and/or floxed HIF2!.  In the 
resultant offspring, the lack of pVHL enabled HIF alpha subunits to escape degradation and 
active downstream gene targets, and the simultaneous mutation of either HIF1!, HIF2!, or both 
HIF1! and HIF2! enabled dissection of their phenotypes.  Intriguingly, in this model, the 
compound mutant pVHL(flox/flox)/HIF1! (flox/flox) had the greatest degree of lipid 
accumulation, suggesting that of the two alpha subunits, HIF2! is primarily responsible for the 
phenotype of lipid accumulation.[155]
74
  
 It is difficult to reconcile the divergent results of these two carefully executed studies.  
One suggests that activation of both HIF isoforms is required for lipid accumulation, whereas 
another suggests that activation of merely HIF2! is sufficient, and would appear to explicitly 
refute the claim that activation of HIF1! is sufficient.  Complicating matters further, generation 
of a whole-organism HIF2! knockout was reported to result in a phenotype of neonatal lethality 
with extensive hepatic lipid accumulation.[153]  The approach that utilizes simultaneous 
introduction of degradation resistant HIF1! and HIF2! has the advantage that other functions of 
pVHL are retained.  The relevance of these various genetic models to human disease conditions 
in which lipid accumulates in the liver, such as NAFLD and ALD, is unclear.
 As described in chapter 2 of this dissertation, we previously found that that HIF1! and 
HIF2! protein accumulated in the nuclear fraction of livers of chronically ethanol-fed mice, and 
that this protein accumulation was accompanied by an upregulation of HIF1! and HIF2! mRNA, 
HIF DNA binding, and activation of HIF target genes.  In order to further dissect the function of 
HIF proteins in ALD, we utilized the degradation-resistant HIF1dPA mouse model.  By co-
expressing HIF1dPA with a Cre allele under the control of the albumin promoter, we generated 
mice with constitutive HIF1! in hepatocytes.  These mice were maintained on the Lieber De 
Carli ethanol diet for up to four weeks.  We found that constitutive activity of HIF1! 
dramatically increased hepatic lipid accumulation with alcohol feeding versus littermate controls. 
Furthermore, the expression of downstream targets that have been implicated in the pathogenesis 
of alcoholic liver disease, including PAI-1, TNF!, iNOS, and KC, was dramatically increased in 
HIF1dPA mice.
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Methods
Animal Studies
All animals received care in compliance with protocols approved by the Institutional Animal Use 
and Care Committee of the University of Massachusetts Medical School.  HIF1dPA mice were 
the kind gift of Dr. William Kim, UNC.  Alb-Cre mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  Litters were tagged by ear notching, and tail snips were 
collected.  DNA was isolated from tail snips using the Extract-N-Amp SYBR Green DNA 
isolation kit (Sigma).  Genotyping was performed by real-time PCR and verified by resolution of 
DNA fragments by agarose gel electrophoresis.  Due to mixed genetic background, littermates 
expressing Alb-Cre but lacking the HIF1dPA transgene were utilized as controls (Alb-Cre mice).  
For all mouse studies, mice were gradually habituated to a Lieber-DeCarli liquid diet with 5% 
ethanol (volume/volume) over a period to two weeks, then maintained on the 5% diet for four 
weeks.  Consumption was recorded daily, and isocaloric amounts of a non-alcohol containing 
diet (in which dextran-maltose replaced calories from ethanol) were dispensed to pair-fed 
animals.  Weights were recorded before the introduction of the diet and weekly thereafter.  At the 
conclusion of the feeding, mice were weighed and euthanized.  Livers were excised and 
weighed, and divided and portions were snap frozen in liquid nitrogen for protein and 
biochemical assays, preserved in 10% neutral-buffered formalin for histopathological analysis, or 
soaked in RNALater (Qiagen GmbH, Hilden, Germany) for RNA extraction.  Blood was 
collected and serum separated for biochemical analysis. 
Biochemical Analysis
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Serum alanine aminotransferase (ALT) was determined using a commercially available reagent 
(Advanced Diagnostics Inc, Plainfield, NJ).  Briefly, 15ul of serum was mixed with 100ul of 
reagent diluted according to the instructions of the manufacturer, and UV absorbance at 37 
degrees celsius was measured over three minutes.  The average change in absorbance per minute 
interval is then multiplied by a conversion factor to yield ALT levels.
For liver triglyceride levels, liver whole-cell lysates were prepared as described below and lipids 
separated by isopropanol precipitation of non-lipid components.  A commercially available kit 
(Wako Chemicals USA Inc., VA) was used to determine the triglyceride concentration.
Protein concentrations were determined by adding 1uL of whole-cell lysate or nuclear extract to 
Bradford reagent (BioRad) and by measuring the difference between absorbance at 650nM and 
595nM on a 96 well plate using a plate reader. Concentrations were determined using a standard 
curve of bovine serum albumin.
RNA analysis
RNA was purified using the RNeasy Mini kit (Qiagen Sciences, Maryland, USA) with on-
column DNA digestion (ProMega).  cDNA was prepared using random hexamer primers and the 
Reverse Transcription System kit (Promega Corp., Madison WI).  Real-time quantitative 
polymerase chain reaction was performed using an iCycler (Bio-Rad laboratories Inc., Hercules, 
CA), using specific primers.  Primer sequences are shown in  Table 1.  Fold-change in gene 
expression was determined by normalizing to 18S mRNA.  
Histopathological Analysis
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Sections of formalin-fixed livers were stained with hematoxylin/eosin and analyzed by 
microscopy. 
Whole Cell Lysate
60mg of liver tissue was washed and subsequently homogenized in lysis buffer (9.5ml RIPA 
buffer, 1mM NaF, 2mM Na3VO4, 1 protease inhibitor tablet, 500ul PMSF) using rotor-stator 
homogenization.  After 10 minutes of incubation on ice, homogenates were centrifuged at 
10,000RPM for 10 minutes at 4 degrees C.  The supernatant was collected and stored in aliquots 
at -80 degrees C.
Nuclear Extraction
60mg of snap-frozen liver tissue was washed in 10-fold excess volume TKM-0.32 buffer (0.32 
molal sucrose, 50mM Tris-HCl, 25mM KCl, 5mM MgCl, 5mM PMSF, with protease inhibitor 
tablets (1 per 10ml of buffer, Sigma) and homogenized using a rotor-stator homogenizer (Ika).  
Homogenates were transferred to microcentrifuge tubes and centrifuged (10mins/1000rpm/4 
degrees C.)  Pelleted material was resuspended in TKM-2.0 buffer (2 molal sucrose, 50mM Tris-
HCl, 25mM KCl, 5mM PMSF) and homogenized again by rotor-stator.  Pellets were collected by 
centrifugation (60mins/14000rpm/4 degrees C) and resuspended in 400ul Buffer A (10mM 
Hepes/KOH, pH 7.9,  2mM MgCl, 1mM EDTA, 10mM KCl, 1mM DTT, 5mM PMSF, 1 
protease inhibitor tablet/5ml buffer).  Pellets were again collected by centrifugation (2mins/
14000rpm/4 degrees C) and resuspended in 50ul Buffer B (10mM Hepes/KOH pH 7.9, 2mM 
MgCl, 1mM EDTA, 50mM KCl, 300mM NaCl, 2mM DTT, 5mM PMSF, 1 protease inhibitor 
tablet (Sigma) per 5mL buffer, 10% glycerol).  Resuspended material was frozen at -80 degrees 
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overnight, thawed with gentle agitation at 4 degrees C.  Supernatant containing nuclear extract 
was collected after centrifugation (10mins/14000rpm/4 degrees C) and assayed for protein 
concentration.
Electrophoretic Mobility Shift Assay
A consensus double-stranded Hypoxia Response Element (HRE) (Santa Cruz Biotech, CA) 
oligonucleotide was used for EMSA. End-labeling was accomplished by treatment with T4 
kinase in the presence of [32P]ATP. Labeled oligonucleotides were purified on a polyacrylamide 
copolymer column (BioRad). Five micrograms of nuclear protein was added to a binding 
reaction mixture containing 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM 
DTT, 250 mM NaCl, 20% glycerol, 20 &g/ml BSA, 2 &g poly(dI–dC) and 30,000 c.p.m. of 32P-
labeled NFB oligonucleotide. Samples were incubated at room temperature for 30 min.  
Reactions were run on a 5% polyacrylamide gel and the dried gel was exposed to an X-ray film 
at –80°C overnight.  Cold competition was done by adding a 20-fold excess of specific unlabeled 
double-stranded probe to the reaction mixture.  Band density was quantified using Labworks 4.0 
image analysis.
Western Blotting
30-50ug of nuclear extract was resolved on 10% polyacrylamide gels and transferred overnight 
to nitrocellulose support.  Membranes were blocked overnight with blocking buffer (5% bovine 
serum albumin in Tris-Borate-SDS with 0.01% Tween 20) with refrigeration, and subsequently 
probed overnight with anti-HIF1! (R&D Biosciences) or anti-HIF2! (Chemicon) mouse 
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monoclonal antibodies.  Detection was performed using an anti-mouse horseradish-peroxidase 
conjugated secondary antibody and chemiluminescent substrates.  Band density was  quantified 
using Labworks 4.0 image analysis.
Results
Liver Pathology in HIF1dPA mice with chronic ethanol
We began by introducing HIF1dPA and control mice to the ad libitum murine model of chronic 
alcohol feeding as previously described.  Briefly, six-to-eight week-old HIF1dPA and control 
mice were habituated to a liquid diet containing a final ethanol concentration of 5% (v/v).  
Consumption was recorded daily, and an isocaloric amount of control diet was dispensed to pair-
fed animals. Weights were recorded weekly, and revealed similar weight-gain between pair-fed 
and ethanol-fed animals. (Figure 10A).  Animals were sacrificed after 2 and 4 weeks of feeding 
with 5% alcohol-containing diet.  Analysis of liver-weight/body-weight ratios revealed increased 
liver weight/body weight in HIF1dPA mice versus controls at 4 weeks.  Specifically, HIF1dPA-
pair-fed mice and control ethanol-fed mice had a statistically significant upregulation of LW/
BW versus pair-fed controls after 4 weeks of ethanol feeding (Figure 10B).  Ethanol-fed 
HIF1dPA mice had the highest LW/BW ratios (p<0.02 versus HIF1dPA pair-fed animals.)
 Serum ALT was assessed as a measure of liver injury (Figure 10C).  HIF1dPA pair-fed 
mice had elevations in serum ALT similar to control mice fed ethanol, and significantly 
upregulated over control mice (p<0.05, HIF1dPA pair-fed versus control pair-fed.)  No further 
upregulation was observed with ethanol feeding in HIF1dPA mice.  
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We then examined liver triglycerides from whole-liver extracts prepared from ethanol fed and 
pair-fed HIF1dPA mice and control mice (Figure 10D).  Ethanol caused an upregulation of 
triglyceride in hepatic extracts in control mice at 2 and 4 weeks.  At both 2 and 4 weeks, 
triglyceride levels were higher in pair-fed HIF1dPA mice versus pair-fed control mice, (p<0.05 
for HIF1dPA pair-fed versus control pair-fed at both 2 and 4 weeks) indicating an effect of 
constitutive HIF1! on lipid accumulation in the absence of any other stimulus.  At 4 weeks, 
HIF1dPA mice fed ethanol had the highest average hepatic triglyceride content (p<0.05 versus all 
other groups).
 Formalin-fixed livers were sectioned and stained with H&E as well as Oil-Red O for 
histological analysis.  HIF1dPA mice on the control diet accumulated a significant degree of lipid 
as evidenced by macrovesicular steatosis in liver tissue sections; this lipid accumulation 
appeared to be further enhanced by ethanol feeding (Figure 11, E-H).  In contrast, control mice 
accumulated less lipid with ethanol feeding, and almost no visible lipid droplets on the control 
diet (Figure 11, A-D).
HIF protein, mRNA, and DNA-binding activity
 We then turned to examine expression of HIF alpha subunit isoforms by western blotting 
(Figure 12). Both HIF1! and HIF2! isoforms were present in the livers of HIF1dPA mice, with 
and without ethanol feeding.  HIF2! was strongly upregulated in control mice with alcohol 
feeding, in accordance with previous results. HIF1! expression was variable in control mice.
 In agreement with these findings, HIF DNA binding activity was strongly upregulated in 
HIF1dPA mice versus control mice. (Figure 13)  With ethanol, there was a trend towards 
upregulation in HIF1dPA and Alb-Cre mice; by densitometry, this was not significant.
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Figure 10.  Parameters of ethanol feeding and liver injury in HIF1dPA mice.  HIF1dPA and 
control mice were maintained on the Lieber-DeCarli ethanol-containing diet for up to 4 weeks.  
All mice tolerated the diet well, and similar weight gain was observed between pair-fed and 
ethanol-fed animals (A).  Ethanol-fed animals had significant upregulation in liver-weight to 
body-weight ratio (B).  Serum ALT was measured using a biochemical assay, and it was found 
that ethanol fed animals had higher serum ALT values in comparison with pair-fed animals.  
HIF1dPA pair-fed mice had similar serum ALT levels to control ethanol-fed mice (C).  Whole-
liver lysates were prepared and analyzed for protein and triglyceride concentration.  Ethanol-fed 
animals had higher levels of hepatic triglycerides (D) than pair-fed animals; at 4 weeks, 
HIF1dPA mice had accumulated the greatest amount of triglyceride.
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Figure 11.  Histology, HIF1dPA and control mice with Ethanol and Pair-Feeding.  Panels A-
D show Alb-Cre mice, whereas panels E-H show HIF1dPA mice.  Little lipid vacuolization is 
observed in Alb-Cre pair-fed mice (A and C), even after 4 weeks.  In contrast, ethanol-fed Alb-
Cre mice accumulated some lipid, which was more apparent histologically by 4 weeks of ethanol 
feeding (D).  In HIF1dPA mice, on the other hand, prominent lipid vacuolization was observed 
after 2 weeks on both the pair-fed and the ethanol fed diet.  By 4 weeks of ethanol feeding, gross 
steatosis and lipid accumulation was observed in most hepatocytes in HIF1dPA mice (H).
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Figure 12.  HIF1! and HIF2! subunit Western Blot.  (A and B) Nuclear HIF1! was 
prominently expressed in HIF1dPA mice, both under the pair-fed and ethanol-fed conditions.  
HIF2! was also expressed in HIF1dPA mice under all conditions.  HIF2! was also expressed in 
albumin-cre ethanol fed mice, but was not detected in Alb-Cre pair-fed mice.  The expression of 
HIF1! was variable in Alb-Cre ETOH-fed and pair-fed mice.  
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Figure 13. HIF1dPA DNA binding by EMSA, HIF1dPA and control mice.  A.  Liver nuclear 
extracts were prepared from wild-type mice fed ethanol or control diets and assayed by EMSA.  
Ethanol-fed wild-type mice showed increased HIF DNA binding.  B.  Nuclear extracts from 
ethanol-fed or pair-fed HIF1dPA or Alb-Cre mice were prepared and assayed for HIF1 DNA 
binding by EMSA.  Significant upregulation of DNA binding was observed in HIF1dPA pair-fed 
mice versus Alb-Cre pair-fed mice (P<0.01, HIF1dPA Pair-Fed versus Alb-Cre Pair-fed), 
indicating that the HIF1dPA transgene was active.  Further trends towards upregulation in 
ethanol fed Alb-Cre and HIF1dPA mice were apparent, but not significant by densitometry. Lane 
marked with a ‘x’ was loaded incorrectly and is excluded from analysis.
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Functional Significance of HIF1dPA expression
 Given the functional increase of HIF1!  DNA binding in HIF1dPA mice and the 
aggravated phenotype of hepatic injury, we then turned to examine genes downstream from HIF, 
to determine whether alcohol feeding had any effect on their expression and to correlate any 
changes with pathology.  MRNA for EGLN-3, a prolyl hydroxylase that is upregulated by HIF in 
an autoregulatory loop, was specifically upregulated in HIF1dPA mice.  Alcohol had differential 
effects on this gene at 2 and 4 weeks, causing a mild upregulation at 2 weeks but a mild 
suppression at 4 weeks.  EGLN3 expression served as an internal confirmation of HIF1dPA 
transgene expression. (Figure 14A)
 Plasminogen activator inhibitor-1 has been correlated with alcoholic liver disease by 
other investigators.[188]  We have confirmed higher expression levels of PAI-1 with ethanol 
feeding in earlier experiments using C57/BL6 mice.  PAI-1 expression was much higher in 
HIF1dPA mice than in control mice.  A trend towards upregulation was observed with ethanol 
feeding in HIF1dPA mice. (Figure 14B)
 Inducible Nitric Oxide Synthase (iNOS) is another gene that has been reported to be 
regulated by HIF and which has a role in alcoholic liver disease.  We examined iNOS mRNA 
expression, and found that HIF1dPA mice robustly increased expression of iNOS, with a similar 
trend towards upregulation observed in ethanol-fed HIF1dPA mice.(Figure 14C)
 Vascular Endothelial Growth Factor was upregulated in HIF1dPA mice, but no change 
was observed with ethanol feeding, consistent with our earlier work in C57/Bl6 mice. (Figure 
14D)
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 Other gene targets examined include Tumor Necrosis Factor-Alpha (TNF!) which was 
also upregulated in HIF1dPA mice. Although there was some further upregulation with chronic 
ethanol feeding, this difference did not prove to be statistically significant. (Figure 14E)
Upregulation of serum chemokine KC in HIF1dPA mice
 The chemokine IL8 is a neutrophil chemoattractant that is upregulated in alcoholic liver 
disease.[189]  Murine and rat homologues of this chemokine are termed KC and CINC, 
respectively, and are also reportedly upregulated in models of alcoholic liver disease.[189] 
We utilized a multiplex cytokine bead array and determined serum levels of MCP-1, MIP1B, 
IL-6, and KC.(Figure 15A). We found that ETOH-fed HIF1dPA mice had higher serum KC than 
ETOH-fed control mice (p<0.02) and pair-fed HIF1dPA mice (p<0.02), suggesting that the 
combination of HIF1! activity and ETOH may cooperatively upregulate KC.  No upregulation of 
MIP1b, MCP-1, or IL-6 was observed in HIF1dPA mice.  We also observed an increase in KC 
mRNA in HIF1dPA mice (Figure 15B).  
Discussion
 As we had previously found an upregulation of HIF1!  protein and mRNA in livers from 
chronic ethanol-fed mice, we hypothesized that HIF1!  activation in hepatocytes would 
accelerate the pathogenesis of alcoholic liver disease.  Utilizing a murine model of hepatocyte-
specific expression of a degradation-resistant mutant of HIF1! , we demonstrated that both 
ethanol and HIF1dPA expression induce lipid accumulation. Furthermore, alcohol fed HIF1dPA 
mice had increased triglyceride content in their livers, and more severe steatosis by
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Figure 14.  Real-Time PCRS for HIF1 downstream targets.  A.  The HIF1! downstream 
target EGLN3 was selected as a marker of HIF1! transgene expression, and was significantly 
upregulated in HIF1dPA mice versus Alb-Cre mice, which showed essentially flat expression of 
EGLN3. (*=p<0.03 versus controls, n>5 for each condition.).  B. Plasminogen Activator 
Inhibitor-1 (PAI-1) was upregulated in HIF1dPA mice versus Alb-Cre controls.  (p<0.01, 
HIF1dPA ET-fed or Pair-fed versus Alb-Cre controls.  C.  Inducible Nitric Oxide Synthase 
(iNOS) mRNA was upregulated several fold in HIF1dPA mice versus controls. (P<0.01, 
HIF1dPA ethanol or pair-fed versus Alb-Cre ethanol or pair-fed.)   D.  Vascular Endothelial 
Growth Factor was also significantly upregulated in HIF1dPA ethanol-fed mice versus Alb-Cre 
ethanol-fed mice.  A strong trend towards significance in HIF1dPA ethanol-fed mice was 
significant versus Alb-Cre pair-fed mice at a level of significance of P<0.07.  E.  Tumor necrosis 
factor-alpha (TNF!) was significantly upregulated in HIF1dPA mice versus Alb-Cre mice, with a 
trend towards further upregulation with ethanol feeding. (P<0.01, HIF1dPA mice versus 
corresponding  group of Alb-Cre mice.)
92
  
32
A.
B.
F
o
ld
 C
h
a
n
g
e
F
o
ld
 C
h
a
n
g
e
iNOS
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
*
*
*
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
Two weeks
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
Four weeks
*= P<0.03 versus control
EGLN3
F
o
ld
 C
h
a
n
g
e
PAI-1
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
F
o
ld
 C
h
a
n
g
e
VEGF
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
F
o
ld
 C
h
a
n
g
e
TNF-Alpha
Ethanol
Fed
Pair 
Fed
Ethanol
Fed
Pair 
fed
Alb-Cre HIF1dPA
C.
D. E.









 
 
P<0.01
P<0 01
Figure 14
93
  
Figure 15.  Serum cytokine levels in HIF1dPA and control mice with ethanol feeding.   
Serum levels of the cytokines MIP1b, MCP-1, IL-6, and KC were determined using a multiplex 
bead array(A).  Serum MCP-1 was significantly upregulated in ethanol-fed wild-type mice 
versus pair-fed controls.  (*=P<0.05 versus wild-type pair-fed group.) Other changes in wild-type 
mice (in IL-6, KC, and MIP1B) were not significant.  KC was significantly upregulated in 
HIF1dPA ethanol-fed mice.  (*=p<0.05 versus Alb-Cre pair- or ethanol-fed or HIF1dPA pair-fed 
groups.) (A).  A corresponding increase in KC mRNA was observed in HIF1dPA mice (B)
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histopathology in comparison with ethanol-fed Alb-Cre control mice, suggesting an additive 
effect in the development of steatosis.
 In the original work of Kim et al, constitutive activation of HIF1! using a HIF1dPA 
transgene resulted in mild lipid accumulation, whereas simultaneous activation of HIF1! and 
HIF2! caused significant lipid accumulation as well as pronounced vascular defects.  Drawing 
on this work, we hypothesized that hypoxia-inducible factors had a role in the pathogenesis of 
alcoholic liver disease, which is marked by hepatic lipid accumulation and inflammation.  Our 
results differed from the results of Kim et al, mainly in that in our experiments the HIF1dPA 
mice accumulated significant amounts of lipid.  This difference is readily attributable to the 
extended length of our feeding, in which mice were maintained on a calorically-dense diet with 
or without alcohol for up to five weeks (including the acclimatization period) and at sacrifice 
were several months (20 weeks) old.  In contrast, Kim et al observed these mice on a chow diet 
and sacrificed them at a much younger age.  We speculate that the difference we observe may be 
due to a cooperative effect of HIF1! expression on lipid accumulation with the effects of the diet 
with or without alcohol.
   Alcohol feeding of HIF1dPA mice resulted in some increased parameters of liver injury 
when compared to Alb-Cre littermate controls.  Notably, HIF1dPA mice and Alb-Cre mice all 
had increased liver-weight/body-weight ratios with ethanol feeding.  By four weeks of feeding, 
HIF1dPA pair-fed mice had LW/BW ratios comparable to ethanol-fed Alb-Cre mice, suggesting 
that ethanol-feeding and HIF1! activation had approximately equal effects on the development 
of hepatomegaly.  Alcohol feeding to HIF1dPA mice resulted in a further increase in 
hepatomegaly versus HIF1dPA pair-fed mice by four weeks.  This predisposition to lipid 
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accumulation in HIF1dPA mice was confirmed by histology and quantification of hepatic 
triglyceride content.  
 Ethanol feeding caused a slight increase in serum ALT levels in ethanol-fed Alb-Cre 
mice.  Although HIF1dPA pair-fed mice had levels of serum ALT that were comparable to Alb-
Cre ethanol-fed mice, ethanol feeding of HIF1dPA mice did not result in a significantly increased 
serum ALT level.     We speculate that the level of serum ALT elevation we observed was limited 
by the absence of LPS stimulation, an omission in our study.  It is possible that activation of 
HIF1! may confer some protection to steatotic hepatocytes; our prediction is that further injury, 
such as that caused by LPS stimulation, would likely overcome that protective effect and result 
in greater liver injury in HIF1dPA mice.  Inclusion of such a group would be expected to reveal 
greater differences among ethanol-fed and pair-fed mice, and may have revealed further 
predisposition to injury in the HIF1dPA mice.
 Interestingly, HIF1! and HIF2! subunit expression was detected in all HIF1dPA mice; 
additionally, HIF2! protein was detected in Alb-Cre ethanol fed mice.  These findings coincide 
with those of Kim et al, reporting that constitutive activation of both HIF1 isoforms induced lipid 
accumulation.
 When downstream gene expression was examined, several-fold upregulation of several 
genes including PAI-1, iNOS, VEGF, and TNF-a was observed in HIF1dPA livers versus control 
livers.  The expression of these genes, several of which have been reported as upregulated in 
alcoholic liver injury, may relate to the higher level of lipid accumulation and liver injury 
observed in ethanol-fed HIF1dPA mice.  For example, the use of PAI1(-/-) mice or 
pharmacological PAI-1 inhibition resulted in prevention of steatosis with chronic ethanol in one 
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mouse model.[190]  However, numerous questions remain about the relationship of HIF1! 
downstream genes to lipid accumulation.  We also observed some differences in gene 
expression between Alb-Cre control mice and C57/Bl6 mice.  Notably, the gene expression 
levels of iNOS and PAI-1 were relatively unchanged with ethanol feeding in Alb-Cre mice, 
whereas a statistically significant upregulation of these targets was observed with alcohol feeding 
in C57/Bl6 mice.  There are two possibilities that might explain this observation.  The first 
possibility is that the Alb-Cre mouse has a phenotype that confers some resistance to alcohol-
mediated liver injury.  In support of this possibility, the serum ALT levels attained with chronic 
ethanol feeding in Alb-Cre mice were also lower than that observed in C57/Bl6 mice, although 
these differences may also be due to other experimental variability, including batch variation of 
the ALT reagent or other conditions.  The mechanism of this resistance might be due to 
integration of the Alb-Cre transgene within a gene locus whose transcription is crucial for the 
development of ALD, or, alternatively, it may be due to a survival-promoting effect of expression 
of the site-specific recombinase on cellular function--for example, inhibitory interaction of the 
recombinase with transcription-factor binding sites implicated in inflammation, apoptosis, or an 
array of other possibilities.  As we did observe increased triglyceride accumulation and an 
elevation in liver-weight/body-weight ratio, as well as some elevation of serum ALT, in Alb-Cre 
mice, we were able to conclude that ethanol feeding had an observable effect on these mice and 
judge the effect of the HIF1dPA transgene thereby.  A second possibility is that the elevation of 
HIF target genes such as PAI-1 and iNOS observed with chronic ethanol owes more to alcohol-
induced hyper-responsiveness of innate immune signaling pathways.  In support of this theory, 
when chronic alcohol-fed mice are challenged with an intraperitoneal injection of LPS, they 
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attain much higher fold-increase in levels of PAI-1 and iNOS.  Thus, the moderate increases we 
observe without exogenous LPS challenge might be indicative of a chronic-low-level LPS 
stimulation.  Subtle variations in the Alb-Cre mice, such as the composition of their gut flora, 
might  account for differences in their portal venous levels of gut derived endotoxin.  
Importantly, whereas C57/Bl6 mice were purchased from an outside vendor, the Alb-Cre 
littermate mice we used in out study were bred and raised within our facility, which suggests a 
possible rationale for suspecting differences in their enteric bacterial composition.
 Induction of pro-inflammatory cytokines, or a priming effect of HIF1dPA transgene 
expression on cytokine induction, plays a role in the pathogenesis of alcoholic liver disease.  In 
support of this hypothesis, we found that the pro-inflammatory cytokine KC, the murine 
homolog of IL8, was upregulated by chronic ethanol and HIF1dPA transgene expression.  We 
also found higher levels of TNF! mRNA, which also has been related to hepatic lipid 
accumulation.  Other cytokines, including MCP-1, MIP1B, and IL-6 were not significantly 
altered in HIF1dPA mice.  Again, it is possible that the addition of LPS stimulation would have 
revealed a difference in the expression of these cytokines, or that, if these cytokines are related to 
HIF1! expression, some cytokines act upstream of HIF1! activation, whereas others (such as 
KC) may be induced by HIF1!.  Another possibility, alluded to previously, is that the Alb-Cre 
transgene interfered with the inflammatory response in these mice.  Lending support to that 
theory, ethanol-fed Alb-Cre mice maintained lower levels of cytokines and gene expression of 
targets such as TNF! than we observed in wild-type mice.  The addition of LPS, again, may have 
clarified these findings.
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 With regards to the differential gene regulation we observed between C57/BL6 mice and 
HIF1dPA and/or Alb-Cre mice, a few disparities should be addressed.  For one thing, although 
we have postulated the increase in HIF1! as a mechanistic possibility for the pathogenesis of 
ALD, the classic HIF1! target gene VEGF is not upregulated, either within the Alb-Cre mice or 
C57/Bl6 mice, with chronic ethanol feeding.  As HIF1! is a transcriptional regulator of both 
inflammation and angiogenesis, it stands to reason that there would be some scenarios in which it  
would be evolutionarily advantageous to decouple these two broad responses.  We have observed 
a situation, namely chronic ethanol, in which upregulation of HIF1! is not accompanied by 
upregulation of VEGF.  This suggests that the proinflammatory and the proangiogenic functions 
of HIF1! can indeed be decoupled.  There are several possible mechanisms whereby this 
decoupling may occur  For one, as HIF1! activity is known to depend upon the recruitment of 
co-factors, competition for co-factor recruitment by proinflammatory transcription factors, such 
as NF#B, might inhibit some, but not all, functions of HIF1!; in particular, those functions of 
HIF1 that also depend upon NF#B, such as the induction of proinflammatory cytokines, might be 
preserved while others that are NF#B-independent might be prevented.  Other mechanisms 
include transcriptional suppression via other DNA binding proteins, or epigenetic regulation e.g., 
histone protein modification and chromatin remodeling.
 Another remaining question is the differential regulation of the chemokine MCP-1 
between HIF1dPA mice, Alb-Cre mice and C57/BL6 mice.  The explanations that we have 
suggested for differential VEGF regulation are not sufficient in this case, as MCP-1 is an 
inflammatory cytokine and hence would not be expected to be decoupled from other functions of 
HIF1! in the manner we have proposed above.  One possibility is that MCP-1 is induced 
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upstream of HIF1! activation, and further stimulation of HIF1! signaling pathways, (for 
example, via introduction of the HIF1dPA transgene) does not result in further upregulation of 
MCP-1. 
 Both direct effects of HIF1 transgene expression on lipid metabolic pathways as well as 
induction of pro-inflammatory cytokines may have effects on hepatic lipid accumulation and the 
progression of liver disease.  In the next chapter, we explore the contribution of MCP-1 in an  in 
vitro model of lipid accumulation, and the relationship of that lipid accumulation to the 
activation of HIF1!.
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CHAPTER 4
IN VITRO STUDIES ON HIF1 AND  LIPID ACCUMULATION
Summary
Our previous studies correlated HIF1!  expression to hepatic lipid accumulation in ethanol-fed 
mice.  We sought to test the hypothesis that HIF1!  could be related to lipid accumulation in 
hepatocytes.  A recent in vitro study using the human hepatoma cell line Huh7 demonstrated that 
lipid accumulation could be induced in this cell line with MCP-1 treatment.  MCP-1 levels were 
synergistically upregulated in wild-type mice with ethanol feeding and LPS injection, thus we 
tested HIF1!  induction using MCP-1 in an in vitro hepatocyte cell line system.  MCP-1 
treatment upregulated HIF1 nuclear protein and HIF DNA binding in Huh7 cells.  Using an 
siRNA-mediated approach, we demonstrate that HIF1 or HIF2 siRNA pretreatment is sufficient 
to block MCP-1-induced triglyceride accumulation in Huh7 cells.  HIF1 siRNA treatment also 
limited lipid accumulation as identified by Oil-Red O staining.  Finally, transfection of Huh7 
cells with HIF1dPA or HIF2dPA plasmids resulted in an increase in triglyceride accumulation.  
We conclude that MCP-1-induced lipid accumulation in the Huh7 cell line occurs at least in part 
via a HIF dependent mechanism, and that HIF overexpression in the Huh7 cell line is sufficient 
to induce lipid accumulation.
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Introduction
 Hepatic lipid accumulation, or steatosis, is an early and reversible feature of hepatic 
pathology observed after chronic ethanol stimulation.  Multiple lines of evidence suggest that 
hepatic lipid accumulation as the result of chronic ethanol treatment proceeds via mechanisms 
that involve the hepatocyte as well as other cell types in the liver (Reviewed in [130]).  In this 
regard, numerous similarities exist between alcoholic liver disease and non-alcoholic fatty liver 
disease (NAFLD).  Notably, the progression of both NAFLD and ALD to NASH and alcoholic 
hepatitis, respectively, appears to be at least partially dependent upon activation of innate 
immune pathways, including signaling through the Toll-like Receptor family of pattern 
recognition receptors.
 Monocyte Chemoattractant Protein-1 (MCP-1) is a member of the C-C group of 
chemokines, identified by the conserved motif of two adjacent cysteine residues.  Four MCP 
isoforms are known in humans.  MCP-1 is known to exert effects through binding its receptor, 
CCR2, in either a dimeric or a monomeric form.  The CCR2 receptor is a G-protein coupled 
receptor whose activation results in the activation of phospholipase C, the formation of inositol 
triphosphate, and ultimately, protein kinase C activation leading to activation of the master 
regulator of inflammation, NF#B.[191]
 MCP-1 has been implicated by various lines of evidence in the pathogenesis of liver 
disease.  MCP-1 has been demonstrated to be secreted by various cell types in the liver, 
including hepatocytes, macrophages (Kupffer cells, KpfCs) as well as hepatic stellate cells.  One 
study demonstrated that KpfCs secreted nitric oxide and MCP-1 in response to LPS stimulation.
[192]  Hepatocyte and whole liver mRNA and protein levels of MCP-1 were increased in 
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response to homocysteine treatment, mimicking the liver injury seen in hereditary 
hyperhomocysteinemia.[193] MCP-1 expression in adipose tissue was reported to increase 
hepatic steatosis. [203]  Blockade of the MCP-1 receptor was reported to decrease hepatic 
steatosis and improve insulin sensitivity in db/db mice, which are deficient in the leptin receptor 
and are predisposed to obesity.[204]  Furthermore, increased serum MCP-1 was observed in 
nonalcoholic steatohepatitis.[205] TLR4 is known to play a role in both ALD as well as NAFLD, 
and hepatic MCP-1 RNA was partially, though not completely,  suppressed in TLR4(-/-) mice fed 
a high-fat, high cholesterol diet (atherogenic diet).  [194]  Another study demonstrated that 
hepatic stellate cells secrete MCP-1 in response to TLR9 receptor stimulation (via the bacterial 
unmethylated CpG DNA motif), and that TLR9 (-/-) mice were protected from hepatic fibrosis 
after bile-duct ligation.[195]  Similarly, anti-MCP-1 gene therapy diminished hepatic fibrosis 
after diethylnitrosamine challenge.[196]
  Clement and colleagues described the finding that treatment of human hepatoma cell line 
Huh7 with the chemokine Monocyte Chemoattractant Protein-1 (MCP-1) resulted in lipid 
accumulation.[197]  We and others report elsewhere that MCP-1 is synergistically upregulated 
by alcohol and lipopolysaccharide injection.1  MCP-1 is a chemokine that is reported to be 
upregulated in visceral adipose tissue in metabolic disease; it is thus positioned as a target of 
interest in two different models of fatty liver disease, namely Non-Alcoholic Fatty Liver Disease 
(NAFLD) as well as alcoholic steatohepatitis.
 Some literature exists on crosstalk between hypoxia-inducible factors and MCP-1 
stimulation.  MCP-1 has been implicated in angiogenesis.  Earlier work described an 
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1 Vide infra.  We report the upregulation of MCP-1 with ethanol and LPS stimulation in Chapter 5.
upregulation of HIF1! in aortic endothelial cells stimulated with MCP-1, and subsequent 
production of VEGF-A.[198]  Other investigators reported that a transcription factor, MCP-1 
Induced Protein, acts downstream of MCP-1 stimulation in monocytes to stimulate VEGF-A and 
HIF1! upregulation.[199]  
 We undertook to determine whether in vitro evidence could suggest a link between 
hepatic steatosis, MCP-1 treatment, and HIF1! activation.  Using the Huh7 cell line, we report 
that HIF1! protein is upregulated by MCP-1 treatment, and that upregulation of MCP-1 is 
associated with hepatic lipid accumulation.  Treatment of the Huh7 cell line with siRNA 
targeting HIF1! or HIF2! prevented hepatic lipid accumulation as observed by Oil-Red O 
staining or by triglyceride assay, whereas treatment with scrambled siRNA conferred no such 
protection.  Finally, treatment of Huh7 cells with a HIF1dPA or HIF2dPA plasmid directly 
induced hepatic lipid accumulation as measured by triglyceride assay.  We conclude that MCP-1 
induced lipid accumulation in the Huh7 cell line is dependent upon hypoxia inducible factor 
activation.
Methods
Cell Culture Studies
All studies were performed using the human hepatocellular carcinoma cell line Huh7.  Cells 
were maintained in complete growth medium (Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 2% Penicillin/Streptomycin, and 1% 100X 
amino-acid supplement mixture.)  Cells were passaged in T75 flasks at 70% confluence by 
washing once with phosphate-buffered saline followed by 5 minute incubation with TryplE 
express trypsin analogue.  Trypsinized cells were resuspended in complete growth medium.  For 
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in vitro  assays, cells were plated on 10cm plates, and then transfected with plasmid DNA or 
siRNA and/or treated with recombinant monocyte chemoattractant protein-1 (MCP-1, R&D 
Systems).
Plasmid transfections
The HIF1dPA and HIF2dPA plasmids were the kind gift of Dr. William Kim (UNC).  Plasmid 
DNA was transfected into Huh7 cells using Fugene transfection reagent according to the 
manufacturers instructions.  Briefly, Huh7 cells on 10cm plates at 50-60% confluence were 
transfected with 5ug plasmid DNA (HIF1dPA or HIF2dPA transgenes encoded into pcDNA3.1) 
with 15ul Fugene 6 and 160ul serum free media.  For verification of plasmid transfection, 
pcDNA3.1 encoding GFP was used and cells imaged 24 hours post-transfection with a  
fluorescent microscope. 
siRNA transfections
 HIF1! siRNA, HIF2! siRNA, or scrambled (scr) siRNA were purchased from Santa Cruz 
Biotechnology.  Transfection was achieved using siPORT Amine transfection agent (Applied 
Biosystems) according to the protocol of the manufacturer.  Briefly, for a 10cm-plate, 17ul 
siPORT Amine reagent at room temperature was added to 333ul Opti-MEM serum-free medium 
and incubated at room temperature for 10 minutes.  7.5ul of 10um HIF1!, HIF2!, or scr siRNA 
was diluted in 142ul Opti-MEM and incubated for 10 minutes at room temperature.  
 Subsequently, both the transfection reagent and the siRNA mixture were mixed and 
transfection complexes allowed to form after a 10 minute incubation at room temperature.   The 
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mixture (500ul) was dispersed on a 10cm plate, and overlaid with 7x105 cells in a final volume 
of 7ml.  After 24 hours, medium was aspirated and replaced with 10ml complete culture medium 
for subsequent treatment with MCP-1 or other assays.
Real Time PCR
 For RNA analysis from cell culture, medium was aspirated from plates and plates were 
washed with 5ml PBS.  500ul of Buffer RLT (Qiagen) was added, the plate surface scraped and 
collected, and passed through a QiaShredder column and stored at -80 until subsequent RNA 
purification using the RNeasy mini kit (Qiagen).  Primer sequences are listed in table 2.
Protein concentrations were determined by adding 1uL of whole-cell lysate or nuclear extract to 
Bradford reagent (BioRad) and by measuring the difference between absorbance at 650nM and 
595nM on a 96 well plate using a plate reader. Concentrations were determined using a standard 
curve of bovine serum albumin.
Oil Red O Staining
Media was removed from cultured and treated cells and plates were washed with 2ml PBS.  2ml 
of 10% formalin was added to each plate and plates were incubated for 10 minutes.  
Subsequently, formalin solution was replaced with fresh 10% formalin (2%), plates were tightly 
wrapped with parafilm and stored at room temperature overnight.  Formalin was then removed, 
and cells were washed twice with ddH2O and then washed for 5 minutes with 60% isopropanol.  
Plates were dried, and then 1ml of Oil Red O working solution was added and plates were 
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TABLE 2.  Human PCR primers
HIF1a F: 5’-ATC CAT GTG ACC ATG AGG AAA TG-3’
HIF1a R: 5’-CTC GGC TAG TTA GGG TAC ACT T-3‘
HIF2a F: 5‘-GTC TCT CCA CCC CAT GTC TC-3’
HIF2a R: 5’-GGT TCT TCA TCC GTT TCC AC-3’
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incubated for 10 minutes.  Oil Red O solution was removed and plates were immediately 
destained with 4 washes of ddH2O.  Plates were then photographed with photomicroscopy.
Nuclear Extraction
Cells were scraped into ice-cold PBS and washed at 1700RPM for 10 minutes at 4 degrees.  
Cells were resuspended in 400ul ice-cold Buffer A (10mM HEPES pH 7.9, 10mM KCl, 0.1mM 
EDTA, 0.1mM EGTA, 1mM DTT, 1mM PMSF, plus 1 Complete Mini protease inhibitor tablet/
10ml buffer.)  Cells were lysed by adding 20ul non-idet P40 substitute and vortexing briefly.  
Lysates were centrifuged for 30 seconds at 12,500RPM/4 degrees C, and supernatants removed.  
Pellets were washed twice in 300ul Buffer A, and resuspended and then frozen at -80 degrees C
in 50ul Buffer B (20% glycerol, 20mM HEPES pH7.9, 400mM KCl, 1mM EDTA, 1mM EGTA, 
1mM DTT, 1mM PMSF, plus 1 Complete Mini Protease Inhibitor Tablets/5ml Buffer B.)   
Lysates were thawed and rocked for 30 minutes at 4 degrees C.  Supernatants were collected 
after centrifugation at 12500RPM for 10 minutes and used for downstream analysis.
Electrophoretic Mobility Shift Assay
A consensus double-stranded Hypoxia Response Element (HRE) (Santa Cruz Biotech, CA) 
oligonucleotide was used for EMSA. End-labeling was accomplished by treatment with T4 
kinase in the presence of [32P]ATP. Labeled oligonucleotides were purified on a polyacrylamide 
copolymer column (BioRad). Five micrograms of nuclear protein was added to a binding 
reaction mixture containing 50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM
DTT, 250 mM NaCl, 20% glycerol, 20 &g/ml BSA, 2 &g poly(dI–dC) and 30,000 c.p.m. of 32P-
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labeled NFB oligonucleotide. Samples were incubated at room temperature for 30 min.  
Reactions were run on a 5% polyacrylamide gel and the dried gel was exposed to an X-ray film 
at –80°C overnight.  Cold competition was done by adding a 20-fold excess of specific unlabeled 
double-stranded probe to the reaction mixture.  Band density was quantified using Labworks 4.0 
image analysis.
Western Blotting
30-50ug of nuclear extract was resolved on 10% polyacrylamide gels and transferred overnight 
to nitrocellulose support.  Membranes were blocked overnight with blocking buffer (5% bovine 
serum albumin in Tris-Borate-SDS with 0.01% Tween 20) with refrigeration, and subsequently 
probed overnight with anti-HIF1! (R&D Biosciences) mouse monoclonal antibodies.  Detection 
was performed using an anti-mouse horseradish-peroxidase conjugated secondary antibody and 
chemiluminescent substrates.  Band density was  quantified using Labworks 4.0 image analysis.
Results
MCP-1 induces lipid accumulation in Huh7 hepatoma cells.
MCP-1 is increased in chronic alcohol feeding, and others have shown that lipid accumulation is 
induced in Huh7 cells with MCP-1 treatment. We first undertook to reproduce the finding that 
MCP-1 treatment induces lipid accumulation in the cell line Huh7.  Huh7 cells were cultured and 
plated on 10cm plates.  At 50%-70% confluence, recombinant MCP-1 was added at 100ng/ml.    
We found that MCP-1 treatment induced an increase in triglyceride content within 24 hours. 
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(Figure 16A)  We also stained culture plates with Oil Red O, and found increased Oil Red O 
staining in MCP-1 treated Huh7 cells after 24 hours.  (Figure 16B).
We then sought to determine whether MCP-1 treatment had any effect on the accumulation of 
HIF1! protein.  Cultured Huh7 cells were treated with MCP-1 as described, and nuclear extracts 
were prepared from cells collected at several time points (Figure 17A).  HIF1! protein in nuclear 
extracts and HIF1 DNA binding were increased by MCP-1 treatment (Figure 17C). Band 
intensity was quantified by densitometry, (Figure 17B and D)
Activation of HIF1 or HIF2 induces hepatic lipid accumulation
Since MCP-1 treatment induced lipid accumulation and HIF1! activation, we then sought to 
determine whether HIF1! activation alone could recapitulate the phenotype of lipid 
accumulation.  HIF1dPA and HIF2dPA plasmids are degradation resistant mutants of HIF1! and 
HIF2!, and were the kind gift of Dr. William Kim, UNC.  We transfected HIF1dPA, HIF2dPA, or 
GFP control into Huh7 cells using the Fugene transfection reagent.  GFP-positive cells 
confirmed that transfection was successful in Huh7 cells.(Figure 18A)  HIF1dPA and HIF2dPA 
transfection was confirmed by specific upregulation of HIF1! or HIF2! mRNA.(Figure 18B and 
18C)  HIF1dPA or HIF2dPA transfection also increased HIF1 DNA binding.(Figure 18E and 
18F).  HIF1dPA or HIF2dPA transfection resulted in increased triglyceride (Figure 18D.)  
Finally, we observed increased lipid accumulation in HIF1dPA or HIF2dPA treated Huh7 cells 
using Oil Red O staining and microscopy. (Figure 19)
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Figure 16. MCP-1 treatment and triglyceride accumulation. Huh7 cells were treated with 
MCP-1.  Intracellular triglyceride was increased using a biochemical assay (A).  MCP-1 treated 
cells accumulation more lipid as demonstrated by increased intensity of Oil Red O staining.(B)  
The first two columns show conventional light microscopy of the culture plates, with Oil-Red O 
visible as red stain; the second two columns show the same images with inverted contrast in 
order to heighten the visibility of Oil-Red O positive areas, which appear as blue regions.
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Figure 17.  MCP-1 Treatment and HIF activation.  Huh7 cells were treated with MCP-1.  
Nuclear extracts were prepared, and western blotting was performed with an anti-HIF1! 
antibody.  Significant upregulation of HIF1! was observed with MCP-1 treatment (20A).  
Densitometry appears in panel B.  Increased HIF DNA binding was observed using a HIF 
specific oligonucleotide. (20C)  Densitometry appears in panel C.
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Figure 18.  HIF1dPA and HIF2dPA plasmid transfections.
Transfection was confirmed using plasmid encoding GFP (A), which was also used as a negative 
control in subsequent experiments.  HIF1dPA plasmid transfection or HIF2dPA plasmid 
transfection was confirmed using RT-PCR (A and B).  HIF1dPA or HIF2dPA plasmid 
transfection resulted in an increase in intracellular triglyceride.(C)  Both HIF1dPA and HIF2dPA 
plasmid transfection increased HIF DNA binding (E), densitometry appears in (F.)   
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Figure 19.  Oil-Red O staining, HIF1dPA/HIF2dPA plasmid transfection.  Huh7 cells 
transfected with HIF1dPA or HIF2dPA plasmid were stained with Oil Red O and photographed 
by microscopy.  (A) Huh7 cells without any treatment.  Little lipid accumulation is visible.  (B) 
Huh7 cells treated with MCP-1.  Lipid accumulation is visible as red refractile particles 
(arrowhead).  (C) Cells treated with reagent only (Fugene 6).  (D) Cells treated with empty 
vector.  (E) Cells treated with HIF1dPA plasmid. (F) Cells treated with HIF2dPA plasmid.  Lipid 
is indicated by arrowhead.
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Prevention of MCP-1 induced lipid accumulation by treatment with HIF1! or HIF2! siRNA
Since we had demonstrated that HIF1! was upregulated by MCP-1 treatment, and that HIF1dPA 
plasmid transfection caused increased lipid accumulation in Huh7 cells, we then wondered 
whether knockdown of HIF1! or HIF2! (via an siRNA approach) would be sufficient to prevent 
lipid accumulation in the Huh7 cell line.  HIF1!, HIF2! siRNA, or scrambled control was 
transfected into Huh7 cells using SiPORT NeoFX transfection reagent.  We confirmed 
knockdown of HIF1! or HIF2! cellular mRNA using qRT-PCR. (Figure 20A) Scrambled siRNA 
did not alter HIF1! or HIF2! mRNA levels.(Figure 20A)  We then designed an approach to 
determine whether HIF1! knockdown could prevent MCP-1 induced lipid accumulation. 
Briefly, cells were transfected with siRNA for HIF1!, HIF2!, or scrambled control, and after 24 
hours, treated with MCP-1.  After an additional 24 hours, cells were assayed for intracellular 
lipid accumulation using a triglyceride assay (Figure 20B) or via Oil Red O staining. (Figure 
20C) We determined that HIF1! or HIF2! siRNA prevented MCP-1 induced lipid accumulation 
in the Huh7 cell line. 
Discussion
The chemokine MCP-1 is secreted by visceral adipose tissue and induces lipid accumulation in 
the hepatocyte cell line Huh7 in vitro.   We found a synergistic upregulation of MCP-1 by 
chronic alcohol and lipopolysaccharide injection in vivo (see chapter 5, below), underscoring the 
potential relevance of this cytokine to the pathogenesis of alcoholic liver disease.  We were able 
to reproduce the results of Clement et al, demonstrating an increase in Oil Red O staining in 
Huh7 cells treated with recombinant MCP-1.  Additionally, we were able to demonstrate an 
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Figure 20.  HIF1! or HIF2! siRNA prevents MCP-1 induced lipid accumulation in the 
Huh7 cell line.  
A.  Huh7 cells were treated with HIF1! or HIF2! siRNAs or scrambled siRNA control sequence 
and specific knockdown of HIF1! and HIF2! mRNA was determined.(*=P<0.05 versus 
untreated control).  B. Cells with transient knockdown of HIF1! or HIF2! were then treated with 
MCP-1.  We found that knockdown of HIF1! or HIF2! prevented lipid accumulation as assayed 
by triglyceride assay   C.  HIF1! siRNA or scrambled control cells were treated with MCP-1, 
and culture plates were stained with Oil Red O for intracellular lipid.  Pretreatment with HIF1! 
siRNA inhibited the lipid accumulation observed with MCP-1 treatment.  Panel 1, cells with 
MCP-1; Panel 2, cells with transfection reagent and MCP-1; panel 3, scrambled siRNA and 
MCP-1; panel 4, HIF1!  siRNA and MCP-1.  Similar results were obtained with HIF2! siRNA 
and MCP-1 (not shown).
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increase in triglyceride using a biochemical assay.  In this group of studies, we extended these 
findings by demonstrating that MCP-1 treatment results in induction of HIF1!  activity, and that 
HIF1!  activity alone is sufficient to induce hepatic lipid accumulation.
 Given that the hepatocyte specific HIF1! degradation resistant mutant (HIF1dPA) was 
able to induce lipid accumulation in hepatocytes in a mouse model, and that we were able to 
demonstrate increased triglyceride accumulation in ethanol-fed HIF1dPA mice versus controls, 
we wondered whether HIF1 activation could be related to MCP-1 induced lipid accumulation.  
We verified MCP-1-induced upregulation of HIF1! protein by western blot, and further verified 
upregulation of HIF1! DNA binding using EMSA.  In order to determine whether HIF1 alone
could induce lipid accumulation in this cell line, we transfected Huh7 cells with the HIF1dPA 
plasmid, and were able to detect triglyceride accumulation using a biochemical assay.  Finally, 
we wondered whether inhibition of HIF would be able to prevent MCP-1 induced lipid 
accumulation.  Using an siRNA approach, we transfected Huh7 cells with HIF1 siRNA or 
scrambled control.  HIF1! siRNA pretreated cells did not accumulate lipid when treated with 
recombinant MCP-1, whereas scrambled siRNA treated cells accumulated lipid in a similar 
fashion to untreated cells.
 Of note, we observed similar effects with HIF2dPA plasmid treatment and HIF2 siRNA 
mediated approaches.  Other work has suggested that both HIF isoforms may have a role in 
modulating lipid accumulation in vivo.  Given that HIF1dPA plasmid transfection showed a small 
but significant effect on HIF2! mRNA levels, it is possible that HIF1!-mediated silencing of 
hepatic lipid accumulation still depends on intact HIF2! signaling; alternatively, both isoforms 
may have redundant effects.  
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 A significant remaining question is the mode of upregulation of HIF1!-by MCP-1 
treatment.  MCP-1 stimulation of the CCR2 receptor is known to result in NF#B activation; 
NF#B activation, in turn, has been described to transcriptionally upregulate HIF1!.[200]  
However, one concern with this model is whether Huh7 cells, or hepatocytes, express the CCR2 
protein.  Indeed, Clement et al, in their report on MCP-1 induced lipid accumulation in vitro, 
were unable to detect CCR2 mRNA in primary hepatocyte cultures, and also detected only a low 
level of CCR2 mRNA in Huh7 cells.  Furthermore, they were not able to prevent lipid 
accumulation in Huh7 cells after treating them with a CCR2 antagonist.  Two methodological 
concerns with regards to their findings are apparent.  For one, they concluded that CCR2 
expression was very low in Huh7 cells by comparing the CCR2 expression level to a positive 
control of peripheral blood mononuclear cells (PBMCs).  Although Huh7 cells had no more than 
1% of the CCR2 expression found in PBMCs, this may still be sufficient to induce a 
biologically-relevant response.  In contrast, they were not able to detect expression of CCR2 
mRNA in primary mouse hepatocytes.  A concern is that primary hepatocytes in cell culture 
rapidly dedifferntiate and lose cell-specific functions, and mRNA may be one of the earlier 
markers of hepatocyte dedifferentiation in culture; hence, lack of expression of mRNA for CCR2 
in culture may not accurately convey the situation in vivo.  A better method might be western 
blotting for CCR2 within freshly isolated hepatocytes, or performing immunostaining on liver 
tissue sections.
 However, assuming that the MCP1 receptor antagonist experiments accurately convey 
that the effect of MCP-1 treatment on lipid accumulation is independent of the CCR2 receptor, 
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this raises the intriguing possibility that the effect of MCP-1 treatment on lipid accumulation is 
via an effect on HIF1! protein levels, and is independent of CCR2.  Clement and colleagues 
reported that inhibition of ERK was sufficient to block lipid accumulation.  In other systems, 
ERK activation has been shown to be involved in HIF1! activation following stimulation with 
TNF!.[201]  We speculate that an unidentified receptor for MCP-1 may be identified that can 
activate HIF1! via an ERK-dependent mechanism.
 One strategy to determine the specificity of each of these isoforms could include stable 
transfections of HIF1! or HIF2! shRNA and subsequent transfection with HIF1dPA or HIF2dPA 
transgenes.  Optimizing parameters for that strategy is one ongoing project in the lab. 
126
  
CHAPTER 5
EFFECT OF PARTIAL CELL-SPECIFIC HIF1! KNOCKDOWN ON THE 
PROGRESSION OF 
  ALCOHOLIC STEATOHEPATITIS
Summary
We sought to determine whether cell-specific suppression of HIF1! could ameliorate alcoholic 
liver disease in an in vivo model.  We used a cre-lox strategy to express a transcriptionally-
inactive mutant of HIF1! in hepatocytes or cells of the myeloid lineage.  Wild-Type, HepHIF(-),  
or MyeHIF(-) mice were treated with chronic ethanol for five weeks.  A subset was also 
challenged with LPS.  We found that HepHIF(-) mice after chronic alcohol feeding had lower 
levels of hepatic triglyceride, decreased LW/BW ratios, and decreased lipid accumulation by 
quantified Oil-Red O staining versus control mice.  QRT-PCR analysis demonstrated that 
HepHIF(-) mice, but not MyeHIF(-) mice, were protected from upregulation of PAI-1 and iNOS 
mRNA.  HepHIF(-) mice, but not MyeHIF(-) mice, had lower levels of serum ALT after chronic 
alcohol/LPS challenge. HepHIF(-) mice, and to some degree MyeHIF(-) mice, were protected 
from an increase in several cytokines after ethanol/LPS challenge including TNF!, KC, IL-6 and 
IL-17.  All mice had suppressed PPARa mRNA, suggesting that protection from lipid 
accumulation in this model is independent of PPARa mRNA levels.  Finally, we observed that 
WT mice, but not HepHIF(-) mice, had upregulation in the downstream target ADRP, a lipid 
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droplet surface marker.  We conclude that hepatocyte specific HIF1! has a role in the progression 
of alcoholic steatohepatitis.
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Introduction
 Our previous studies have correlated HIF1! expression to hepatic lipid accumulation in 
ethanol-fed mice and demonstrated that pretreatment of Huh7 hepatoma cells with a HIF1! 
siRNA was sufficient to prevent lipid accumulation.  Given these findings, we sought to 
determine whether disrupting HIF1! signaling would be able to prevent alcoholic liver disease in 
an in vivo mouse model.
 A recurring theme in the pathogenesis of alcoholic liver disease is the interplay between 
cell types in the progression of liver injury.  All aspects of ALD, from steatotic change in the 
hepatocyte, to inflammation, to fibrotic change, to cirrhosis, appear to be modifiable by multiple 
factors in different cell types.[130]  A basic pathogenic mechanism in the progression of 
alcoholic steatosis to alcoholic steatohepatitis is the hyper-responsiveness of Kupffer cells upon 
stimulation with gut-derived lipopolysaccharide within the hepatic portal circulation, and 
subsequent release of necroinflammatory mediators including TNF! and other pro-inflammatory 
cytokines.[130]  The steatotic hepatocyte, in turn, may have a diminished ability to survive an 
inflammatory insult.
 Cre-lox strains have been used successfully in previous studies to characterize the 
specific contribution of various liver cell types in mouse models of alcoholic liver disease.[36]  
For example, mice bearing a mutant transgene  that is activated or inactivated upon co-
expression of the Cre-recombinase gene, and crossed into strains expressing Cre under the 
control of the Alb- or the LyzM- promoter, results in hepatocyte-specific (Alb-Cre)  or myeloid 
lineage-specific (LyzM-Cre) transgene expression or inactivation, respectively.  Using this 
system, for example, Horiguchi and colleagues offered data to suggest that hepatocyte-specific 
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deletion of STAT3 resulted in greater steatosis and upregulation of liposynthetic pathways, but 
less hepatic inflammation, whereas myeloid-lineage-specific STAT3 deletion resulted in greater 
levels of pro-inflammatory cytokines and hepatic inflammation after 8 weeks of an ethanol-
containing diet. [36]
 Previous work in other laboratories has demonstrated that HIF1! inactivation in cells of 
the myeloid lineage was protective against sepsis induced by high doses of LPS.[143]  Other 
investigators have presented data suggesting that HIF1! inactivation in hepatocytes and immune 
cells (via the Mx-Cre interferon-inducible promoter)  prevents fibrosis in an experimental bile 
duct ligation model.[160]  HIF1! activation in hepatocytes resulted in mild lipid accumulation, 
whereas activation of both HIF1! and HIF2! resulted in marked steatosis.[155]  In another 
model, hepatocyte-specific HIF1! knockout in combination with pVHL knockout (a phenotype 
resembling constitutive HIF2 activation) resulted in marked lipid accumulation, whereas VHL 
knockout in combination with HIF2! knockout (a phenotype resembling HIF1 activation) did not 
result in lipid accumulation, suggesting that HIF2 is a primary mediator of hepatic lipid 
accumulation.[155]  In that report, inhibition of the HIF degradation pathway in combination 
with HIF1!(-) resulted in upregulation of fatty acid synthetic pathways along with the lipid 
droplet surface-associated protein Adipocyte Differentiation Related Protein (ADRP).  Indeed, 
although we have described a consistent upregulation of HIF2 in alcohol-fed mice, we have also 
reported that HIF1dPA mice fed ethanol accumulated higher amounts of lipid as determined by 
tissue microscopy and triglyceride content of whole-liver lysates.
 Given the central role of HIF1! activation in response to LPS stimulation, we postulated 
that specific suppression of HIF1! in cells of the myeloid lineage (MyeHIF(-) mice) would result  
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in prevention of hepatic injury through attenuation of the inflammatory response of gut derived 
endotoxin, whereas partial suppression of HIF1! in hepatocytes (HepHIF(-) mice) might result in 
less hepatomegaly and hepatic lipid accumulation, but have a similar cytokine profile in response 
to pro-inflammatory stimulus.  In order to obtain a robust model of alcoholic liver disease, we 
performed alcohol or pair feeding for five weeks, and further randomized mice into LPS or saline 
injected groups.
 Consistent with our hypothesis, we found that HepHIF(-) mice exhibited less 
hepatomegaly, hepatic triglyceride, and steatosis than wild-type mice or MyeHIf(-) mice.  To our 
surprise, both HepHIF(-) mice and MyeHIF(-) mice had decreased expression of several 
cytokines, including, importantly, TNF!.  Correspondingly, HepHIF(-) mice were strongly 
protected from increased serum ALT in response to LPS challenge, whereas MyeHIF(-) only 
displayed a nonsignificant trend towards protection.  We conclude that HIF1! activity in both 
hepatocytes and myeloid cells affects the progression of alcoholic steatohepatitis, and that 
modifying HIF1! activity may have therapeutic value in the treatment of alcoholic liver disease.
Methods
Animal Studies
 All animals received care in compliance with protocols approved by the Institutional 
Animal Use and Care Committee of the University of Massachusetts Medical School.  
HIF1(flox/flox) mice, Alb-Cre mice, and LyzM-Cre mice were purchased from Jackson 
Laboratories (Bar Harbor, ME).  The HIF1! floxed allele has been previously described.[143]  
All mice were supplied backcrossed onto a pure C57/Bl6 background, and C57/Bl6 mice 
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purchased from Jackson Laboratories were used as wild-type controls. Offpsring of HIF1(flox/
flox) and Alb-Cre homozygous mice (HIF1(flox)/Alb-Cre mice, HepHIF(-) mice, henceforth) 
and offspring of  HIF1(Flox/flox) and  LyzM-Cre mice (HIF1(flox)/LyzMCre mice, MyeHIF(-) 
mice, henceforth) were generated, tagged by ear notching, and housed in separate cages.  For 
initial studies to guide the timing of lipopolysaccharide (LPS) injections and serum ALT and 
hepatic triglyceride measurements, WT mice were given intraperitoneal injections of LPS and 
sacrificed at 2, 4, 6, 18, and 24 hours. For all other mouse studies, mice were gradually 
habituated to a Lieber-DeCarli liquid diet with 5% ethanol (volume/volume) or isocaloric pair-
fed diet over a period of two weeks, then maintained on the 5% diet for five weeks.   
Consumption was recorded daily, and isocaloric amounts of a non-alcohol containing diet (in 
which dextran-maltose replaced calories from ethanol) were dispensed to pair-fed animals.  
Weights were recorded before the introduction of the diet and weekly thereafter.  Prior to the 
conclusion of the study, the mice were randomly assigned to receive lipopolysaccharide (LPS, 
Sigma) injection (50ug/kg) or saline injection.  Mice were sacrificed 18 hours after LPS 
injection; alternatively, a second cohort of mice had blood drawn from the cheek venous plexus 
at 2 hours after injection, and subsequently sacrificed at 18 hours after LPS injection.  At the 
conclusion of the feeding, mice were weighed and euthanized.  Livers were excised and 
weighed, and divided and portions were snap frozen in liquid nitrogen for protein and 
biochemical assays, preserved in 10% neutral-buffered formalin for histopathological analysis, 
preserved in OCT frozen section preparation solution, or soaked in RNALater (Qiagen GmbH, 
Hilden, Germany) for RNA extraction.  Blood was collected and serum separated for 
biochemical analysis. 
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Biochemical Analysis
 Serum alanine aminotransferase (ALT) was determined using a commercially available 
reagent (Advanced Diagnostics Inc, Plainfield, NJ).  Briefly, 15ul of serum was mixed with 
100ul of reagent diluted according to the instructions of the manufacturer, and UV absorbance at 
37 degrees celsius was measured over three minutes.  The average change in absorbance per 
minute interval is then multiplied by a conversion factor to yield ALT levels.
 For liver triglyceride levels, liver whole-cell lysates were prepared as described below 
and lipids separated by isopropanol precipitation of non-lipid components.  A commercially 
available kit (Wako Chemicals USA Inc., VA) was used to determine the triglyceride 
concentration.
 Protein concentrations were determined by adding 1uL of whole-cell lysate to Bradford 
reagent (BioRad) and by measuring the difference between absorbance at 650nM and 595nM on 
a 96 well plate using a plate reader. Concentrations were determined using a standard curve of 
bovine serum albumin.
RNA analysis
 RNA was purified using the RNeasy Mini kit (Qiagen Sciences, Maryland, USA) with 
on-column DNA digestion (ProMega).  cDNA was prepared using random hexamer primers and 
the Reverse Transcription System kit (Promega Corp., Madison WI).  Real-time quantitative 
polymerase chain reaction was performed using an iCycler (Bio-Rad laboratories Inc., Hercules, 
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CA), using specific primers.  Primer sequences are shown in  Table 1.  Fold-change in gene 
expression was determined by normalizing to 18S mRNA.  Primers are listed in Table 1.
Histopathological Analysis
 Sections of formalin-fixed livers were stained with hematoxylin/eosin and analyzed by 
microscopy.  Frozen sections were prepared from liver tissue frozen in OCT media, and stained 
with Oil-Red O.  Photomicrographs were collected as TIFF files and subsequently analyzed with 
Metamorph software.  Images were thresholded to isolate the Oil-Red O positive staining 
section, and the percentage of image area thresholded in this manner was calculated by the 
program and recorded for statistical analysis. 
Whole Cell Lysate
 60mg of liver tissue was washed and subsequently homogenized in lysis buffer (9.5ml 
RIPA buffer, 1mM NaF, 2mM Na3VO4, 1 protease inhibitor tablet, 500ul PMSF) using rotor-
stator homogenization.  After 10 minutes of incubation on ice, homogenates were centrifuged at 
10,000RPM for 10 minutes at 4 degrees C.  The supernatant was collected and stored in aliquots 
at -80 degrees C.
Nuclear Extraction
 60mg of snap-frozen liver tissue was washed in 10-fold excess volume TKM-0.32 buffer 
(0.32 molal sucrose, 50mM Tris-HCl, 25mM KCl, 5mM MgCl, 5mM PMSF, with protease 
inhibitor tablets (1 per 10ml of buffer, Sigma) and homogenized using a rotor-stator homogenizer 
(Ika).  Homogenates were transferred to microcentrifuge tubes and centrifuged (10mins/
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1000rpm/4 degrees C.)  Pelleted material was resuspended in TKM-2.0 buffer (2 molal sucrose, 
50mM Tris-HCl, 25mM KCl, 5mM PMSF) and homogenized again by rotor-stator.  Pellets were 
collected by centrifugation (60mins/14000rpm/4 degrees C) and resuspended in 400ul Buffer A 
(10mM Hepes/KOH, pH 7.9,  2mM MgCl, 1mM EDTA, 10mM KCl, 1mM DTT, 5mM PMSF, 1 
protease inhibitor tablet/5ml buffer).  Pellets were again collected by centrifugation (2mins/
14000rpm/4 degrees C) and resuspended in 50ul Buffer B (10mM Hepes/KOH pH 7.9, 2mM 
MgCl, 1mM EDTA, 50mM KCl, 300mM NaCl, 2mM DTT, 5mM PMSF, 1 protease inhibitor 
tablet (Sigma) per 5mL buffer, 10% glycerol).  Resuspended material was frozen at -80 degrees 
overnight, thawed with gentle agitation at 4 degrees C.  Supernatant containing nuclear extract 
was collected after centrifugation (10mins/14000rpm/4 degrees C) and assayed for protein 
concentration.
Western Blotting
30-50ug of nuclear extract was resolved on 10% polyacrylamide gels and transferred overnight 
to nitrocellulose support.  Membranes were blocked overnight with blocking buffer (5% bovine 
serum albumin in Tris-Borate-SDS with 0.01% Tween 20) with refrigeration, and subsequently 
probed overnight with anti-HIF1! (R&D Biosciences) or anti-HIF2! (Chemicon) mouse 
monoclonal antibodies.  Detection was performed using an anti-mouse horseradish-peroxidase 
conjugated secondary antibody and chemiluminescent substrates.  Band density was  quantified 
using Labworks 4.0 image analysis.
Multiplex Cytokine Bead Array
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 Multiplex cytokine bead array was performed using the BioRad Precision Pro multiplex 
cytokine bead array kit (BioRad) according to the instructions of the manufacturer.  Briefly, 
serum aliquots stored at -80 degrees were diluted at a 1:4 ratio using dilution buffer provided in 
the kit.  Serum was allowed to mix with beads coated with antibodies to one of 8 different 
cytokines and subsequently incubated with a second antibody that detects conjugated bead-
cytokine pairs.  
Results
 We first established the manner in which samples would be collected by conducting a 
pilot experiment with wild-type mice challenged with lipopolysaccharide injection.  LPS was 
administered intraperitoneally to wild-type mice, and livers and blood were collected at varying 
time points.  Serum ALT was analyzed using a biochemical assay, and found to peak at 18 hours 
after LPS injection (Figure 21A).  Whole liver lysates were prepared and analyzed for 
triglyceride content.  Of interest, liver triglycerides increases appreciably within 18 hours after 
LPS injection, returning to baseline levels by 24 hours. (Figure 21B).  Finally, we performed 
Western Blotting for HIF1! on nuclear extracts prepared from whole liver. HIF1! protein 
accumulated in nuclear extracts from whole liver by 4 hours post LPS injection, and appeared to 
be upregulated through the 24 hour time point. (Figure 21C and 21D).  We thus decided to 
collect samples from mice 18 hours after LPS injection in subsequent experiments.
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Figure 21.  Time course of liver injury in Wild Type Mice after LPS injection.  Wild-type 
mice were administered lipopolysaccharide intraperitoneally at a dose of 50ug/kg and sacrificed 
at various time points.  A.  Serum ALT was found to reach a peak between 12 and 18 hours after 
LPS injection (U<0.05, Mann-Whitney U Test).  B.  Whole liver lysates were prepared and 
analyzed for triglyceride content using a biochemical assay.  Results were normalized to protein 
concentrations.  Liver triglycerides also reached a peak at 18 hours post LPS injection.  C.  
Nuclear extracts were prepared and western blotting was performed for HIF1!.  HIF1! protein 
was upregulated by 4 hours after LPS injection, and remained elevated through the remaining 
time points (p<0.05 versus control.)
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Ethanol feeding and Parameters of Liver Injury in WT, HepHIF(-) and MyeHIF(-) mice
 HepHIF(-), MyeHIF(-), or WT mice were acclimated to the 5% ethanol diet and 
maintained on the diet for five weeks.  The experiment was repeated twice, with 6-8 mice per
group.  HepHIF(-), MyeHIF(-) and WT mice showed similar weight gains between pair-fed and 
ethanol-fed groups. (Figure 22A).  Some mortality was observed in the WT group, with 3 of 12 
mice (two males and one female) expiring before the end of the study in one cohort; in a second 
cohort, no mortality was noted in any of the groups.  All deaths occurred in the final week of the 
five week feeding.  No mortality was observed in the HepHIF(-) or the MyeHIF(-) groups.  
(Figure 22B.)
 Analysis of liver-weight/body-weight ratios revealed increased liver weight/body weight 
in WT ethanol-fed mice versus control mice at 4 weeks.  In contrast, HepHIF(-) mice showed 
little difference between pair-fed and ethanol fed groups, while a trend towards increased LW/
BW ratio in MyeHIF(-) ethanol-fed mice was not significant. (Figure 22C.) We performed 
immunoblotting on nuclear extracts from wild-type and HepHIF(-) mice.  Ethanol feeding 
resulted in a significant increase in HIF1! expression in nuclear extracts prepared from WT 
mice.  In contrast, nuclear extracts from HepHIF(-) mice had very low levels of HIF1! 
expression, and no further upregulation with ethanol feeding was observed, confirming 
suppression of HIF1! signaling in our mouse model.(Figure 23A and B.)  Consistent with the 
role of HIF1!  in hepatocyte steatosis, HepHIF(-) mice were protected from the increase in 
triglyceride content observed in wild-type mice.(Figure 23C). 
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Figure 22.  Weight gain, Mortality, and Liver-Weight/Body-Weight Ratio with ethanol 
feeding. WT, HepHIF(-), and MyeHIF(-) mice were maintained on the Lieber DeCarli ethanol 
diet for five weeks.  A. Weight gain was similar between ethanol and pair-fed mice of each 
genotype.  B.  There was no mortality in the HepHIF(-) or the MyeHIF(-) mice; however, the 
alcohol-fed WT group had almost 10% mortality across the two feedings.  All deaths occurred in 
the last week of the feeding.  C.  WT mice had significantly elevated LW/BW ratio with alcohol 
feeding (*=p<0.05).  In contrast, HepHIF(-) mice were protected from an increase in LW/BW 
ratio (**=P<0.05 versus corresponding WT group).  MyeHIF(-) mice trended towards an 
increase in LW/BW ratio, but the results were not significant (p<0.08, MyeHIF(-) PF vs 
MyeHIF(-) ET).
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FIGURE 23.  Western Blotting for HIF1!  and hepatic triglycerides. A. Nuclear Extracts 
were prepared from the livers of WT and HepHIF(-) mice.  30ug total protein was loaded per 
lane.   Ethanol resulted in an upregulation of HIF1! protein (p<0.05 versus WT PF group) in 
WT mice.  In the HepHIF(-) mice, as expected, little HIF1! protein was detected, and no further 
upregulation was detected with chronic alcohol stimulation.  Densitometry for immunoblot 
appears in B.   C.  Whole liver extracts were prepared, and triglyceride content was quantified 
using a biochemical assay.  Data are the average from two cohorts (N=9-11 per group).  
HepHIF(-) ET-fed mice had significant protection against triglyceride increase (*=P<0.05 vs 
WT-ET group) versus WT ET-Fed mice.  Due to high variability within the WT cohort, PF and 
ET-Fed WT mice did not differ significantly in the mean triglyceride content (#=p<0.095 versus 
WT Pair-Fed) although a similar trend as was observed repeatedly in earlier feedings was 
apparent.
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 Serum ALT levels were not dramatically different among ethanol-fed and pair-fed mice in 
the absence of LPS stimulation.  (Figure 24A)  With LPS stimulation, however, a clear pattern 
emerged.  Alcohol-fed WT mice had the greatest increase in serum ALT after LPS injection,
significantly elevated over the ALT values obtained for WT pair-fed, LPS injected mice.  In 
contrast, ethanol-fed HepHIF(-) mice were protected from serum ALT increase after LPS 
injection.  Ethanol-fed, LPS injected MyeHIF(-) mice had the greatest average serum ALT 
among the MyeHIF(-) groups, however, this difference was not statistically significant in either 
cohort. (Figure 24).
HIF pathway suppression in hepatocytes also revealed some protection against lipid 
accumulation n HepHIF(-) mice after alcohol feeding(Fig 25).  Tissue microscopy was somewhat 
ambiguous, with vacuolated spaces appearing in some ethanol fed animals from each cohort.  
Oil-Red O staining was performed on frozen section and quantified using MetaMorph image 
analysis software to discern differences between the groups (Figure 26A). Briefly, Oil Red O 
positive areas were thresholded, and the percent thresholded area was quantified by the software.  
We found that the average Oil-Red O positive area in HepHIF(-) ethanol-fed mice was similar to 
that in HepHIF(-) pair-fed mice.  In contrast, WT ethanol-fed mice had greater Oil Red O 
positive areas than pair-fed mice, and a similar trend was observed in MyeHIF(-) mice (Figure 
26B).  In general, quantification of Oil Red O staining paralleled LW/BW ratio calculations, and 
supported a protective role for hepatocyte-specific HIF1!  suppression in alcohol induced 
steatosis.
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FIGURE 24.  Serum ALT levels.  
A.  Serum ALT levels in the first cohort of mice.  Blood was collected 18 hours after LPS 
injection.  B.  Serum ALT levels in the second cohort.  Blood was drawn 2hrs post LPS injection 
from the cheek pouch venous plexus.  C.  Serum ALT levels in the second cohort.  Blood was 
collected at sacrifice, 18 hours post LPS injection.
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Figure 25.   Histology, WT/HepHIF(-)/MyeHIF(-) mice with ethanol feeding.
Panels A and B show photomicrographs of H&E stained sections from ethanol and pair-fed wild-
type mice, respectively.  Ethanol-fed wild-type mice had prominent lipid vacuolization.  Panels 
C and D show photomicrographs from ethanol-fed and pair-fed HepHIF(-) mice.  Some lipid 
vacuolization was observable in both conditions, but was less, on average, than was observed for 
ethanol-fed WT mice.  Panels E and F show photomicrographs from ethanol-fed and pair-fed 
MyHIF(-) mice.  Similar lipid accumulation as was observed in WT mice was observed with 
chronic ethanol feeding.
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Figure 26.  Quantification of Oil Red O positive areas.   A.  The column on the right shows 
representative micrographs from pair-fed animals from each genotype.  The column in the 
middle shows representative micrographs from ethanol-fed animals from each genotype.  The 
column on the left shows the binary image threshold mask created from the corresponding 
ethanol-fed micrograph appearing in the middle column.  B.  The average thresholded area as 
described in A was calculated.  WT mice showed a significant increase in Oil-Red O positive 
area, whereas protection was observed in HepHIF(-) mice.
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Secretion of Pro-inflammatory Cytokines is affected by hepatocyte-specific HIF1! 
 In addition to steatosis, alcohol liver disease is also associated with activation of the 
inflammatory cascade.  The suppression of serum ALT increase after chronic alcohol and LPS 
injection in HepHIF(-) mice prompted us to look for changes in cytokine expression.  Using a 
multiplex cytokine bead array, we analyzed serum levels of several cytokines.  Most cytokines 
were observed at both 2 hours (from blood drawn from cheek venous plexuses) as well as at 18 
hours after LPS injection, although some cytokines were only measured at 18 hours.
 Serum TNF! increases dramatically after chronic alcohol feeding and LPS injection.  At 
2 hours, there was a profound upregulation of TNF! in WT ethanol-fed, LPS injected mice.  At 
18 hours, there was still a detectable elevation of TNF! in LPS versus non-LPS-injected WT 
mice.  Surprisingly, in HepHIF(-) mice TNF-a was suppressed, and no synergistic upregulation 
with ethanol was observed.  In MyeHIF(-) mice, TNF! was suppressed in ethanol/LPS treated 
mice versus WT mice, though still significantly elevated over HepHIF(-) mice.  (Figure 27A)
 The cytokine IL-6 has potent pro-inflammatory effects and has previously been 
implicated in the pathogenesis of alcoholic liver disease.  We examined serum levels of IL-6 at 2 
and 18 hours post LPS injection in our cohort of WT, HepHIF(-) and MyeHIF(-) mice.  IL-6 was 
profoundly upregulated by LPS stimulation in WT mice within 2 hours of LPS injection. (Figure 
27B) Alcohol increased the duration and amplitude of IL-6 secretion in response to LPS, as IL-6 
was increased by 2 hours and remained elevated through the 18 hour time point (Figure 27C).  In 
contrast, no synergism was observed in ethanol-fed, LPS injected HepHIF(-) or MyeHIF(-) mice, 
although LPS had potent stimulatory effects on IL-6 levels in both.  By 18 hours, a cooperative 
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upregulation of IL-6 was observed in C57/BL6 ethanol-fed/LPS injected mice, whereas no such 
effect was observed in MyeHIF(-) or HepHIF(-) mice. (Figure 27D)
 IFN" showed a different pattern of regulation.  IFN" levels were quite low in comparison 
to the other cytokines observed.  Ethanol had no effect on IFN" levels in sera of ethanol-fed WT 
mice. IFN" was upregulated by LPS to a statistically similar extend in sera of pair-fed and 
ethanol-fed LPS WT mice.  Similar patterns were observed in HepHIF(-) mice, though an 
opposite pattern (of higher levels of IFN" in PF mice) were observed in MyeHIF(-) mice.  The 
biological relevance of these very low levels of IFN" are unclear.  (Figure 28A)
IL-13 is a chemokine that is thought to regulate allergic and anti-parasitic immune responses.  
Serum levels of IL-13 were consistently low and did not change significantly with any treatment 
in any group.  (Figure 28B)
 IL-10, an anti-inflammatory cytokine, is co-secreted with pro-inflammatory cytokines in 
alcoholic liver disease and  was synergistically increased with LPS injection and ethanol in WT 
mice.  In contrast, no synergistic upregulation is observed in HepHIF(-) mice, with serum levels 
of IL-10 remaining similar to that observed in pair-fed, LPS injected WT mice.  This implies that 
the synergistic effect of ethanol and LPS is at least partially dependent upon high levels of 
hepatocyte-specific HIF activation.  In MyeHIF(-) pair-fed/LPS injected mice, IL-10 levels were 
comparable to WT mice with ethanol/LPS injection, but were lower with ethanol feeding.  This 
paradoxical suppression of IL-10 levels with ethanol/LPS injection in MyeHIF(-) mice suggests 
an unknown additional counter-regulatory mechanism in myeloid cells that is normally 
suppressed by HIF. (Figure 28C)
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Figure 27.  Serum Cytokines:  TNF! and IL-6.  
Serum cytokines were quantified using a multiplex bead array.  A. A profound upregulation of 
TNF! was observed in WT-mice at 2 hours after LPS injection.(A)  HepHIF(-) and MyeHIF(-) 
were completely protected from this upregulation with LPS injection. (*=P<0.01 versus WT PF/
LPS injected mice; **=P<0.01 versus WT ET/LPS mice.)  B.  Serum IL-6 showed a similar 
pattern, with synergistic upregulation with ethanol and LPS in WT mice after 2 hours. (*=p<0.01 
versus WT PF/LPS mice). No synergistic effect of ethanol was observed in HepHIF(-) mice.  
MyeHIF(-) mice had high levels of IL-6, comparable to WT mice. C.  By 18 hours, upregulation 
of IL-6 with ethanol/LPS challenge was still observable in WT mice, but not in HepHIF(-) or 
MyeHIF(-) mice. (*=P<0.05, WT ET-LPS versus Wt PF LPS mice; **=P<0.05 versus WT ET 
LPS mice).
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Figure 28.  Serum Cytokines:  IFNg, IL-13 and IL10.  
Serum cytokines were quantified using a multiplex bead array.  A.   The cytokine IFN" was 
significantly upregulated at 18 hours in WT ET LPS mice (*=P<0.05 versus WT PF LPS mice).  
HepHIF(-) ET LPS mice were not significantly different from WT ET-LPS mice, nor was the 
trend towards increased IFN" in HepHIF(-) ET LPS mice significantly increased versus 
HepHIF(-) PF LPS mice.  B.  The cytokine IL-13 remained relatively unchanged among all the 
groups.  C.  Serum IL-10 was significantly upregulated by ethanol and LPS at 18 hours; a trend 
towards significance was also observed at 2 hours.  Significant protection from IL-10 elevation 
was observed in HepHIF(-) and MyeHIF(-) mice.
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Differential secretion of chemoattractant cytokines in WT and HepHIF(-) mice
 Inflammatory cell recruitment to the liver occurs in alcoholic liver disease, and is 
mediated by cytokines including the neutrophil chemoattractant IL8/KC, as well as the monocyte 
chemoattractant MCP-1.  MCP-1 was synergistically upregulated by ethanol and LPS in WT 
mice.  Again, no upregulation was observed with ethanol/LPS injection in HepHIF(-) mice at 2 
hours.  MyeHIF(-) groups also showed a significant protection against LPS/ethanol upregulation 
at 2 hours.  By 18 hours, though significant differences were observed among the groups, all had 
levels that were under 4000pg/ml, whereas concentrations above 100,000pg/ml were achieved at 
2 hours post LPS injection in WT mice. (Figure 29A and B)
 The cytokine RANTES was upregulated with LPS challenge.  No synergistic effect of 
alcohol was observed, and levels were similar in HepHIF(-) and MyeHIF(-) mice to those 
observed in WT mice. (Figure 30A)
 KC, the murine homologue of IL-8, was modestly increased by ethanol and LPS at 2 
hours in WT mice, although the significance did not pass the p<0.05 threshold.  (Figure 30B) No 
synergistic upregulation with ethanol was observed in HepHIF(-) mice, although LPS did 
dramatically increase serum KC after two hours.  At 18 hours, KC remained upregulated in WT 
ET-fed/LPS injected mice, but was suppressed in HepHIF(-) mice versus WT mice after ethanol/
LPS injection.(Figure 30C)
 
Real-Time PCR analysis
 We first examined HIF1! mRNA expression.  We found that after five weeks of chronic 
ethanol, HIF1! mRNA was significantly upregulated in hepatic tissue (Figure 33A).  LPS 
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Figure 29.  Serum MCP-1
A.  Serum MCP-1 was significantly elevated with ethanol and LPS injection in WT mice 
(*=P<0.05 versus WT PF LPS).  HepHIF(-) ET LPS mice were protected from this upregulation 
versus WT ET LPS mice.  B.  By 18 hours, significant MCP-1 elevation in WT ET LPS mice 
versus WT PF LPS mice was still observed; in contrast, the trend towards protection in 
HepHIF(-) ET LPS mice was not significant. (*=P<0.05 versus WT PF LPS; **=P<0.05 versus 
WT ET LPS). 
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Figure 30.  Serum Cytokines: RANTES and KC
Serum cytokines were quantified using a multiplex bead array.  A.  Serum RANTES was 
upregulated with LPS injection.  No synergistic effect of ethanol was observed, and no 
significant differences between WT, HepHIF(-) and MyeHIF(-) groups was observed. 
B.  Serum KC at 2 hours.  High levels of KC were detected in all LPS samples at 2 hours.  
Although some protection was observed in HepHIF(-) mice, these data were compromised by the 
extremely high levels of cytokines that were at or extrapolated beyond the linear range of the 
assay.  C.  By 18 hours, a synergistic upregulation of KC was still measurable in sera from WT 
ET LPS mice, and prevented in HepHIF(-) mice.  (*=P<0.05 versus WT PF LPS; **=P<0.05 
versus WT ET LPS).
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synergistically upregulated HIF1! mRNA to almost 6-fold over control  (Figure 33A).  In 
distinction, HIF1! mRNA remained low and unchanged by all conditions in HepHIF(-) mice as 
well as MyeHIF(-) mice, suggesting that transcriptionally active HIF1! mRNA involved in the 
pathogenesis of alcoholic liver disease is required in both hepatocytes as well as cells of the 
myeloid lineage.  In the first feeding, HIF2! showed little regulation between the groups.  
however, in the second cohort, after including a blood draw at 2 hours after LPS injection, some 
upregulation of HIF2! was observed in WT mice after ethanol and LPS feeding, and a similar 
(though non-significant) trend was observed in HepHIF(-) mice. (Figure 31A and 31B)
 Downstream targets of HIF implicated in the pathogenesis of alcoholic liver disease were 
upregulated by alcohol and LPS injection in WT mice.  PAI-1 was synergistically upregulated by 
alcohol and LPS (p<0.05, PF-LPS versus ET-LPS groups) whereas iNOS showed a similar 
though nonsignificant trend. (Figure 31C)  In HepHIF(-) mice, both PAI-1 and iNOS were 
upregulated with LPS injection, but no further upregulation was observed with chronic ethanol. 
(Figure 31C).
 As differences in lipid accumulation were observed, we then turned our attention to 
PPARa, a master regulator of hepatic lipid metabolism.  PPARa is reported to be decreased by 
chronic ethanol, and PPARa activation has been shown to ameliorate alcoholic liver disease.
[130]  Consistent with earlier reports, PPARa mRNA was suppressed by almost 50% in WT mice 
with chronic ethanol feeding.  Surprisingly, this change was similar in HepHIF(-) mice, with 
suppression of PPARa to a similar extent observed in all conditions. (Figure 32A)
 We then turned to examine other potential mediators of the effect on lipid accumulation.  
We identified the HIF-responsive gene Adipocyte Differentiation Related Protein (ADRP), which 
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Figure 31. QRT-PCR of HIF pathway genes with ethanol feeding and LPS injection  A. We 
found significant upregulation of HIF1! mRNA with ethanol, and further upregulation with LPS 
injection in WT mice. (*=P<0.01 versus corresponding WT PF group) In contrast, HIF1! 
mRNA (normalized to same genotype mice) was unchanged in HepHIF(-) and MyeHIF(-) mice.  
B.  HIF2! mRNA expression.  C.  Gene expression of PAI-1 and iNOS.  Both PAI-1 and iNOS 
were upregulated with LPS injection.  PAI-1 increased further with chronic ethanol in WT mice.  
However, no further upregulation was observed in HepHIF(-) mice.  (*=P<0.05 versus PF-LPS 
group; #=P<0.05 versus Wt ET LPS group).
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has recently been implicated elsewhere in hepatic lipid accumulation in a HIF-2 dependent 
manner.  We found that hepatic expression of ADRP was significantly upregulated with ethanol 
and LPS injection in WT mice.  There was no upregulation of ADRP observed in HepHIF(-) 
mice or MyeHIF(-) mice. (Figure 32B).  
 In a second cohort of mice that included a two hour blood draw after LPS stimulation 
prior to sacrifice at 18 hours, we found some elevation of HIF2a mRNA with ethanol alone, and 
more significant elevation of HIF2a with ethanol and LPS.  HepHIF(-) mice did not differ 
significantly among the groups, and HepHIF(-) ET/LPS mice had significantly less HIF2a 
mRNA than WT ET/LPS mice.  The altered patterns observed in HIF2a regulation may have 
been partially responsible for a somewhat different , though statistically similar, pattern observed 
in ADRP mRNA from this second cohort. (Figure 33).
Discussion
 We found that disruption of HIF1!  in hepatocytes was protective against numerous 
indices of alcoholic steatosis and steatohepatitis, including elevations in serum ALT, 
hepatomegaly and hepatic triglyceride accumulation, and increase in pro-inflammatory cytokine 
production.  We were surprised to find an equally strong protection against TNF!  induction in 
HepHIF(-) mice as we observed in MyeHIF(-) mice, strengthening other observations that the 
interaction between Kupffer cells and hepatocytes is crucial for the maximal development of 
injury in alcoholic steatohepatitis.  Our results suggest dual protective roles for HIF1!  inhibition 
in parenchymal cells and non-parenchymal cells of the liver in ALD.  On the one hand, HIF1!  
appears to have a role in the development of steatosis, which may predispose hepatocytes to 
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Figure 32.  PPARa and ADRP mRNA with ethanol and LPS injection.  
(A) PPAR-alpha mRNA was suppressed by ethanol feeding in wild-type mice (#p<0.05 versus 
WT PF group) as well as in HepHIF(-) mice (*p<0.05 versus HepHIF(-) group.)  (B)  Adipocyte 
differentiation related protein (ADRP) was upregulated by ethanol/LPS injection in WT mice 
(*p<0.05 versus WT PF group) but was suppressed by ethanol and remain unchanged after 
ethanol/LPS injection in HepHIF(-) mice. 
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Figure 33.  HIF2! and ADRP mRNA, second cohort.  A. In the second cohort of ethanol 
feeding, we included a two-hour blood draw in all mice after LPS challenge and prior to sample 
collection at 18 hours.  Some alteration in mRNA levels was apparent in whole liver RNA 
analysis by qRT-PCR at 18 hours.  Notably, HIF2! levels were dramatically upregulated in WT 
mice with ethanol or ethanol and LPS challenge.  Trends among HepHIF(-) groups were similar 
but non-significant, and significant suppression of HIF2! mRNA levels was observed in 
HepHIF(-) ET-LPS mice versus WT ET-LPS mice.  (*=P<0.05, WT Ethanol versus WT Pair-fed 
groups; **=P<0.05, WT ET LPS versus all other WT groups; ***P<0.05 HepHIF(-) ET LPS 
versus WT ET LPS group).  B.  ADRP mRNA levels also showed a slightly different pattern, 
albeit with similar trends.  WT ET-LPS mice continued to have the greatest amount of ADRP 
mRNA (#=p<0.06 versus all other WT groups.  No significant changes were observed among 
HepHIF(-) or MyeHIF(-) mice.
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cellular damage after subsequent pro-inflammatory stimuli.  On the other hand, HIF1!  in both 
hepatocytes as well as myeloid cells appears to have protective effects against the secretion of 
those pro-inflammatory cytokines themselves.  Additionally, although we did not directly 
measure inflammatory cell recruitment to the liver, we found differential regulation of the 
chemoattractant KC and MCP-1, but not RANTES, with alcohol and LPS injection.
Alcoholic Steatosis and HIF1! 
 Lipid homeostasis in the liver represents a complex balance of many factors, including 
metabolic load (for example, caloric load), catabolic pathways (e.g., b-oxidation), hormonal 
mediators, and regulation of lipid storage capacity.  To this list, we can add inflammatory stimuli, 
as we demonstrated an upregulation of hepatic triglyceride in chow-fed mice within 18 hours 
after LPS challenge.  The list of transcription factors associated with lipid accumulation now 
includes members of the hypoxia-inducible factor family.  We offered data showing that HIF1! is 
upregulated after LPS challenge in chow-fed mice, and that the combination of chronic alcohol 
and LPS injection results in further upregulation of HIF1! mRNA.  Others have also offered data 
suggesting that HIF1! is involved in lipid accumulation, as HIF1! activation has been reported 
to result in foam-cell formation from macrophages, result in lipid loading in cardiomyocytes, and 
cause hepatic lipid accumulation in other mouse models.[97, 148, 151, 155]  Here we report the 
novel finding that partial disruption of HIF1! in hepatocytes results in a suppression of lipid 
accumulation in response to chronic ethanol.  HepHIF(-) mice had less HIF1! protein in 
response to chronic alcohol as assayed by immunoblot.  Hepatic lipid content was assayed by 
hepatomegaly, hepatic triglyceride, and quantitative analysis of lipid content in oil-red O stained 
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section; in each of those parameters, HepHIF(-) mice were protected in comparison with WT, 
ethanol-fed mice.  These results correlate well with our findings in a mouse model that utilized 
the opposite condition, namely in which we saw increased triglyceride and gross appearance of 
steatosis in chronic ethanol-fed mice with constitutive hepatocyte-specific HIF1! expression.  
Notably, we did not detect an intermediate phenotype of HIF! mRNA expression in the 
MyeHIF(-) or the HepHIF(-) mice.  This may be due to detection of the endogenous as well as 
the truncated HIF1! protein by the pCR strategy we utilized.
 There are several possible explanations for the relationship between HIF1! and lipid 
accumulation, and in this study, we explored the contribution of Adipocyte Differentiation 
Related Protein (ADRP).  ADRP is a lipid droplet-associated surface protein that has been 
reported to be regulated by hypoxia inducible factors in other models. [97, 155]  ADRP has been 
shown to be upregulated in human steatosis as well as in mice developing steatosis after a high-
fat diet.[202]  Additionally administration of an ADRP antisense oligonucleotide ameliorated 
hepatic steatosis, while normal adipogenesis but diminished hepatic steatosis was observed in an 
ADRP knockout mouse.[203][204] While Rankin et al have reported that HIF2! has a more 
profound effect on the regulation of ADRP than HIF1!, data within their own reports suggests 
that HIF1! also regulates ADRP expression.[155] Importantly, we found upregulation of ADRP 
consistently in WT mice that had been chronically exposed to ethanol and challenged with LPS; 
indeed, little upregulation of ADRP was evident with chronic ethanol alone, while HepHIF(-) 
mice were protected from any upregulation of ADRP.  We also found a consistent upregulation of 
HIF1! mRNA in chronic ethanol/LPS-challenged mice, but a less consistent effect on HIF2! 
mRNA.  Taken together, these data suggest that while HIF2! may indeed be a stronger regulator 
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of hepatic ADRP expression, the use of profound mouse models of HIF activation (such as 
complete VHL protein loss, as in the model of Rankin et al) may not mimic the physiologically 
dominant modes of regulation of HIF expression.
 If ADRP is a predominant regulator of hepatic lipid accumulation, the question remains 
why upregulation of ADRP mRNA was not observed in ethanol-fed, non-LPS injected WT mice.  
This likely represents the power of the chronic ethanol/LPS model to create a robust static 
picture of a dynamic process that occurs with chronic alcohol abuse.  For example, chronic 
alcoholics are rarely, if ever, exposed to the level of lipopolysaccharide challenge as we utilize in 
the mouse model; however, the utility of the model lies in reproducing in a robust fashion a 
phenomenon that is occurring chronically at a lower level, e.g., with small increases in portal 
vein endotoxin resulting in chronic mild inflammation.  
 In support of the idea that ADRP is a dominant regulator of hepatic lipid accumulation, 
ADRP knockout was able to prevent hepatic steatosis in a high-fat diet model, and ADRP 
antisense oligonucleotides were able to reduce hepatic steatosis in leptin-pathway deficient mice.  
[204][203]  However, the possibility that other genes affecting lipid metabolism are affected by 
HIF should not be discounted.  If ADRP is a key regulator of hepatic steatosis in ALD 
downstream of HIF1!, however, the question remains about what the role of ADRP may be.  One 
possibility is that increased ADRP limits lipid availability for efflux or oxidative/degradative 
pathways.  Future work is needed to determine the functional dependence of lipid accumulation 
on the ADRP protein.
 Hepatocyte-Specific HIF1! -dependent regulation of inflammation in ALD
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 Indeed, one emerging picture suggests that lipid accumulation is profoundly affected by  
pro-inflammatory stimuli. In this view, even the hepatic lipid accumulation owing to chronic 
ethanol exposure may be more a function of ethanol effects on immune hyper-responsiveness 
than solely an effect of ethanol.  In support of this, the chemokine MCP-1 was recently 
demonstrated to cause increased triglyceride deposition in the human hepatoma cell line Huh7.  
We also found synergistic upregulation of serum MCP-1 in chronic ethanol/LPS treated mice.  
Our previous work demonstrated induction of HIF1! protein with MCP-1 treatment in Huh7 
cells, as well prevention of lipid accumulation with HIF1! siRNA pretreatment in Huh7 cells, 
suggesting that hepatocytic HIF1! is intimately involved in the immune response.  Indeed, we 
found a profound suppression of serum ALT levels after challenge with LPS in ethanol-fed 
HepHIF(-) mice.  As expected, HepHIF(-) mice did not demonstrate an upregulation of HIF1! 
protein in hepatic nuclear extracts after chronic ethanol and/or chronic ethanol/LPS challenge, 
whereas, consistent with earlier studies, HIF1! was upregulated in chronic ethanol-fed mice, and 
also upregulated by LPS injection alone in WT mice.  In order to characterize the changes in 
serum cytokines we utilized a multiplex cytokine bead array system.   We found that chronic 
ethanol caused a dramatic increase in the secretion of several cytokines, including TNF!, IL-6, 
KC, MCP-1, IL-10, and IFN" after LPS challenge in wild-type mice when compared to pair-fed, 
LPS-injected WT mice.  Little synergistic upregulation of these cytokines was observed with 
chronic ethanol feeding in HepHIF(-) mice, underscoring the role of HIF1! as a master regulator 
of inflammation.  Perhaps more surprising is the finding that these results were robust in 
HepHIF(-) mice as well as in MyeHIF(-) mice.  Interestingly, the pattern of regulation of several 
cytokines, including TNF!, IL-6, IL-10, and MCP-1, suggested that MyeHIF(-) mice actually 
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had higher cytokine levels in pair-fed animals than in ethanol fed animals, whereas HepHIF(-) 
mice had comparable levels of cytokines between ethanol and pair-fed animals after LPS 
injection.  This suggests a more complex pattern of HIF-dependent regulation.
 In summary, we found that excision of a floxed HIF1! allele in hepatocytes  by co-
expression of the cre-recombinase transgene under the control of the albumin promoter resulted 
in decreased HIF1! expression after chronic alcohol feeding, and that this decreased expression 
correlated to decreased liver-weight body-weight ratios, decreased hepatic triglyceride, and 
decreased steatosis as determined through quantified Oil-red O staining.  We further found that 
HepHIF(-) mice had vastly decreased secretion of pro-inflammatory cytokines in comparison 
with WT mice.  In contrast, MyeHIF(-) mice had increases in LW/BW ratios and the triglyceride 
content of ethanol-fed MyeHIF(-) mice was similar to that in ethanol-fed wild-type mice.  
MyeHIF(-) mice also had diminished levels of several cytokines after ethanol/LPS challenge, 
including TNF!.  Other cytokines, including KC, IL-6, and IL-10, were not diminished in 
MyeHIF(-) mice.  The pattern of differential regulation of cytokines we report in myeHIF(-) 
mice is nearly identical to that reported by other investigators using myeloid-lineage-specific 
HIF1! KO mice in models of sepsis.[143]  Either the increased steatosis or the lack of protection 
in other cytokines (such as KC) between MyeHIF(-) ethanol-fed/LPS challenged mice and WT 
ethanol-fed/LPS challenged mice, may be partially responsible for the lack of protection against 
elevations in serum ALT in ethanol-fed MyeHIF(-) mice.  These results establish targeting of 
HIF1! as a potential therapeutic strategy in the treatment of alcoholic steatohepatitis.
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CHAPTER 6
FINAL SUMMARY AND DISCUSSION
 Our work has demonstrated a role for Hypoxia Inducible Factors in the pathogenesis of 
alcoholic liver disease.  Broadly speaking, our results can be summarized in three areas.  First, 
we provide evidence for a role for HIF1!  in hepatic lipid accumulation; second, we provide 
evidence that HIF1!  activation is a possible mechanism for the dysregulation of downstream 
signaling networks in alcoholic liver disease, particularly through regulation of PAI-1 and iNOS; 
and third, that HIF1!  activation in hepatocytes alters immune activation as determined by 
measured levels of cytokines.  A schematic illustrating some of these findings is included in 
Figure 34.
HIF1!  and lipid accumulation
We have described that constitutive activation of HIF1! in hepatocytes accelerates lipid 
accumulation with chronic ethanol feeding, reporting in Chapter 3 that HIF1dPA mice had higher 
steatosis by microscopy and increased hepatic triglyceride versus control mice. Furthermore, 
using an in vitro system in Chapter 4,  we offered data to suggests that inhibition of HIF1! 
prevents lipid accumulation.  Finally, in Chapter 5, we described the finding that deficiency of 
HIF1! in hepatocytes results in prevention of increased liver-weight to body-weight ratio and 
diminished hepatic triglycerides.  
 Our findings differ from those of Rankin et al, in that they argue that HIF1! has little or 
no role in hepatic lipid accumulation.  We have described that constitutive activation of HIF1! in 
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Figure 34.  Pathways of HIF involvement in the Pathogenesis of Alcoholic Liver Disease
Chronic alcohol causes increased gut permeability, which results in increased LPS entering the 
portal circulation.  This stimulates TLR4 receptors in the hepatic macrophage, which in turn 
cause TNFa secretion via an NF#B, HIF1! dependent mechanism.  A remaining question is 
whether LPS may also stimulate hepatic TLR4 to result in HIF1! activation, which we did not 
address in this study.  Chronic alcohol increases results in an increase in HIF1! in whole liver, 
possibly mediated through the known effects of ethanol on increased metabolic demand, 
alteration in cellular redox state, and the creation of reactive oxygen species, all of which can 
increase HIF1!.  Suppression of HIF1! signaling i hepatocytes prevented upregulation of PAI-1 
and iNOS in response to chronic alcohol and LPS challenge.  HIF1! activation increases lipid 
accumulation.  MCP-1 also increases lipid accumulation, and was shown to increase HIF1! in a 
hepatoma cell line in vitro.  Finally, suppression of HIF1! in hepatocytes decreased TNF! and 
KC.
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hepatocytes accelerates lipid accumulation with chronic ethanol feeding, that inhibition of HIF1! 
prevents lipid accumulation in vitro,  and that partial deficiency of HIF1! in hepatocytes results 
in prevention of increased liver-weight to body-weight ratio and diminished hepatic triglycerides. 
 Rankin et al demonstrated a role for HIF2-alpha in the regulation of hepatic lipid 
metabolism by utilizing compound cre-lox knockout mouse models.  By knocking out pVHL in 
combination with HIF1! or HIF2!, they were able to create models of hepatocyte-specific 
constitutively active HIF1 or HIF2.  Using this model, they suggested that constitutive activation 
of HIF2, but not HIF1, was a major regulator of lipid metabolism.[155]  This is in sharp contrast 
to earlier work by Scortegagna et al, which demonstrated that in adult HIF2! KO mice, multiple 
organ pathologies including severe steatosis developed, suggesting that HIF2! is dispensable for 
the development of steatosis.  Additionally, Scortegagna et al offered data to suggest that hepatic 
steatosis in HIF2! (-/-) mice could be reversed by treatment with a superoxide dismutase (SOD1) 
inhibitor. [153] In support of that mechanism, a more recent study has suggested that inhibition 
of HIF2! recruitment to the SOD1 promoter prevents SOD1 transcription.[205]  Kim et al, on 
the other hand, found no significant contribution to hepatic lipid accumulation with a 
degradation-resistant mutant of HIF2, despite finding a robust effect on angiogenesis.  On the 
other hand, they demonstrated a mild HIF1! dependent effect on lipid accumulation.[97]  One 
important explanation of the discrepancies found in these studies derives from the varying 
strategies each employs.  In the work of Rankin and colleagues, disruption of VHL creates a 
milieu where multiple protein-protein interactions may be compromised.  Other proteins, 
including an RNA polymerase subunit and HIF3a, have been reported to be regulated by VHL-
dependent ubiquitination.[206]  Neither study considers a potential role for HIF3a, which has 
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been shown to have inhibitory effects on HIF transcription.  HIF3a is transcriptionally 
upregulated by HIF1!; data demonstrating transcriptional upregulation of HIF3a by HIF2! is not 
currently available.[207]  It is possible in the model of Rankin and colleagues that absence of 
HIF1! alters other counter-regulatory mechanisms, such as asparaginyl hydroxylation of HIF2! 
or induction of HIF3a, whereas in the model of Kim et al, native HIF1! and VHL functions are 
preserved, accounting for the difference observed in phenotype.
 Others have described higher activity for asparaginyl hydroxylase-mediated inhibition of 
HIF1! transactivation than HIF2! transactivation; consequently, absence of degradation of 
HIF1! or HIF2! on the VHL scaffold may neglect effects of asparaginyl hydroxylation on 
transactivator recruitment, which would  be anticipated to be greater for HIF1! than HIF2!.[208]  
Additionally, other alternative degradation pathways for HIF1! have been described that may be 
distinct from pVHL interactions.[209]
 The distinctions between genetic models of constitutive activation of HIF subunits and 
diet-induced disease models are also quite significant.  Some investigators have offered evidence 
to suggest cyclic regulation of HIF1! mRNA in chronic ethanol feeding models.[138]  Those and 
other variations, including diurnal/circadian variations in gene expression, are lost in models of 
forced constitutive gene expression, and may have quite a large effect on resultant phenotype.  
For example, constitutive HIF1! expression or HIF1! expression mediated by chronic ethanol or 
intermittent activation of TLRs may in turn promote HIF2! activation.  Thus, activation of 
HIF1!  in a forced genetic model may only have effects when HIF2! signaling is also present; 
conversely, constitutively active HIF2! activity may not require HIF1! for effects on hepatic 
lipid accumulation.  If that is the case, then the question arises:  why was lipid accumulation not 
179
  
observed in the constitutively active HIF2! model described by Kim et al?  One explanation may 
be that in that model, native HIF1! activity or pVHL activity resulted in retained counter-
regulatory mechanisms that limited some, but not all, effects of HIF2!-dependent transcription.  
For example, recent work has suggested that maximal activity of HIF2! is crucially dependent 
upon a protein-protein interaction (i.e., a non-histone related interaction) with the histone 
deacetylase Sirtuin 1[210]; it is possible that such protein protein interactions are also dependent 
upon regulation by other HIF pathway members.
 Another significant difference between our work and the work of both Kim and 
colleagues and Rankin and colleagues is that while their models relied heavily on genetic 
knockout strategies alone, we added the additional stimulus of a pro-steatotic ethanol-containing 
diet.  In fact, deeper analysis of the work of Rankin et al reveals that their VHL/HIF1! 
compound knockout (expected to have constitutive HIF2! activation) reveals that these mice 
expired at 4-8 weeks of age, and had severe total body weight loss, whereas VHL/HIF2! 
compound knockout mice were phenotypically normal; furthermore, they found a nearly two-
fold increase in hepatic triglyceride content in VHL/HIF2! mice, a change that was statistically 
significant when compared to Alb-Cre control mice.[211]  In fact, the changes they describe in 
mice with constitutive HIF1! activation are nearly identical to those described by Kim and 
colleagues.   Since our studies involve the additional caloric stimulus of alcohol feeding, and our 
mice are sacrificed at a later age than Rankin and colleagues report, it follows that the 
accelerating effect on lipid accumulation we observed in HIF1dPA mice is not at odds with their 
findings.  Furthermore, the profound effect on weight gain that Rankin and colleagues and Kim 
and colleagues both described in mice with constitutive HIF2! activation suggests that a 
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different mechanism may be at play.  The phenotype that Rankin and colleagues describe in mice 
with constitutively active HIF2! is quite similar to that seen in a different diet induced model of 
fatty liver disease, the methionine-choline deficient model.  This model restricts mice to a diet 
that is absolutely deficient in methionine and choline, with the resultant effect that mice display 
profound weight loss, and hepatic steatosis with significantly increased liver-weight/body-weight 
ratios, despite livers that are smaller (in absolute weight terms) than those in methionine-choline 
supplemented diet controls.[212]  Our work is consonant with the work of Rankin and colleagues 
as well as Kim and colleagues in that their studies suggest that  HIF1! promotes lipid 
accumulation, and our studies extend these findings by suggesting that alcohol promotes lipid 
accumulation via a HIF1!-dependent mechanism.  While Rankin and colleagues find that the 
absence of HIF1! activation (in the constitutive HIF2! mouse) did not prevent lipid 
accumulation, the interpretation of the phenotype of that mouse is severely compromised by the 
severe weight loss, which suggests that the steatosis they observe may bear more similarity to 
that observed in human disease states such as fasting, rather than that induced by chronic 
alcohol.
 Further work may clarify these findings.  The use of mice with hepatocyte-specific HIF2! 
deletion, which only became available in the last six months of the work described here, in 
models of chronic alcohol feeding, may clarify whether HIF2! is truly required for alcohol-
mediated hepatic steatosis. 
HIF1!  and cytokines in Alcoholic Liver Disease
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 We also found significant effects of HIF on the production of cytokines with chronic 
ethanol.  In Chapter 3, we described the finding that constitutive activation of HIF in hepatocytes 
resulted in significantly higher levels of TNF! mRNA than in control mice.  Conversely, in 
Chapter 5 we described the opposite scenario, namely, that ethanol-fed HepHIF(-) and 
MyeHIF(-) mice both had much lower levels of TNF! at two hours post LPS injection than did 
wild-type mice.  While the extent of protection against TNF! elevation induced by LPS in 
MyeHIF(-) mice was in good agreement with published reports on the prevention of TNF! 
elevation induced by LPS, [155] the protection in HepHIF(-) mice was novel and surprising, and 
even more pronounced.  The pattern observed in TNF! followed the trend observed in serum 
ALT, with HIF1dPA pair-fed mice having higher levels of TNF! mRNA and higher serum ALT 
values than pair-fed control mice, and conversely, HepHIF(-) mice having much lower levels of 
serum TNF! and decreased serum ALT after ethanol and LPS challenge.  A regrettable absence 
in the HIF1dPA study was the lack of an LPS injection arm of the study, and ongoing efforts in 
the lab may include that experiment.  Nevertheless, even in the absence of that experiment, the 
correlations we describe provide compelling evidence that hepatocyte-specific HIF1! dependent-
modulation of TNF! levels is a potential mechanism of HIF involvement in the pathogenesis of 
alcoholic liver disease.  
 Other cytokines showed varying results.  Notably, some protection in upregulation of KC 
was observed in HepHIF(-) at 2 hours, while by 18 hours both HepHIF(-) and MyeHIF(-) mice 
had low levels of KC after ET LPS challenge.  Given this finding, a natural next step would be to 
assay neutrophil recruitment to the liver after ethanol and LPS challenge, and compare neutrophil 
recruitment in HepHIF(-) mice versus MyeHIF(-) mice; indeed, IL-8 is increased in alcoholic 
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hepatitis, (see [189] for review) and increased neutrophil recruitment and increased IL-8, among 
other CXC chemokines, is associated with a worse prognosis in human alcoholic hepatitis.[213]  
Although we were not able to complete such a study during the timeline of this project, the 
protection in HepHIF(-) mice against ethanol-induced upregulation of the chemoattractant 
cytokines KC and MCP-1 after LPS challenge offers a potential mechanism for the ability of 
HIF1!  deficiency in hepatocytes to diminish the rise in serum ALT observed in WT mice.  This 
potential mechanism would position hepatocyte HIF activation in response to chronic alcohol 
and LPS as part of an amplifying cascade that resulted in the recruitment of inflammatory cells, 
including neutrophils, monocytes and macrophages.  This finding underscores the central 
premise that alcoholic liver injury proceeds via a multi-step process that depends on dysregulated 
signaling both within and without the hepatocyte. 
 Previous work in has identified HIF1! activation in other cell types as modifying the 
immune response; notably, two pivotal studies have identified different roles for HIF1!  in the 
modulation of the immune response in cells of the myeloid lineage (such as hepatic Kupffer 
cells) and T cells.[143, 146]  Whereas in the former, a suppression of cytokine levels in myeloid 
lineage-specific HIF1!  knockout mice in response to LPS suggested that HIF activation is 
NF#B dependent and has a pro-inflammatory role in myeloid cells, in the latter study, knockout 
of HIF1!  in T-cells was associated with increased cytokines, again via an NF#B dependent 
mechanism.  In both studies, HIF1!  suppression was associated with higher survival, however, 
as the first study used lethal doses of endotoxin as pro-inflammatory stimulus, and the latter used 
active bacterial infection, the mechanisms by which inflammation is related to survival in those 
two models is necessarily different.  The emerging picture suggests that the role of HIF1!  is 
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highly cell-specific, and our data suggests that in hepatocytes, HIF1!  has a largely pro-
inflammatory role.
 A remaining question is the mechanism of HIF1! activation in hepatocytes and hepatic 
nonparenchymal cells.  Numerous lines of evidence support a role for TLR4-NF#B-dependent 
signaling in the activation of HIF1! in macrophages.[142, 214]  However, recent work has also 
suggested that alcoholic liver disease progresses via stimulation of the MyD88-independent-limb 
of the LPS-TLR4 signaling pathway.[58, 59]  Further investigation may reveal the specific 
dependence of HIF1! signaling on LPS-TLR4 pathways in alcoholic liver disease.  Some recent 
data from other laboratories suggests other possibilities for HIF regulation include novel protein-
protein interactions, such as Sirt1 (in the case of HIF2!) or chaperone proteins such as those in 
the heat-shock proteins family.[210][215, 216]
HIF1!  and dysregulation of downstream signaling networks 
In both Chapter 3 and Chapter 5, we have also reported findings suggesting strong HIF1!-
dependent effects on the expression of genes involved in the pathogenesis of alcoholic 
steatohepatitis.  In chapter 3, HIF1dPA mice had much higher levels of PAI-1 and iNOS, both of 
which have been previously reported as upregulated in alcoholic liver disease.  Furthermore, in 
Chapter 5, use of the hepatocyte-specific HIF1!  mutant (HepHIF(-) mouse) prevented induction 
of HIF1!  expression with chronic alcohol feeding,and resulted in decreased PAI-1 and iNOS 
expression after LPS challenge.  As HIF1! is a master regulator of transcription, it is quite likely 
that further study will reveal multiple other gene targets that are both downstream of HIF1!  
activation and upregulated in alcoholic liver disease.  With PAI-1, iNOS, and other HIF1!  target 
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genes, an important question will be whether the upregulation of the gene is incidental to the 
pathogenesis of alcoholic liver disease, and merely correlated with the activation of broader 
transcriptional networks, or whether a gene product is truly implicated in the pathogenesis of the 
condition.  For example, some protection was observed in PAI-1 KO mice maintained on a 
chronic ethanol diet.[217]  Dissecting the relative contribution of PAI-1, or any other gene target, 
to phenotypes observed in constitutive activation or suppression of master regulator genes such 
as HIF1!  will continue to be a formidable challenge. Several strategies, such as breeding cre-lox 
models onto genetic knockout strains, can be readily imagined and are promising ways to 
investigate these questions.
Future directions
 The most proximal questions that arise from these studies include the role of ADRP in 
hepatic lipid accumulation, the path from MCP-1 treatment to HIF1! activation, and the role of 
hepatocyte-specific HIF1! in the cooperative induction of inflammatory cytokines, such as 
TNF! and others, by alcohol and lipopolysaccharide.  With regards to the latter, the conventional 
wisdom is that the Kupffer cell is the source of TNF!.  However, an intriguing possibility 
implied by our results is that whereas normoxic hepatocytes may remain unable to secrete TNF!, 
hypoxic hepatocytes may behave quite differently.  If the combination of hypoxia and 
lipopolysaccharide treatment resulted in secretion of TNF! from hepatocytes, it also would 
explain the zonal necrosis observed in several forms of hepatitis, as reviewed in chapter 1B, 
above.  
 In final summary, we have offered compelling data to suggest that HIF1! is implicated in 
the pathogenesis of alcoholic liver disease.  It is not at all surprising that human, as aerobic 
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organisms, are profoundly susceptible to hypoxic tissue injury; more surprising, however, is the 
fact that the regulatory networks activated in response to hypoxia result in such a broad set of 
responses that may be at turns adaptive, maladaptive, or somewhere in between.  Given that 
alcoholic liver disease bears important similarities and differences to other forms of liver injury, 
and that many forms of liver injury are aggravated by hypoxia or implicate the hypoxia-inducible 
factors, the investigation of modification of hypoxia-inducible-factors activity in ALD and other 
hepatic diseases will likely have important roles in therapy.  
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